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Inflammation is vital in the repair following an acute coronary syndrome (ACS). 
Studies suggest that excess inflammation is pathological and may lead to major adverse 
cardiovascular events (MACE). Hence, inflammatory markers may be potential MACE 
predictors, although it is currently unknown which marker(s) best predict MACE. 
We firstly investigated common inflammatory markers as MACE predictors in two 
acute myocardial infarction (AMI) cohorts, using simple methods of combining markers 
to determine if such approaches could better predict MACE. The first study with 860 
patients investigated white blood cell subtypes, markers routinely used in clinical 
practice. Individual subtypes were not associated with MACE. Ratios of these subtypes 
were predictive on univariate, but not multivariate analysis. The second study measured 
a small panel of inflammatory markers (C-reactive protein, interleukin (IL) -6 and 
tumour necrosis factor alpha) in a case-control study. Cases were defined as patients 
who developed MACE within one year. No significant association was found with MACE 
when using individual or combined markers. This finding might have been influenced by 
time as a confounder, as we did not strictly control the sampling time. 
Next, we investigated cytokines because these markers are more reflective of acute 
inflammatory changes. We conducted a systematic review to investigate whether a 
combined cytokine approach would be superior to individual cytokines to predict MACE 
in ACS. Analysis of 10 studies meeting our eligibility criteria revealed inconsistent 
associations with MACE for an identical cytokine. The four studies using simple 
combined cytokine approaches found significant associations with MACE, suggesting 
that a combined approach could be superior to an individual one for MACE prediction. 
However, the 10 studies could not answer how best to combine the non-independent 
cytokines, or when it was best to measure them. 
We next examined temporal variation of six cytokines in 23 AMI patients. This was 
to determine if time was a potential confounder and if an optimal timepoint existed to 
capture peak cytokine levels (representing excess inflammation). There was significant 
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variation in cytokine concentrations over time, so no optimal timepoint could be 
determined. Only IL-6 had a clear trend with a peak on Day 1, and this peak was 
produced by half the cohort. The observed variation could not be explained by clinical 
risk factors or surrogate markers of infarct size. We concluded sampling time might be 
an important consideration when designing future studies.  
Finally, we trialled the use of principal component analysis (PCA), a mathematical 
technique allowing non-independent variables to be reduced into combined scores, to 
create a combined cytokine score and tested its prognostic utility. Six cytokines were 
measured in a cohort of 320 patients. We found that IL-6, IL-8, all cytokines combined 
into a PCA score, and an IL-6-IL-8 PCA score univariately predicted MACE. Only the IL-6-
IL-8 score and IL-6 were independently associated with MACE, with the IL-6-IL-8 score 
having a stronger relationship than IL-6 alone. 
Collectively, these studies demonstrate the complexity of inflammation in ACS. 
While we could not answer how best to characterise inflammation, we showed that 
using single biomarkers was unlikely to be sufficiently representative of pathological 
inflammation. As a proof-of-concept, we demonstrated PCA was one mathematical 
approach that could be used to combine collinear markers. However, further studies 
are required to determine the best method to create a prognostic inflammatory score 
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1.1 Acute coronary syndrome 
Acute coronary syndrome (ACS) is an important clinical presentation of 
atherosclerosis and is an umbrella term encompassing acute myocardial infarction 
(AMI) and unstable angina (UA). AMI is one of the acute presentations resulting from 
myocardial injury.1 The presenting coronary ischaemia manifests as changes in cardiac 
troponin levels and is evident by clinical symptoms, abnormal electrocardiogram (ECG) 
readings, imaging, and/or autopsy findings.1 These pieces of clinical evidence lead to 
the diagnosis of AMI.1 Myocardial infarction (MI) is often further subdivided into two 
common clinical diagnoses, ST-elevation myocardial infarction (STEMI) and non-ST 
elevation myocardial infarction (NSTEMI), based on ECG changes.1 STEMI is defined by 
at least two contiguous ECG leads showing a significant, new ST-elevation, which 
generally occurs because of total or subtotal coronary occlusion that results in 
transmural ischaemia,1,2 whereas NSTEMI is defined as having no persistent ST-
elevation.1 In UA, there is myocardial ischaemia without cell death and presents with 
the same symptoms with or without ECG changes, but no elevation in troponin or other 
markers of myocyte death.3 In terms of severity, STEMI is regarded as the most severe 
presentation because there is often a greater degree of ischaemia.3 UA is the least 
severe of the three diagnoses. NSTEMI and UA may be grouped into the nomenclature, 
non-ST elevation acute coronary syndrome (NSTE-ACS).4 
 
1.1.1 Epidemiology 
A significant proportion of mortality and morbidity worldwide is attributed to 
cardiovascular disease (CVD).5,6 It is estimated that a new diagnosis of AMI occurs every 
40 seconds in the United States alone.6 After the first incidence of AMI, 47% of women 
and 36% of men die within five years, while another 50% of women and 37% of men 
experience a different adverse outcome, such as another AMI, heart failure, or stroke.6 
New Zealand (NZ) is not exempt from the health burden of AMI. The All New Zealand 
Acute Coronary Syndrome Quality Improvement (ANZACS-QI) Registry found that 
within 12 months after a first-time diagnosis of ACS, 6% of patients experienced all-
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cause death, 9% experienced recurrent ACS and 14% were readmitted to hospital due 
to their cardiovascular disease.7 The ANZACS-QI registry also shows that in 2016, ACS 
accounted for 14,464 of hospitalisations nationally,8 while the Ministry of Health data 
stated that AMI accounted for 11,807 (0.98%) of hospitalisations.9 Māori and Pacific 
peoples are disproportionately affected by this disease, with consistently higher rates 
of hospitalisation for AMI and death compared with Europeans and Asians.10 
 
1.1.2 Pathophysiology 
There are five pathological classifications of MI according to the current universal 
definition of MI.1 Type I MI is AMI caused by atherosclerotic plaque rupture or erosion 
in a coronary artery, while type II MI is due to a mismatch in myocardial oxygen demand 
and supply, so it does not typically involve plaque rupture.1 Type III MI includes sudden 
cardiac death patients who are believed to have experienced myocardial ischaemia, 
which is either unable to be confirmed with clinical biomarker testing or that the 
biomarker tests are not yet elevated at the time of testing.1 Type IV MI is MI related to 
percutaneous coronary intervention (PCI), with or without stent thrombosis.1 Finally, 
Type V MI is MI related to coronary artery bypass grafting (CABG).1 The studies in this 
thesis will largely focus on patients with Type I MI. However, due to the inherent 
difficulty of differentiating between Type I and II MI prior to angiography, and the fact 
that our study designs require us to collect blood samples prior to angiography, it is 
possible that our study cohorts have a small number of Type II MI patients. To minimise 
this, we collected information on the final diagnoses patients were given prior to 
hospital discharge, and subsequently excluded these patients that were believed to 




Figure 1.1 summarises the progression from atherosclerosis to AMI. Animal studies 
were originally used to determine the majority of the pathogenesis details of 
atherosclerosis. However, subsequent human, cell and/or epidemiological studies have 
supported these findings.11 For an atherosclerotic plaque rupture or erosion to occur, 
there must first be an atherosclerotic lesion growing in the intima, the innermost wall 
layer of an artery.12 The landmark review by Ross and Glomset in 1976 described the 
model proposing how the pathogenesis of atherosclerosis was initiated.13 It stated that 
excess cholesterol and endothelial injury in areas of haemodynamic strain resulted in 
low density lipoprotein (LDL) accumulation in the sub-endothelial space.13 Ross 
subsequently published an updated model that suggested an atherosclerotic lesion 
begin via risk factors triggering an inflammatory response.14 A number of risk factors 
have been linked to the development of atherosclerosis, such as hypertension, smoking, 
central adiposity, dyslipidaemia, insulin resistance and/or diabetes mellitus, age, and a 
sedentary lifestyle.12 These risk factors are believed to cause endothelial dysfunction, 
where the endothelial cells are activated and trigger an inflammatory response.12,14 
LDLs then enter the sub-endothelial space, forming the initial lesion.11 The LDLs are 
oxidised by monocytes, leading to the activation of macrophages and formation of foam 
cells.11 This results in a fatty streak.11 T cells have also been found in the fatty streak and 




Figure 1.1  Pathogenesis of atherosclerosis and AMI 
This figure presents the development of atherosclerosis and progression towards acute myocardial infarction. A brief description of the 
histological finding with each stage of atherosclerosis and the main inflammatory components of an atheroma are shown. Details of 
inflammatory response and growth of lesion are not included. The figure was created using BioRender.com, Toronto, Ontario, Canada.
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Fatty streaks are common, do not cause clinical symptoms, and may regress or 
progress toward an intermediate lesion.11 If a fatty streak progresses, the existing  
leukocytes attract more immune cells, inflammatory molecules and LDLs, causing 
further endothelial dysfunction and growth of the atherosclerotic plaque.11 The 
immune cells also cause smooth muscle cells to migrate into the plaque.14 Ongoing 
activation of these “players” causes the vessel to expand and the wall to thicken, 
resulting in the intermediate lesion.14 Further accumulation of lipids, macrophages, 
cytokines, growth factors and other immune cells or products leads to focal necrosis 
within the lesion.14 Smooth muscle cells and fibrous extracellular matrix (ECM) form the 
fibrous cap covering the atheroma.11,14 Calcium can also enter the plaque and collect 
there, and along with more accumulation of fibrous tissue, this creates a fibrous 
plaque.12 Eventually, the progressive growth of the plaque means that arterial dilation 
and wall thickening is no longer sufficient to maintain the normal activity of the artery, 
and the atherosclerotic lesion intrudes into the lumen.14  
There are several hypotheses regarding plaque rupture. One hypothesis is that as 
the plaque continues to grow over time, the fibrous cap may slowly thin, which occurs 
as a result of ongoing or upregulated inflammatory processes destroying components 
of the fibrous cap that is crucial for maintaining its structural framework.12 This results 
in what is termed a “vulnerable plaque”, where the plaque is considered unstable and 
at increased risk of rupturing.12 Plaque rupture occurs suddenly and without warning. It 
exposes the contents of the plaque to the blood flowing through the lumen, including a 
protein called tissue factor, which triggers blood stasis and thrombus formation.12 If the 
thrombus impedes blood flow or occludes the lumen, myocardial ischaemia occurs.12,15 
If this occurs persistently, it leads to cardiomyocyte death and results in AMI.12,15  
There is another pathological mechanism leading to ACS and Type I MI where some 
plaques do not have a thin fibrous cap and instead have large amounts of ECM.12 With 
these types of plaques, plaque rupture is unlikely to occur but instead plaque erosion 
may occur. This process is thought to be regulated by the innate immune system, such 
as Toll-like receptor-2 and other pattern-recognition receptors, and polymorphonuclear 
leukocytes promoting thrombotic processes.12  
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1.1.2.2 Pathogenesis Following AMI 
A theory surrounding the pathogenesis after the onset of AMI is the three-phase 
response (inflammatory, proliferative and maturation phases), which has largely 





Figure 1.2  Acute and chronic inflammatory responses following AMI 
This figure depicts the inflammatory response following the onset of AMI. The nomenclature of the phases, the timeline and the main 
immune cells and biomarkers involved in each phase are shown. The figure was created using BioRender.com, Toronto, Ontario, Canada. 
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It is believed that there is a cascade immune response following myocardial 
ischaemia from plaque rupture or erosion, and after the onset of myocardial 
infarction.15 The dying cardiomyocytes release danger signals that attract an influx of 
inflammatory molecules, such as neutrophils, to the infarcted region, initiating this 
inflammatory response.15 Neutrophils help to clear the debris by producing reactive 
oxygen species (ROS), and proteolytic enzymes.15 In vitro and animal studies have 
shown that ROS has a range of actions, including activating the complement system.15 
This further stimulates necrosis of the cardiomyocytes, attracts more leukocytes to the 
region, and activates inflammatory responses.15 ROS also activates the nuclear factor 
(NF)-κB pathway, which stimulates cytokine and chemokine production and other 
mediators of inflammation.15 These laboratory studies have shown that the 
inflammatory response is critical for wound healing and the initiation of cardiac 
repair.15,16 However, an exaggerated inflammatory response can be deleterious. For 
example, too much ROS may instead cause further cell apoptosis and ECM damage.15 
That is why a balance of inflammatory cells is important for a good outcome. 
This pathological model described by Frangogiannis defines the proliferative phase 
as a period of debris clearing, angiogenesis and scar tissue formation.15 Neutrophils 
undergo apoptosis, which attracts phagocytes to clear debris.15 The phagocytes release 
anti-inflammatory cytokines to dampen the pro-inflammatory response.15 Leukocytes 
are also involved in this process.15 Myofibroblasts (activated by growth factors, 
angiotensin II and matricellular proteins) and vascular cells then enter the infarcted 
region to repair the extracellular matrix and form new vessels.15 The end product of this 
proliferative phase is the infarcted region becoming scar tissue.15 However, suboptimal 
myocardial repair can occur if there are issues with limiting the pro-inflammatory 
pathways, such as increased cardiomyocyte death, further degradation of the ECM and 
increased fibrosis, all of which would expand the damaged region.15 It is estimated from 
in vitro and animal studies that the inflammatory phase occurs in the first three days 
after AMI, while the reparative phase overlaps and begins towards the end of the 
inflammatory phase and lasts until about a week after AMI onset.17 
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The final stage of this pathological model is the maturation phase, where the active 
cells in the proliferative phase dampen their activity in order to prevent the formation 
of an overly-fibrotic scar.15 Based on the findings from studies using human heart 
models, this process can take weeks to months.18 Due to the MI reducing the amount 
of viable myocardium that is able to meet oxygen demand, ventricular remodelling 
occurs through all three phases.15 As a preservation mechanism, cytokines released as 
part of the acute response help to decrease myocardial contractility and reduce the 
demand on the myocardium.16 This thins and dilates the infarcted region.15 However, 
too much remodelling can cause systolic dysfunction, thus increasing the risk of adverse 
events such as arrhythmia and cardiac death.15 An excess of several cytokines in the 
chronic phase of an MI has been associated with adverse remodelling and major 
adverse cardiovascular events (MACE).16,19,20 
As mentioned earlier, this three-phase model described by Frangogiannis et al. is 
largely derived from animal-based studies. Although subsequent clinical studies have 
supported aspects of this model,19-22 there are known limitations of animal-based 
studies. For example, the events leading up to the onset of AMI differ in animal models 
compared with humans, who have a long period of atherosclerotic plaque growth.15,21 
Inflammation occurs during atherosclerosis and plaque build-up, so the longer 
inflammatory period before AMI in humans may lead to differences in the inflammatory 
response. However, animal-based studies have provided us with an insight to the 
complexities of myocardial healing and repair following AMI that would not be possible 
with human studies alone.23  
Additionally, it is important to note that the mediators of myocardial repair are 
systemically activated. This means that inflammatory molecules may also cause 
progression of atherosclerosis in other coronary arteries and/or increase the risk of 
rupture of existing atherosclerotic plaques.12,24,25 That is why an excessive or 
“pathological” inflammatory response will not only adversely affect the repair of the 
myocardium damaged by the infarction, but also increase the risk for future AMIs that 
may occur in other coronary arteries. 
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1.2 Inflammatory markers 
There are a large number of inflammatory markers that have been studied in the 
acute phase of an ACS, with some being proposed as potential biomarkers of 
pathological inflammation and adverse outcome or MACE. However, it is evident that a 
greater understanding of the inflammatory process is required, as several markers were 
found to be associated with MACE in some studies, but had no association in other 
studies. The majority of studies have investigated inflammatory markers acutely 
(inflammatory and proliferative phases) after the onset of ACS for their prognostic 
potential.22,26-30  The rationale for this is because the acute period provides the greatest 
opportunity to manage patients appropriately while they are still in hospital to prevent 
short-term and/or long-term adverse outcomes. However, to date, it remains unknown 
when exactly it is best to measure these markers. Possible reasons for this are that most 
biomarker studies have used opportunistic blood sampling methods and tried to 
characterise the complex inflammatory network with only a single marker.22,31-34 
The subsections below discuss the groups of inflammatory markers that have been 
identified in the literature as being key players of the inflammatory process in ACS. It 
must be noted that there are an extensive number of inflammatory markers within the 
ACS context and it is not be feasible to discuss every molecule. This thesis has chosen 
to focus on white blood cells (WBCs), C-reactive protein (CRP) and cytokines. Other 
inflammatory molecules include matrix metalloproteinases (proteolytic enzymes that 
help stimulate ECM breakdown and recruit inflammatory cells to clear necrotic 
debris35), complement components, genetic markers of inflammation, inflammatory 
receptor markers and inflammatory receptor antagonists. These markers have not been 
covered in this thesis. 
 
1.2.1 White blood cell counts 
WBCs are a subset of inflammatory markers consisting of neutrophils, 
lymphocytes, monocytes, basophils and eosinophils. WBC counts are routinely 
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measured in clinical practice to indicate systemic inflammation and have been shown 
to be acutely elevated in AMI. Several studies have also shown that WBC count is an 
independent predictor of MACE in AMI patients.36-38 The following sections will discuss 
the four WBC subtypes that have been investigated in ACS patients as potential 
predictors of MACE: neutrophils, lymphocytes, monocytes and eosinophils. 
1.2.1.1 Neutrophils  
Neutrophils are the first WBC subtype to respond and infiltrate the infarcted 
myocardium within the first few hours of ischaemia.39 At the site of injury, neutrophils 
conduct phagocytosis, degranulation and release of neutrophil extracellular traps.39 
This causes further damage and attracts monocytes and macrophages to the site of 
injury.39 Several observational studies have shown that neutrophil count is associated 
with adverse outcomes in ACS patients.40-42 Additionally, a few functional studies have 
recently proposed that neutrophils may also play a role in myocardial repair.39 
Horckmans et al. found that dampening the neutrophil response resulted in greater 
fibrosis, which would suggest a greater adverse remodelling.43  
1.2.1.2 Monocytes 
Monocytes are the next leukocyte to enter the infarcted myocardium after AMI 
and are released from the spleen and bone marrow.44 They are a heterogeneous cell 
population that have a number of different functions, including production of ROS, 
platelet interactions, and differentiation into macrophages in the myocardium.43,45 
Once monocytes enter tissues spaces and are no longer in circulation, they transform 
into macrophages.44 There are several subtypes of macrophages. In animal models, pro-
inflammatory macrophages clear debris via phagocytosis and secrete proteolytic 
enzymes, while another subset of macrophages help with wound healing and repair via 
stimulation of collagen deposition, angiogenesis and myofibroblast accumulation.44 
One study by Grau et al. showed that high monocyte count was associated with 
increased risk of MACE,46 while Shiyovich et al. showed that there was an increased risk 
of mortality up to five years of follow-up with both the lowest and highest monocyte 




Lymphocytes are involved in the adaptive immune response and consist of a variety 
of T cell and B cell subtypes.48 They also enter the myocardium and facilitate the 
adaptive immune response, helping to heal the tissue by influencing mononuclear cell 
phenotype and causing tissue inhibition of metalloproteinase-1 expression.49,50 
Functional studies have shown some subsets of T cells are involved in the ischaemic-
reperfusion injury, but can also improve wound healing post-MI.51 In general, there is a 
poorer understanding of the role B cells play in AMI, but B cells are known to release 
antibodies and some cytokines, such as tumour necrosis factor alpha (TNFα).48 Nelson 
et al. conducted a functional study and showed that low lymphocyte counts were 
associated with increased cortisol levels, which induced stress and a pro-inflammatory 
response.52 A few human studies have supported Nelson et al.’s findings, showing that 
low lymphocyte count was associated with adverse outcome post-AMI.47,53 However, 
Grau et al. showed high lymphocyte count was associated with reinfarction, which 
reflected that the role of lymphocytes in pathological inflammation was not fully 
understood.46 The assumed pro-inflammatory effects of low lymphocyte counts, and 
the pro-inflammatory actions of neutrophils and monocytes, have led to several studies 
combining these subtypes into ratios.54-56 In theory, this will allow pathological 
inflammation to be better characterised and adverse outcomes to be more strongly 
associated with these markers.54-56 Several studies have found that neutrophil-
lymphocyte ratios and lymphocyte-monocyte ratios independently predict MACE.54-56  
1.2.1.4 Eosinophils 
Eosinophils are leukocytes that are commonly associated with hypersensitivity or 
allergic immune responses but are active in other disease states, including coronary 
disease.57 Eosinophils have previously been found in thrombi of ACS patients, where it 
is believed they help promote thrombus formation via activation of platelets.58 There 
has recently been a growing interest in eosinophils as a marker of adverse outcome in 
ACS. One study by Alkhalil et al. found that low eosinophil count in STEMI patients with 
normal to moderately impaired left ventricular function was associated with MACE.59 
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Deng et al. combined eosinophil and monocyte counts into a ratio and found that a low 
ratio was associated with all-cause death in STEMI patients.60  
 
1.2.2 C-reactive protein 
CRP is well established in clinical practice as an indicator for systemic inflammation. 
It is an acute phase protein that is largely produced in the liver, but is also produced in 
atherosclerotic lesions by smooth muscle cell lymphocytes and monocytes.61 
Concentrations start to increase within six hours following an inflammatory stimulus 
and reach maximal levels within 48 hours.62 Following the end of the acute phase 
response, CRP levels decrease at a half-life of 19 hours.62,63 CRP has been found to be 
relatively stable, with the change in concentration over years in a healthy cohort being 
similar to that of systolic blood pressure and total cholesterol levels.64 Its relative 
stability makes it a potentially useful clinical marker. In atherosclerosis, CRP is involved 
in the proliferation of the plaque in multiple ways.61 After the onset of ACS, CRP binds 
to dead or damaged myocardial cells with lysophosphatidyl choline present on their 
membranes, which results in complement activation and subsequent stimulation of the 
inflammatory response, and further myocardial cell damage and death.61 CRP has been 
shown to correlate with atherosclerotic plaque instability, inflammation in the plaque 
and damage to the wall of coronary vessels in CVD.65 Positive correlations have also 
been found between CRP and infarct size measured by magnetic resonance imaging 
(MRI), and between CRP and the number of coronary lesions.65,66 These findings suggest 
that CRP may provide information regarding disease severity. 
Many observational studies have investigated the prognostic value of CRP in the 
ACS context, with varying results. It is established that CRP is associated with all-cause 
mortality, and may be weakly associated with recurrent MI.65,67 However, its association 
with MACE is less clear. Some studies found an association between CRP and MACE, 
such as cardiac death, MI and repeat revascularisation.68-70 Meanwhile, a few studies 
have found no significant association between CRP and MACE.71,72 This might partially 
be due to the concentration of CRP levels found in these studies, as a meta-analysis by 
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the Emerging Risk Factors Collaboration found that the risk of adverse outcome 
increased with higher levels of CRP.64 In addition to its correlation with MACE or other 
clinical endpoints, CRP has been found to minimally improve existing clinical scores. 
Klingenberg et al. found that hsCRP produced a 4% improvement in risk stratification of 
all cause death or reinfarction at one year to the Global Registry of Acute Coronary 
Events (GRACE) score in ACS patients, while van Diepen et al. found no improvement 
when adding high sensitivity CRP (hsCRP) to clinical scores (composed of clinical risk 
factors alone, risk factors and interleukin-6, or risk factors and N-terminal pro-brain 
natriuretic peptide) in STEMI patients.73,74 Based on these studies, current guidelines 
from the European Society of Cardiology (ESC) state that the improvement C-reactive 
protein may add to a clinical score in the setting of NSTE-ACS is not clinically significant,4 
and that there is no evidence that routine use of CRP as a prognostic marker improves 
clinical outcomes for patients with chronic coronary syndromes.75 CRP for the prognosis 
of STEMI patients has not been mentioned in guidelines from the ESC.76 
 
1.2.3 Cytokines 
Cytokines are a wide variety of proteins that have a specific effect on how cells 
interact or communicate, and often have multiple actions.77 It is used as the overarching 
term for interleukins (cytokines made by a leukocyte that acts on another leukocyte), 
chemokines (cytokines with chemotactic actions), lymphokines (cytokines secreted by 
lymphocytes), monokines (cytokines secreted by monocytes and macrophages), and 
other families.77 The following sections provide a more detailed discussion of the 
interleukin family, chemokines and other cytokines commonly assessed in the ACS 
context.  
Most studies that investigate the prognostic utility of cytokines assume that 
abnormal levels of the cytokine of interest implies a suboptimal healing response in ACS 
patients. However, it is interesting to note that although the cytokines in Tables 1.1-1.3 
below have been proven to be involved in the inflammatory process in ACS via 
mechanistic studies, not all of them were found to be independent predictors of 
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adverse outcome. This suggests that there are gaps in understanding how cytokine 
levels indicate adverse outcome.  
1.2.3.1 Interleukins 
Interleukins are cytokines that were originally believed to be expressed by 
leukocytes alone.78 However, some interleukins have since been found to be released 
by other cells as well.78 Although most interleukins are named with the prefix, 
interleukin, not all are. For example, granulocyte macrophage colony stimulating factor 
(GM-CSF) is considered as a member of the IL-2 family.79 There are numerous 
interleukins that have been identified as being involved in the inflammatory response 
following ACS with pro- and/or anti-inflammatory actions. Interleukins may be released 
by the same cell, such as interleukin (IL)-6 and IL-8, which are both released by 
neutrophils as well as other cells.78,80 Some interleukins influence other cytokines or 
inflammatory markers along the same pathway. For example, IL-1β affects IL-6 
production, which in turn regulates CRP production from liver cells.81 There are mixed 
findings on the ability of individual cytokines to characterise excessive inflammation and 
act as predictors of adverse outcome. Some studies have demonstrated significant 
correlations between interleukins and adverse outcomes, with the most commonly 
studied interleukins being IL-6 and IL-10. Meanwhile, other studies found no significant 
associations. Table 1.1 summarises the actions of common interleukins that were 
studied in an ACS context and assessed for their prognostic utility in either clinical or 
functional studies.   
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Table 1.1   Interleukins commonly studied in ACS patients – Activation, function and prognostic utility 
Interleukin Stimulated by or released 
from 
Action in ACS context Prognostic utility for adverse outcomes  
IL-1α Dead cardiomyocytes.82 Stimulates apoptosis of cardiomyocytes and lengthens 
ischaemic injury.82 
Mouse model study showed IL-1α blockade was 
associated with reduced ischaemic reperfusion 
injury & subsequent LV dysfunction.83 
IL-1β Inflammasomes.84  Stimulates metalloproteinase activity, attracts 
inflammatory cells, stimulates pyroptosis in leukocytes 
and cardiac cells,84 and regulates IL-6 production 81; 
may have an anti-inflammatory role in cardiac 
repair.82 
Elevated levels were associated with poor LV 
remodelling,20 but not associated with MACE in 
another study.85 
IL-2 Th1 cells and natural killer 
cells.77 
Mediates apoptosis, activates growth and 
differentiation of T cells, stimulates activity of natural 
killer cells, & affects immunoglobulin production via B 
cells.78 
Not associated with MACE in two studies,29,86 but 
the LILACS trial is currently investigating low-dose 
IL-2 therapy in ACS patients.87 
GM-CSF TNFα.88 Has both pro-inflammatory and anti-inflammatory 
actions.79 Stimulates the activity, proliferation and 
differentiation of myeloid cells.79 
Elevated levels weakly associated with increased 
LVEDV.89 As a therapeutic agent, it improved LV 
dysfunction compared with placebo.90 However, 
no association with MACE was found in a study.29 
IL-4 Mainly by T cells but also 
eosinophils, basophils & 
mast cells.78 
Anti-inflammatory via activation of M2 macrophages 
for cardiac repair.78 
Correlated with left ventricular dysfunction.78 Not 
associated with MACE in two studies.29,85 
IL-6 Many cells, including 
macrophages, neutrophils & 
local cells at the site of 
injury.80 
Pro-inflammatory – regulates CRP production.81 Elevated levels associated with MACE and LV 
dysfunction in some studies.91-95 Not associated 
with MACE or surrogate markers of myocardial 
damage in others.20,29,96,97 
IL-7 Bone marrow stromal cells & 
epithelial cells.98 
Pro-inflammatory – regulates T cell activity, activates 
monocytes and natural killer cells, and can increase 
expression of some chemokines e.g. IL-8, MCP-1.99 
Elevated levels associated with predicting survival 
in AMI complicated by cardiogenic shock 100; not 
associated with MACE in another study.29 
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Interleukin Stimulated by or released 
from 
Action in ACS context Prognostic utility for adverse outcomes  
IL-8 (CXCL8) Many cells, including 
monocytes, neutrophils & 
fibroblasts.78 
Involved in ischaemic-reperfusion injury but also with 
angiogenesis post-AMI.78 
Elevated levels associated with MACE in some 
studies or degree of chronic heart damage.78,97,101 
No association found in one study.29 
IL-10 Many cells, including Th2 
cells, B cells, monocytes, 
eosinophils, dendritic cells, & 
mast cells.78 
Anti-inflammatory – blocks secretion of pro-
inflammatory cytokines and secretion of ROS.78 
Elevated levels85 or reduced levels32,102 associated 
with MACE in some studies. No association found 
in two studies.29,97 
IL-12 T cells.98 Activates NK cells.98 Elevated levels associated with MACE in one 
study.97 No associations found with MACE in 
some studies.29,74,85  
IL-17A Various T cell subsets 
(especially γδ T cells), 
macrophages, dendritic cells 
& natural killer cells.103 
Has pro-inflammatory actions, activating endothelial 
cells & recruiting leukocytes to ischaemic 
myocardium.103 
Reduced levels associated with MACE in one 
study,31 No association found in another study.29 
IL-18 Stimulated by NLRP3-
inflammasomes, released by 
macrophages & other cells.78 
Pro-inflammatory - stimulates release of IFNγ and 
production of other cytokines, involved in ischaemic-
reperfusion injury.78,99 
Elevated levels associated with MACE found in 
three studies.86,104,105 One study found IL-18 was 
not associated with MACE alone but was with IL-
18/IL-10 ratio.32 
IL-27 Mainly by myeloid cells.19 Has both pro-inflammatory and anti-inflammatory 
activities on T cell subsets and IL-10.19 
Elevated levels associated with MACE.19 
IL-33 Many cells, including those 
in vessels.106 
Helps stimulate anti-inflammatory activity via 
increasing soluble ST2 levels but also has pro-
inflammatory actions e.g. activating dendritic cells.82 
Elevated levels associated with MACE.107 
IL-37 Released by epithelial cells 
and macrophages.108 
Anti-inflammatory – suppresses pro-inflammatory 
cytokines e.g. TNFα.109 
Elevated levels associated with MACE.108 
This table summarises the activation of interleukins commonly investigated in ACS patients, their role in the ACS context, and evidence of 
their ability to predict adverse outcomes post-ACS. CXCL8 is the alternative name for IL-8. The full names of the abbreviations in this table can 




Chemokines are a family of cytokines that stimulate chemotaxis.77 There are 
several chemokines that have been studied in the ACS context. Table 1.2 summarises 
the actions of common chemokines that have been investigated in ACS patients and 
assessed for their prognostic utility, with the exception of IL-8, which was included in 
Table 1.1 with the other interleukins. There are some chemokines with dual properties 
and belong in two families of cytokines. The main cytokine in the ACS context that meets 
this criterion is IL-8. IL-8 is released from leukocytes like other interleukins, has a variety 
of functions like other interleukins (such as angiogenesis).78 It also has chemotactic 
functions, where it attracts neutrophils and lymphocytes.78 A similar observation can be 
made as with the interleukins in Table 1.1, where different studies have found opposing 
results in relation to MACE for certain chemokines. 
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Table 1.2   Chemokines commonly studied in ACS patients – Activation, function and prognostic utility 
Chemokine Stimulated by or released 
from 
Action in ACS context Prognostic utility for adverse outcomes  
IP-10 (CXCL10) Released from endothelial 
cells, macrophages and 
other cells.110 
Causes T cell polarisation into effector 
Th1/Th17, and subsequent release of pro-
inflammatory mediators via its receptor 
CXCR3.110 
Elevated levels associated with MACE and greater 
infarct size at 60 days in one study,101 while another 
study found that reduced levels were associated 
with MACE.74 No association with MACE found in 
two studies.29,97 
MCP-1 (CCL2) Many cells, especially 
monocytes & 
macrophages.111 
Causes more monocytes to travel to the 
cardiac injury site via its chemokine receptor, 
CCR2.111 
Elevated levels associated with MACE in two 
studies.97,112 No association with MACE found in one 
study.29 
MIP-1α (CCL3) Released by activated 
platelets and other immune 
cells.113,114 
Causes leukocytes to travel to the cardiac 
injury site via its receptors CCR1 and 
CCR5.111,113 
Elevated levels associated with MACE in one 
study,113 but not in two studies.29,101  Reduced levels 
associated with LV dysfunction in one study.115 
MIP-1β (CCL4) Released by various immune 
cells.114 
Causes monocytes to travel to the cardiac 
injury site via its receptor CCR5.111,116 
Elevated levels associated with in-hospital death in 
ACS patients with cardiogenic shock.116 No 
association with MACE or LV dysfunction.29,101 
RANTES (CCL5) Released by leukocytes, 
smooth muscle cells and 
activated platelets.113 
Causes monocytes, T cells & natural killer cells 
to travel to the cardiac injury site via its 
chemokine receptor, CCR5.117,118 
Elevated levels associated with MACE,113 but 
reduced levels associated with LV dysfunction or 
infarct size.101,115 No association with MACE found 
in two studies.29,97 
This table summarises the activation of chemokines commonly investigated in acute coronary syndrome (ACS) patients, their role in the ACS 
context, and evidence of their ability to predict adverse outcomes post-ACS. The bracketed names in the chemokine column are the alternative 
name for the respective chemokine. CCL - C-C motif chemokine ligand; CCR - C-C motif chemokine receptor; CXCL - C-X-C motif chemokine ligand; 
CXCR - C-X-C motif chemokine receptor; IP-10 - interferon gamma-induced protein-10; LV - left ventricular; MACE - major adverse cardiovascular 
events; MCP-1 - monocyte chemoattractant protein-1; MIP - macrophage inflammatory protein; RANTES - regulated upon activation, normal T 
cell expressed and secreted; Th(number) - T helper (number) cell.
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1.2.3.3 Remaining cytokines with important functions in ACS 
There are many additional cytokines outside of the interleukin or chemokine 
families that have important functions in inflammation and repair following ACS. 
Growth factors, such as fibroblast growth factors (FGF), granulocyte colony-stimulating 
factor (G-CSF) and vascular endothelial growth factor (VEGF), are one group of these 
cytokines. They support the growth of various cells essential for inflammation or repair, 
such as smooth muscle cells, new blood vessels, and neutrophil progenitor cells.119-121 
Tumour necrosis factor (TNF) is a “superfamily” of cytokines and ligands with a variety 
of functions, such as apoptosis and activation of the nuclear factor kappa B pathway.122 
TNFα is the main cytokine and CD40 ligand (CD40L) is the main ligand of the family that 
are frequently investigated in ACS patients. Selectins, such as P-selectin and E-selectin, 
help immune cells to adhere to the endothelial wall or sites of injury.123 Cell adhesion 
molecules are another family that facilitate movement of leukocytes areas where they 
are required.99,124 Vascular cell adhesion molecule-1 (VCAM-1) and intracellular 
adhesion molecule-1 (ICAM-1) are a few examples of this. Finally, interferons are a 
family of cytokines that help attract leukocytes to the site of injury and stimulate the 
production of chemokines and cell adhesion molecules.125 Interferon gamma (IFNγ) is 
the main interferon investigated in ACS patients. 
Table 1.3 summarises these remaining cytokines that are commonly investigated 
in the ACS context for their inflammatory actions and their ability to predict adverse 
outcomes. As with the previous two tables (Tables 1.1 and 1.2), there are mixed findings 
for several of the cytokines on their associations with adverse outcome in ACS patients.
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Table 1.3   Other cytokines commonly studied in ACS patients – Activation, function and prognostic utility 
Cytokine Family Stimulated by or 
released from 
Action in ACS context Prognostic utility for adverse outcomes 
bFGF (FGF-2) Growth factor Extracellular 
matrix.126 
Stimulates angiogenesis and 
mitosis of smooth muscle cells and 
endothelial cells.119 
No association found between bFGF and MACE 
in two studies.86,127 
CD40L TNF Mainly platelets.128 Activates CD40 molecule.128 Elevated sCD40L associated with death and re-
infarction in one study.129 No association with 
cardiac death in another study.130 
E-selectin Selectin IL-6 & IL-17.103,131 Involved in leukocyte adhesion to 
sites of injury and endothelial 
cells.123 
No association with MACE or long-term 
death.22,132,133 
FGF-23 Growth factor Extracellular 
matrix.126 
Stimulates angiogenesis and 
mitosis of smooth muscle cells and 
endothelial cells.119 
Elevated levels associated with MACE and long-
term death.22,134  




Acts in the bone marrow and 
controls the proliferation, growth 
and survival of neutrophil 
progenitor cells.120 
Elevated levels weakly associated with increased 
LV volume.89 No association with survival in AMI 
patients with cardiogenic shock.116 As a 
therapeutic agent, a Cochrane meta-analysis 
showed no association with outcomes compared 
with a placebo group.136  
ICAM-1 Immunoglobulin 
superfamily of cell 
adhesion molecules 
Various cells e.g. 
endothelial, 
fibroblasts.137 
Causes leukocytes to travel to 
inflammatory sites e.g. the cardiac 
injury site.124 
Elevated levels associated with death and CHF in 
one study,138 but not for MACE in two 
studies.133,137 
IFNy Interferon Stimulated by IL-18 & 
released by T cells.78 
Stimulates ICAM-1, VCAM-1 & 
selectins, & stimulates leukocyte 
adhesion.79 
Elevated levels associated with MACE74 & in-




Cytokine Family Stimulated by or 
released from 
Action in ACS context Prognostic utility for adverse outcomes 
P-selectin Selectin Endothelial cells and 
platelets.99 
Pro-inflammatory - involved in 
leukocyte adhesion, thrombus 
formation and formation of scar 
tissue.139 
No association with MACE.132,133 
PDGF Growth factor Platelets, 
macrophages, 
smooth muscle cells 
& endothelial cells.121 
Involved in wound repair – 
stimulates mitosis of fibroblasts & 
smooth muscle cells, and causes 
immune cells to travel to the site of 
injury.121 
No association with MACE.22,29,86 
TGF-β1 Growth factor Endothelial cells & 
macrophages.140 
Suppresses chemokine 
production.140 Involved in cardiac 
fibrosis & remodelling, 
angiogenesis, & cardiomyocyte 
apoptosis.78 
No association with LV dysfunction 
parameters.20 
TNFα TNF Mainly by 
macrophages but also 
released from other 
immune cells.78 
Involved in various actions e.g. 
dampens cardiac contractility 
causing reduced heart rate, 
angiogenesis, & apoptosis.78 
Elevated levels associated with death & CHF in 
one study.141 No association with MACE or 
parameters of LV dysfunction in three 
studies.74,142,143 
VCAM-1 Immunoglobulin 
superfamily of cell 
adhesion molecules 
Macrophages.99 Causes leukocytes to adhere to the 
endothelium and travel to the site 
of injury.99 
Elevated levels associated with MACE in one 
study,137 but no association with MACE in 
another study.133 
VEGF Growth factor Transcription factor 
hypoxia-induced 
factor-1.127 
Stimulates angiogenesis, & 
endothelial cell migration & 
production.121 
Elevated levels of VEGF, VEGF-A & VEGF-D were 
associated with MACE in two studies.22,127 
Another study found no association.86 
This table summarises the activation of cytokines commonly investigated in ACS patients, their role in the ACS context, and evidence of their 
ability to predict adverse outcomes post-ACS.  This table excludes the cytokines previously included in Tables 1.1 and 1.2. The full names of the 
abbreviations in this thesis can be found in the Abbreviations section.
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1.3 Anti-inflammatory trials 
With such an abundant number of inflammatory markers that have been found to 
be involved in ACS, it is no surprise that many clinical trials have been conducted to 
assess the use of anti-inflammatory therapies in ACS patients. If these therapies can 
minimise the risk of an overexpressed or prolonged inflammatory response, it may lead 
to improved healing and long-term outcomes for the patients. However, as discussed in 
section 1.1.2, a certain level of inflammation is required to promote the essential repair 
and healing following AMI. Therefore, a fine balancing act is needed to dampen 
exaggerated inflammatory responses without preventing critical responses for repair. It 
is unknown how much of the inflammation measured in ACS patients is pathological. 
Most randomised controlled trials (RCTs) assumed that the majority of inflammation in 
ACS patients was excessive and so did not incorporate measurement of inflammatory 
levels prior to commencing treatment or placebo. This has led to some landmark anti-
inflammatory trials having unfavourable outcomes, which is discussed in the sub-
sections below. There is also the inherent problem of the randomness in RCT study 
designs. Different RCTs have chosen to target one inflammatory molecule over another, 
and used different sampling times, patient populations, and/or endpoints.144-149 These 
factors contributed to the inconsistent findings between studies. However, this 
randomness in study design reflects our limited understanding of the inflammatory 
network.  
The following subsection titled “universal trials” present RCTs where all patients 
were treated with an anti-inflammatory therapy regardless of whether or not the 
patients had elevated inflammation prior to commencing the therapy. The other 
subsection has been labelled as “targeted trials”, where signs of elevated inflammation 




1.3.1 “Universal trials” 
Table 1.4 summarises the major RCTs on anti-inflammatory therapies that were 
given to MI patients regardless of inflammatory marker levels. A wide variety of anti-
inflammatory medications have been studied, ranging from drugs that inhibit individual 
inflammatory markers to drugs that target a number of inflammatory pathways. For 
eight trials, there was no statistically significant different in MACE between the 
treatment and control groups.144,145,147,150-154 Three RCTs investigated the use of 
colchicine in different MI populations, and all found a significant difference in MACE 
rates in the treatment group.148,155,156 Two of the studies found adverse events 
(pneumonia and myalgia) that might limit the feasibility of the drug being used in MI 
patients.148,156 The remaining study did not discuss adverse events in the paper.155 One 
study that investigated anakinra, an IL-1β inhibitor,149 and two studies that investigated 
a MMP inhibitor, doxycycline157 and PG-116800,144 found reduced rates of MACE in 
patients who were randomised to these treatments, with only non-serious adverse 
events being more frequent in most of these studies.144,149 Contrary to the positive 
finding from the Virginia Commonwealth University Anakinra Remodelling Trial 3 (VCU-
ART3), the Medical Research Council Interleukin-1 Antagonist Heart (MRC-ILA-Heart) 
study found increased MACE rates in patients treated with anakinra.146 
The differences in the associations with MACE above may partially be due to the 
different definitions of MACE that were used. MACE is a composite of adverse outcomes 
that are known to occur post-ACS. MACE may include some or all of the following: 
cardiac-related death, all-cause death, resuscitated cardiac arrest, non-fatal myocardial 
infarction, heart failure, stroke, stent thrombosis, significant cardiac arrhythmia, 
unplanned revascularisation, and unstable angina (that may or may not have required 
hospitalisation or invasive intervention). There is no gold standard definition of MACE 
that is used in clinical research and it is unknown which definition of MACE is most 
appropriate when investigating inflammatory biomarkers. However, MACE is commonly 
used in cardiovascular research because it increases the power to investigate outcomes 
with a smaller study population. This means that studies can be completed in a shorter 
timeframe with fewer resources, making it more cost-effective. This is why MACE is such 
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a popular endpoint. A disadvantage is that because using a composite score allows a 
smaller study population, studies are often not powered to investigate associations 
between inflammation and individual endpoints that make up MACE. This has led to a 
limited understanding of how inflammation may be associated with MACE. It is 
unknown how much of the pathological inflammation following ACS affects the adverse 
outcomes within MACE. 
A disadvantage of this approach is that these anti-inflammatory therapies dampen 
an aspect of the inflammatory response in all ACS patients. As explained in section 
1.1.2.2, some elevation of inflammatory markers is required for wound healing and 
repair to occur. In an era of increasing personalised medicine, this has led to the 
hypothesis that if only patients with excessively high levels of inflammation were 
treated, this would produce more favourable outcomes. There is also insufficient 
evidence to determine the optimal time to start patients on these anti-inflammatory 
therapies and how long they should be prescribed the medications for.
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Table 1.4   Summary of major clinical trials of anti-inflammatory therapies in MI patients 
Study 
(year) 
Population (n) Treatment; control Outcome; follow-up 
length 





presenting <12 hours 
from symptom onset 
(99) 
Anakinra for 14 days, 1-2 
times daily; placebo 
MACE (all-cause death & 
HF); 12 months 
Rate of death + HF was 
lower in the treatment 
group (9.4% vs 25.7%, p = 
0.046).  
Higher injection-site 
reactions in the treatment 
group (p = 0.016); no 
significant differences in 





<48 hours from 
symptom onset (182) 
Anakinra (IL-1β antagonist) 
for 14 days; placebo 
MACE (death, stroke & 
MI) at 30 days, 3 months 
& 1 year 
MACE rate was significantly 
higher in the treatment 
group at 1 year (p = 0.023) 
Higher injection-site 
reactions in the treatment 
group (p<0.0001); no 
significant differences in 





Colchicine for the duration 
of the study; placebo 
MACE (cardiac death, 
spontaneous MI, 





HR = 0.69, p<0.001 Higher rates of myalgia in 
the treatment group 
(p<0.05); non-significant 
higher rates of non-cardiac 




MI + PCI within 30 
days of recruitment 
(4745) 
Colchicine for the duration 
of the study; placebo 
MACE (cardiac death, 
resuscitated cardiac 
arrests, MI, stroke or 
urgent hospitalisation for 
angina leading to 
revascularisation); 
median 22.6 months 
HR = 0.77, p = 0.02 Higher rates of pneumonia, 
flatulence & nausea in the 





Population (n) Treatment; control Outcome; follow-up 
length 





Colchicine for the duration 
of the study; standard 
treatment 
MACE (ACS, out-of-
hospital cardiac arrest, 
ischaemic stroke); 
median 3 years 
HR = 0.33, p<0.001 Not discussed 
TIPTOP 
(2013)157 
STEMI patients with 
LVEF <40%, 
presenting <12 hours 
from symptom onset 
(110) 
Doxycycline (MMP 
inhibitor) for 7 days; 
standard care 
MACE (death, 
reinfarction, CHF or 
stroke); 6 months 
Rate was lower in the 
treatment group (10.9% vs 




STEMI + LVEF 15-
40%, measured 
48±24 hours from 
symptom onset (253) 
PG-116800 (MMP inhibitor) 
for 90 days; placebo 
MACE (death, 
reinfarction, cardiac 
arrest or major 
arrhythmia) and 
individual cardiac events; 
90 days 
Non-significant difference 
in MACE rate (p = 0.10). 
Major arrhythmia alone 
was significantly higher in 
the treatment group (p = 
0.03) 
Dyspepsia and joint stiffness 
were significantly more 
common in the treatment 
group (p<0.05); no 
significant differences in 




ACS, recruited within 
30 days of onset 
(13,026) 
Darapladib (sPLA2 
inhibitor) for the duration 
of the study; placebo 
MACE (cardiac death, 
non-fatal MI or 
myocardial ischaemia 
leading to urgent 
revascularisation); 
median 2.5 years 
HR = 1.00, p = 0.93 Higher complaint of odour of 
faeces, urine and/or skin and 
diarrhoea in the treatment 
group (p<0.05); no 
significant differences in 
serious adverse events 
VISTA-16 
(2014)145 
ACS, <96 hours from 
admission (5145) 
Varespladib (sPLA2 
inhibitor) for mean of 13.4 
weeks; placebo 
MACE (cardiac death, 
non-fatal MI, stroke or 
UA leading to urgent 
revascularisation); 16 
weeks 
HR = 1.35, p = 0.08 Higher discontinuation rate 
in treatment group (2.8% vs 
1.4%) & higher rate of 





Population (n) Treatment; control Outcome; follow-up 
length 





Type I AMI, <24 
hours for NSTEMI or 
<12 hours for STEMI 
(3503) 
Losampimod (p38 MAPK 
inhibitor) for 12 weeks; 
placebo 
MACE (cardiac death, 
non-fatal MI or recurrent 
ischaemia requiring 
urgent revascularisation); 
24 weeks after enrolment 
HR = 1.16, p = 0.24 Similar rates of adverse 
events between treatment 
and control groups 
APEX-AMI 
(2007)151 
STEMI patients who 
presented <6 hours 
of symptom onset 
(5745) 
Pexelizumab (Complement 
C5 monoclonal antibody), 
given as an IV bolus prior 
to PCI and a 24-hour 
infusion post-PCI; placebo 
All-cause mortality; 30 
days 
HR = 1.04, p = 0.78 Uncommon and similar rates 
between treatment and 
control groups for both 




STEMI + PCI, 
presenting <6 hours 
before symptom 
onset (960) 
Pexelizumab, either as IV 
bolus or IV bolus + IV 
infusion for 20 hours; 
placebo 
MACE (death, new or 
worsened HF, shock or 
stroke); 90 days 
Non-significant differences 
in rates between the 3 
groups (p>0.05) 
Uncommon and similar rates 
between treatment and 
control groups for both 




STEMI + fibrinolysis, 
presenting <6 hours 
before symptom 
onset (943) 
Pexelizumab, either as IV 
bolus or IV bolus + IV 
infusion for 20 hours; 
placebo 
MACE (death, new or 
worsened HF, shock or 
stroke); 90 days 
Non-significant differences 
in rates between the 3 
groups (p>0.05) 
Uncommon and similar rates 
between treatment and 
control groups for both 










rhuMAb CD18 (CD18 
recombinant monoclonal 
antibody) at 0.5mg/kg or 
2.0mg/kg IV bolus; placebo 
MACE (death, recurrent 
MI, serious/severe HF); 
30 days 
No significant differences 
between the 3 groups 
(p>0.05) 
Similar rates of adverse 
events between treatment 
and control groups 
This table summarises the major anti-inflammatory therapy trials in acute coronary syndrome or stable MI patients where elevated 
inflammatory levels was not a study criteria. The results included were MACE outcomes if they were assessed. Otherwise, a hard clinical endpoint 
was included. The full names of the abbreviations in this table can be found in the Abbreviations section.
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1.3.2  “Targeted trials” 
Table 1.5 summarises the major trials on anti-inflammatory therapies that were 
given to stable MI patients with signs of elevated inflammation. Only two RCTs had tried 
to stratify their study population to patients with elevated levels of inflammation.  The 
Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) investigators 
used a direct measure of inflammation and only included MI patients with high CRP 
levels.158 Meanwhile, in the Cardiovascular Inflammation Reduction Trial (CIRT), indirect 
criteria of elevated inflammation were used, where only patients who also had the 
inflammatory conditions of diabetes or metabolic syndrome were included.159 CANTOS 
found that canakinumab, an anti-IL-1β monoclonal antibody, reduced the incidence of 
MACE,158 but in the CIRT study, methotrexate was of no benefit.159 Both trials found 
that patients in the treatment group had significantly greater rates of serious adverse 
events.158,159  
It is interesting that the relationship between inflammatory cytokines and MACE 
do not always correlate with the relationship between anti-cytokine therapies and 
MACE. In Tables 1.4 and 1.5, anakinra and canakinumab, two IL-1β antagonists, were 
found to have reduced the incidence of MACE in two out of three clinical trials.146,149,158 
However, Table 1.1 shows that although one study found that elevated IL-1β 
concentrations were associated with impaired LV remodelling,20 another study found it 
was not associated with MACE.85 This may reflect the differences in trial designs or the 
complexities of the inflammatory network. There is insufficient knowledge surrounding 
pathological inflammation in ACS patients and how it may lead to suboptimal 
myocardial repair or other adverse outcomes. A greater understanding of the 
inflammatory biomarkers and the action of anti-inflammatory therapies in the ACS 
context is required. 
It is important to note that Ridker et al., who were the investigators for both 
CANTOS and CIRT, used different definitions of MACE in the two trials. The definition of 
MACE used in CANTOS was a composite of cardiac death, recurrent MI or stroke, where 
they found that MACE rates were lower in patients who were prescribed 150mg of 
canakinumab.158 CIRT initially used the same definition of MACE that CANTOS had 
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used.159 However, in an attempt to increase the power of the study, UA leading to 
hospitalisation and urgent revascularisation were added to the MACE definition.159 
Unfortunately methotrexate did not affect MACE rates, even with a broader definition 
of MACE.159 This again reflects our poor understanding of how pathological 
inflammation may contribute to adverse outcomes. However, CANTOS and CIRT used 
stable MI patients as their study participants,158,159 so it might be that the adverse 
events seen in these patients were partially be driven by inflammatory processes that 
were not in response to the initial AMI. 
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Table 1.5   Summary of major clinical trials of anti-inflammatory therapies in MI patients with elevated inflammation 
Study (year) Population (n) Treatment Control Primary outcome; follow-
up length 
Results Adverse effects 
CANTOS 
(2017)158 






300mg, for the 
duration of 
the study 
Placebo First MACE (composite of 
non-fatal MI, non-fatal 
stroke or cardiac death); 
median follow up 3.7 years 
Only the group on 
150mg of canakinumab 
had significantly lower 
MACE than the placebo 
group (HR = 0.85, p = 
0.0208) 
Significantly higher rates 
of death due to infection 
or sepsis, 
pseudomembranous 
colitis, leukopenia and 
thrombocytopenia, but 
lower rates of cancer and 




MI or multivessel 
coronary disease 










First MACE (composite of 
cardiac death, non-fatal MI, 
stroke & UA leading to 
hospitalisation & urgent 
revascularisation); median 
follow-up 2.3 years 
HR = 0.96, p = 0.67 Significantly higher rates 
of infection or 
infestation, mouth sores, 
oral pain, unintended 
weight loss, modest 
leukopenia, elevated ALT 
and AST, & cancer 
incidence in the 
treatment group 
(p<0.05) 
This table displays the major anti-inflammatory therapy trials in acute coronary syndrome or stable MI patients where a study criterion that 
aimed to stratify for patients with higher levels of inflammation was included. Outcomes included are only the primary outcome if a hard clinical 
endpoint was the primary outcome assessed, or a secondary outcome that assessed a hard clinical endpoint.  
ALT - alanine transaminase; AST - aspartate aminotransferase; CANTOS - Canakinumab Anti-Inflammatory Thrombosis Outcome Study; CIRT 
- Cardiovascular Inflammation Reduction Trial; CRP - C-reactive protein; HR - hazard ratio; MACE - major adverse cardiovascular events; MI - 
myocardial infarction; UA - unstable angina.
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1.4 ACS Management 
This section will present an overview of the clinical context in which the research 
presented in this thesis has occurred as well as the common cardiovascular medications 
prescribed to ACS patients, several of which modulate inflammation.  
 
1.4.1 Clinical context of research 
This research has largely been situated at Wellington Regional Hospital, New 
Zealand, which acts as a tertiary centre that accepts referrals for coronary angiography 
and/or PCI from Whanganui, Hawkes Bay, Palmerston North, Wairarapa, and Hutt 
Hospitals. The clinical pathways for patients differ depending on which District Health 
Board region they live in and what type of ACS they are diagnosed with (STEMI, NSTEMI 
or UA).  
Wellington Regional Hospital follows the ESC guidelines. Although the ESC 
guidelines for NSTE-ACS were recently updated in August 2020,4 all patient recruitment 
for the studies in this thesis occurred between 2012 and 2018. Therefore, clinical 
management based on the 2015 and 2011 ESC NSTE-ACS guidelines, and the 2017 and 
2012 ESC STEMI guidelines will be discussed below.67,76,160,161 The Cardiac Society of 
Australia and New Zealand (CSANZ) also published their own guidelines for STEMI 
patients in 2013 and NSTE-ACS patients in 2012.162,163 Different District Health Boards 
may also have their own guidelines. The NZ-specific guidelines are usually based on the 
ESC guidelines, but any differences in guidelines are highlighted in the paragraphs 
below. 
According to the 2017 ESC STEMI guidelines,76  patients who have been confirmed 
to have STEMI from their ECG results and cardiac troponin levels require reperfusion 
management. The gold standard treatment is coronary angiography and immediate 
reperfusion via primary PCI, but this is only recommended for patients who are able to 
arrive at Wellington Regional Hospital and receive PCI within 120 minutes of initial 
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hospital presentation. This is the main reperfusion strategy for STEMI patients from the 
Greater Wellington City and the Hutt Valley.164 For STEMI patients who are unable to 
arrive at Wellington Regional Hospital within 120 minutes i.e. those from Masterton, 
Palmerston North, Hawkes Bay and Whanganui Hospitals, the ESC guidelines suggest 
they are reperfused via fibrinolysis first, and then be transferred for angiography and 
PCI. If at 60 to 90 minutes, there is less than 50% resolution of the ST elevation seen at 
diagnosis, or new ST depression is present, it is recommended that rescue PCI is 
conducted as it signifies fibrinolysis was not successful.76 However, if fibrinolysis is 
successful, then coronary angiography may be considered between two and 24 hours 
post-fibrinolysis.76 The 2012 ESC STEMI guidelines and the 2013 CSANZ guidelines are 
largely identical to the 2017 guidelines.76,161,163 Some exceptions are that both the 2012 
and 2013 guidelines suggest that rescue PCI be considered at 60 minutes (not up to 90 
minutes) post-fibrinolysis and that routine coronary angiography following successful 
fibrinolysis may occur from three to 24 hours (instead of two to 24 hours).76,161,163  
According to the 2015 ESC NSTE-ACS guidelines, patients who are confirmed to 
have NSTE-ACS should have an acute risk assessment to help inform the optimal 
management strategy.67 Risk assessment is conducted using a combination of the 
clinical presentation, troponin levels, ECG, GRACE risk score (which is a score used to 
assess risk of mortality at 30 days or 12 months162), bleeding risk using a score such as 
the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse 
Outcomes With Early Implementation of the American College of Cardiology 
(ACC)/American Heart Association (AHA) Guidelines (CRUSADE) risk score, and other 
considerations such as the patient’s frailty and cognitive status.67 There are four risk 
categories: very high risk, high risk, intermediate risk, and low risk.67 Patients are 
considered at very high risk if they have recurrent or persistent angina and either acute 
heart failure, life-threatening arrhythmia, haemodynamic instability, cardiogenic shock, 
ECG changes that are significant and recurrent or demonstrate occlusion of the left 
circumflex artery, or mechanical complications of MI.67 These patients should receive 
invasive management (coronary angiography with or without PCI) within two hours of 
hospital admission or immediately be transferred to a hospital that can conduct PCI, 
such as Wellington Regional Hospital.67 High risk patients are defined as those with 
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significant changes in troponin levels, ECG changes evident of ischaemia and a GRACE 
score above 140.67 It is recommended that these patients receive invasive management 
within 24 hours and should be transferred to Wellington Hospital on the same day they 
are admitted to the first hospital they presented to.67 Intermediate risk patients are 
those who either have diabetes, renal insufficiency (with an estimated glomerular 
filtration rate, eGFR, of below 60), a left ventricular ejection fraction below 40%, a 
previous PCI or coronary artery bypass graft (CABG), a GRACE risk score of between 109 
and 140, or early post-infarction chest pain.67 The ESC guidelines recommend that 
intermediate risk patients receive angiography within 72 hours of initial hospital 
admission,67 which gives adequate time for patients in the lower North Island to be 
transferred to Wellington Hospital. The remaining NSTE-ACS patients are considered 
low risk and non-invasive medical management may be indicated.67 Additionally, a non-
invasive stress test, ideally with cardiac imaging, should be conducted to elucidate if 
inducible ischaemia is present, before considering angiography with or without PCI.67 
The 2012 CSANZ and 2011 ESC guidelines for NSTE-ACS are similar to the 2015 ESC 
guidelines, with the exceptions that mechanical complications of MI is not considered 
as a factor for very high risk patients and that there is no detailed criteria list for 
intermediate risk.160,162 In addition, imaging along with the non-invasive test for low risk 
patients is not mentioned in the 2012 CSANZ guidelines.162 
The invasive management recommendations described in the previous two 
paragraphs highlight the fact that ACS patients referred to Wellington Hospital may 
present several days following symptom onset. This increases the variance of the time 
ACS patients present to Wellington Hospital following symptom onset. Another layer of 
complexity when considering study design is that some of the referring hospitals, such 
as Hawkes Bay Hospital, have the ability to perform coronary angiographies but are 
unable to conduct PCIs. This may further delay patients presenting to Wellington 




1.4.2 Medications commonly prescribed for ACS management 
In terms of adjunctive management recommendations, symptomatic relief 
medications such as sublingual glyceryl trinitrate and/or intravenous opioids for pain 
relief, anti-emetics, and oxygen supplementation in patients who are in shock or have 
low oxygen saturation levels (below 90% in the 2017 ESC STEMI guidelines or below 92% 
in the CSANZ 2013 STEMI and 2012 NSTE-ACS guidelines), may be given to ACS patients 
at presentation.67,76,162,163 A loading dose of aspirin (300mg) should be prescribed in the 
ambulance or in the Emergency Department, and a P2Y12 receptor antagonist (either 
ticagrelor, clopidogrel or prasugrel) is recommended prior to angiography.67,76,162,163 
Heparin (either low molecular weight heparin or unfractionated heparin) is often 
prescribed during PCI to prevent clot formation and embolisation.67,76,162,163 A statin, 
beta-blocker or calcium channel blocker, angiotensin converting enzyme inhibitor or 
angiotensin receptor blocker, and/or diuretic are often prescribed during this acute 
admission for long-term management.67,76,162,163 Some of these medications affect the 
immune system. The most relevant medications to immune modulation are discussed 
below. 
1.4.2.1 Statins 
Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors that produce lipid-lowering effects by inhibiting the conversion of HMG-CoA 
reductase to mevalonic acid, a cholesterol precursor, in the liver.15,165 This causes a 
reduction of cholesterol in the hepatocytes, which leads to cholesterol in the circulation 
to return to the liver, and an overall decrease in plasma lipid levels.165 Its actions have 
been proven in a meta-analysis of RCTs to relatively lower the risk of all-cause death by 
12% per mmol/L decrease in LDL cholesterol, and cardiac-related mortality by 19% per 
mmol/L in patients with coronary artery disease, hypertension or diabetes.166 RCTs 
investigating the effects of statins on inflammation have found that they reduced levels 
of CRP and that they improved outcomes in patients with elevated levels of CRP, 
independent of lipid level.167-170 Statins have pleiotropic effects on the inflammatory 
process, such as inhibiting ROS and blocking MMP release.171 In addition, studies have 
found that statin therapy was associated with a reduction of the necrotic core size and 
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stabilisation of the thin fibrous cap covering the atheroma.172,173 The 2017 ESC 
guidelines for STEMI and 2020 ESC guidelines for NSTE-ACS recommend early 
administration of statins to all ACS patients regardless of cholesterol levels, as long as 
there are no contraindications for the patients.4,76 
1.4.2.2 Aspirin 
Aspirin, or acetyl salicylic acid, is an antiplatelet agent that inhibits platelet 
activation through the blockage of cyclo-oxygenase-1, preventing the production of 
thromboxane A2 (TXA2), a molecule that stimulates platelet activation and 
aggregation.174 This helps to reduce clot formation in coronary vessels of patients at risk 
of ACS.174 Platelets are also involved with inflammation in ACS. They release 
inflammatory mediators such as ROS, plasma activating factor, and serotonin.175 These 
molecules contribute to increased damage during ACS and increased infarct size.175 
Previous studies have confirmed this by showing that a reduction in levels of 
inflammatory markers occurred in ACS patients who were prescribed aspirin.176,177 
Some functional studies have shown that platelet interaction with neutrophils is 
associated with worsened cardiac functions.175 Therefore, prescribing antiplatelet 
agents such as aspirin in ACS patients can help to reduce the excess inflammation that 
leads to damage rather than healing.  
1.4.2.3 P2Y12 receptor antagonists 
P2Y12 receptor antagonists are another class of antiplatelet agents.178 They inhibit 
the P2Y12 receptor, which prevents adenosine diphosphate from activating the platelet, 
inhibiting degranulation and aggregation.178 There are two sub-categories of P2Y12 
receptor antagonists – thienopyridines, such as clopidogrel and prasugrel, and non-
thienopyridines, such as ticagrelor.178 RCTs have shown that prescribing dual 
antiplatelet therapy, aspirin and a P2Y12 receptor antagonist, results in a greater 




Heparin binds to the enzyme inhibitor, antithrombin III, causing a conformational 
change that results in its activation, accelerating the inhibition of the target enzymes, 
Factors Xa and IXa.182 There are two types of heparin that may be used in the treatment 
of an ACS or during PCI to treat or prevent clot formation – unfractionated heparin 
(UFH) and low molecular weight heparin (LMWH). Treatment with UFH and LMWH has 
been shown to improve outcomes in ACS and is recommended by current 
guidelines.4,76,183 Heparin may also modulate the inflammatory response following ACS. 
A study by Nasiripour et al. found that patients who were administered UFH had 
decreased levels of CRP than at baseline, while patients who were administered 
enoxaparin had lower levels of IL-6 and CRP than at baseline.184    
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1.5 Overall aims 
As shown in the previous sections, excessive inflammation following ACS is 
pathological and may lead to adverse outcomes. This concept has been summarised in 
Figure 1.3. Anti-inflammatory therapy is a possible option for minimising the effects of 
pathological inflammation. However, we still have a poor understanding of pathological 
inflammation, as shown by the mixed success of anti-inflammatory trials. There are a 
multitude of inflammatory markers involved in ACS that may characterise pathological 
inflammation and may be promising therapeutic targets. When investigating the 
prognostic utility of individual biomarkers, there are often mixed findings, as highlighted 
in section 1.2. This is because the knowledge surrounding how pathological 
inflammation may be characterised is not well understood. Further information is 
required to determine which biomarkers are most informative for indicating a 
suboptimal inflammatory response post-ACS. Theoretically, inflammatory biomarkers 
would be the most promising targets for either informing which patients would benefit 




Figure 1.3  Simplified relationship between inflammatory response post-ACS and MACE 
The figure summarises how a “healthy” inflammatory response post-acute coronary syndrome (ACS) will lead to minimal infarct expansion, 
whereas excess or “pathological” inflammation may lead to major adverse cardiovascular events (MACE). Characterising “pathological” 




Therefore, the overall aim of this thesis is to explore and characterise inflammatory 
biomarkers in ACS patients to determine how they may provide information on 
pathological inflammation and may predict adverse outcomes. The specific hypotheses 
and aims for the studies contained in this thesis are stated below: 
We firstly hypothesised that WBC subtypes, the markers which are routinely 
measured in clinical practice, could be used to predict MACE in AMI patients and that 
circadian rhythm of WBC levels might affect MACE risk. This hypothesis was explored in 
Chapter 2 with the following aims: 
1. To investigate the extent to which WBC subtypes can predict MACE in AMI 
patients. 
2. To determine the relationship between peak levels of WBC subtypes, symptom 
onset time and risk of MACE. 
Our second hypothesis was that CRP, IL-6 and tumour necrosis factor alpha (TNFα) 
could predict MACE in AMI patients, either individually or when added together, and 
that collectively, they might provide further information on a patient’s inflammatory 
state. The study in Chapter 3 explored this hypothesis with the following aims: 
3. To determine whether using multiple markers (CRP, IL-6 and TNFα) allow for 
better separation of cases (patients with MACE) from controls. 
4. To investigate the relationships between the three markers – whether they 
have a high degree of correlation that allows us to use just one marker to 
represent them or whether they are all distinct. 
5. To examine whether a combined multi-marker approach alters our 
classification of patients’ position on an inflammatory spectrum. 
By conducting a systematic search of the literature, we hypothesised that previous 
studies would show that a combined cytokine approach was superior to an individual 
approach for predicting MACE. This hypothesis led to the systematic review in Chapter 
4 with the following aim: 
42 
 
6. To investigate whether multi-marker approaches for predicting long-term 
MACE is superior to single-marker approaches in patients with ACS. 
Our fourth hypothesis was that investigating the dynamic changes in cytokine 
concentrations over time would allow us to determine an optimal sampling time that 
reflected pathological inflammation, and to better characterise inflammation in ACS. 
We investigated this hypothesis in Chapter 5 with the following aims: 
7. To investigate the changes in cytokine concentrations within patients over 
time. 
8. To determine an optimal sampling timepoint within the acute phase.  
9. To explore any variation in dynamic changes in cytokine concentrations 
between patients. 
Our final hypothesis was that using a mathematical technique (principal 
component analysis) that could combine non-independent variables would allow us to 
create a combined cytokine score that was predictive of MACE. This hypothesis was 
explored in Chapters 6 and 7 with the following aims: 
10. To create a principal component analysis-derived score composed of cytokines 
associated with inflammation in AMI patients, and assess its association with 
major adverse cardiovascular events (MACE). 
11. To measure the association between clinical factors and the cytokine score, to 
assess how much additional information a patient’s inflammatory state might 
contribute beyond well-known risk factors. 




1.6 Publications from this thesis 
1.6.1 Full-text publications 
Three of these studies described in Chapters 2, 4, 6 and 7 were published as 
original, full-text articles in international, peer-reviewed journals.185-187 Below are the 
details surrounding the publications: 
Chapter 2: 
Kristono GA, Holley AS, Harding SA, Larsen PD. White blood cell subtypes as 
predictors of adverse cardiac events. Coron Artery Dis. 2020 Aug;31(5):446-450. 
https://doi.org/10.1097/mca.0000000000000860. Copyright Wolters Kluwer Health, 
Inc. 
Authors’ contributions: Gisela Kristono co-selected the cohort, collected some of 
the data, conducted the statistical analyses, wrote the first draft of the manuscript and 
contributed to subsequent manuscript edits. The co-authors supervised Gisela Kristono, 
co-selected the cohort, collected some of the data and/or edited the manuscript. 
Permission to include the published work in this thesis was granted by the 
Copyright Clearance Center’s Rightslink service that the publisher, Wolters Kluwer 
Health, partners with.  
Chapter 4: 
Kristono GA, Holley AS, Lakshman P, Brunton-O’Sullivan MM, Harding SA, Larsen 
PD. Association between inflammatory cytokines and long-term adverse outcomes in 
acute coronary syndromes: A systematic review. Heliyon. 2020 Apr;6(4):e03704. 
https://doi.org/10.1016/j.heliyon.2020.e03704. Copyright Elsevier. 
Authors’ contributions: Gisela Kristono co-created the review question, conducted 
the systematic search, assessed all potential studies for their eligibility, extracted the 
data, co-assessed the quality of each study included in the review, conducted the 
statistical analysis, wrote the first draft of the manuscript and contributed to 
subsequent manuscript edits. The co-authors co-created the review question, co-
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assessed the quality of the studies included in the review, supervised Gisela Kristono 
and/or edited the manuscript. 
Permission to include the published work in this thesis was granted by the 
publisher, Elsevier. 
Chapters 6 and 7: 
Kristono GA, Holley AS, Hally, KE, Brunton-O’Sullivan MM, Shi B, Harding SA, Larsen 
PD. An IL-6-IL-8 score derived from principal component analysis is predictive of adverse 
outcome in acute myocardial infarction. Cytokine: X. 2020 Dec;2(4):100037.  
https://doi.org/10.1016/j.cytox.2020.100037. Copyright Elsevier. 
Authors’ contributions: Gisela Kristono co-selected the cohort, conducted the 
majority of the enzyme-linked immunosorbent assay (ELISA) experiments, conducted 
the statistical analyses, wrote the first draft of the manuscript and contributed to 
subsequent manuscript edits. The co-authors co-selected the cohort, conducted the 
cytometric bead array experiments and some of the ELISA experiments, supervised 
Gisela Kristono and/or edited the manuscript. 
Permission to include the published work in this thesis was granted by the 
publisher, Elsevier. 
 
1.6.2 Conference abstracts and presentations 
Three of the studies described in Chapters 2, 4, and 5 were accepted for 
presentation at conferences, and the conference abstracts were published in the 
international, peer-reviewed journal, Heart, Lung and Circulation.188-190 Permission was 
granted by the publisher, Elsevier, to include the published works in this thesis. Below 
are the details surrounding the publications: 
Chapter 2: 
Kristono G, Holley A, Sasse A, Harding S, Larsen P. Neutrophil-lymphocyte ratio 
as a prognostic marker in acute myocardial infarction. Heart Lung Circ. 2018 
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Jan;27(S2):S332-S333. Paper accepted for a mini-oral presentation at the 66th Annual 
Scientific Meeting of the CSANZ; 2018 Aug 2-5; Brisbane, QLD, AU. 
https://doi.org/10.1016/j.hlc.2018.06.645. Copyright Elsevier. 
Authors’ contributions: Gisela Kristono co-selected the cohort, collected some of 
the data, conducted the statistical analyses, wrote the first draft of the abstract, 
contributed to subsequent abstract edits and presented the work at the conference. 
The co-authors supervised Gisela Kristono, co-selected the cohort, collected some of 
the data and/or edited the abstract. 
Chapter 4: 
Kristono G, Holley A, Lakshman P, Brunton-O’Sullivan M, Harding S, Larsen P. A 
systematic review of inflammatory cytokines as predictors of long-term outcomes in 
acute coronary syndromes. Heart Lung Circ. 2019 Jan;27(S1):S19. Paper accepted for a 
combined oral-poster presentation at the 2019 Cardiac Society of Australia and New 
Zealand (CSANZ) New Zealand Annual Scientific Meeting; 2019 Jun 13-15; Wellington, 
NZ. https://doi.org/10.1016/j.hlc.2019.05.051. Copyright Elsevier. 
Authors’ contributions: Gisela Kristono co-created the review question, conducted 
the systematic search, assessed all potential studies for their eligibility, extracted the 
data, co-assessed the quality of each study included in the review, conducted the 
statistical analysis, wrote the first draft of the abstract, contributed to subsequent 
abstract edits and presented the work at the conference. The co-authors co-created the 
review question, co-assessed the quality of the studies included in the review, 
supervised Gisela Kristono and/or edited the abstract. 
Chapter 5: 
Kristono G, Holley A, Hally K, Brunton-O’Sullivan M, Harding S, Larsen P. Trends 
in inflammatory cytokine levels over acute and chronic phases of acute myocardial 
infarction. Heart Lung Circ. 2020 Jan;27(S2):S293. Paper accepted for an electronic 
poster at the 68th Annual Scientific Meeting of the CSANZ (Virtual); 2020 Dec 11-13; 
Gold Coast, QLD, AU. https://doi.org/10.1016/j.hlc.2020.09.574. Copyright Elsevier.  
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Authors’ contributions: Gisela Kristono applied for ethical approval of this study, 
helped to recruit patients and collect samples, selected the cohort, conducted the ELISA 
experiments, conducted the statistical analyses, wrote the first draft of the abstract and 
contributed to subsequent abstract edits. The co-authors helped to recruit patients and 
collect samples, conducted the cytometric bead array experiments, supervised Gisela 
Kristono and/or edited the abstract.
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As discussed in Chapter 1, inflammation plays a vital role in healing and repair after 
AMI, but also contributes towards adverse effects, which can lead to poor myocardial 
function and impaired ventricular remodelling.41 Research into using inflammatory 
markers as predictors of MACE is ongoing, with WBC subtypes being a group of these 
markers.191 Previous studies have found neutrophil, lymphocyte and monocyte counts, 
and neutrophil-to-lymphocyte ratio (NLR) to be associated with MACE.26,47,50 More 
recently, a few studies investigated the prognostic significance of lymphocyte-to-
monocyte ratio (LMR) in patients with ST elevation myocardial infarction and coronary 
artery disease, with promising results.54,55,192 Tests to measure levels of WBC subtypes 
are routinely conducted in clinical practice, so using NLR and LMR from readily-available 
results would be convenient for predicting MACE. 
It is well established that the timing of MI shows a circadian variation, with the 
peak rates of symptom onset occurring between 6am and 10am,193 and some studies 
suggest that these morning MIs are associated with worse clinical outcomes.194-196 
Neutrophil levels and Ly6Chigh monocyte counts have previously been shown by Schloss 
et al. to have diurnal variation in animal models.197,198 In these models, infiltration of 
the infarct by neutrophils and monocytes was greater when the infarction occurred at 
the time neutrophil count was at its diurnal peak, resulting in a greater infarct 
area.197,198 It has therefore been suggested that a circadian variation in neutrophil levels 
may contribute to an increased infarct size. To explore this theory, we examined WBC 
levels by time of symptom onset.   
Therefore, the primary aim of this study is to investigate the extent to which WBC 
subtypes can predict MACE in AMI patients. The secondary aim is to determine the 





2.2.1 Study population 
The population for this observational cohort study was selected from an existing 
biobank of 1340 AMI patients recruited for the Outcomes and Platelet Reactivity in 
Acute Coronary Syndrome (OPRA) study. These patients were admitted to Wellington 
Regional Hospital between January 2012 and February 2016 with a diagnosis of ACS and 
a planned invasive approach (coronary angiography with or without percutaneous 
coronary intervention). ACS was defined using the third universal definition of ACS, i.e. 
symptoms of myocardial ischaemia lasting for at least ten minutes with either elevated 
troponin levels or ECG results showing ≥1mm of ST-segment deviation (STEMI) or T-
wave inversion (NSTEMI) in at least two contiguous leads.199 All patients gave voluntary 
written consents for their participation in this study and the study was approved by the 
Lower South Ethics Committee (LRS/11/09/035). 
From this biobank, patients were selected for the study if records of their symptom 
onset and clinical results for their full blood count prior to angiography were able to be 
obtained. Follow-up was conducted by telephone calls at 12 months, review of clinical 
records, and where necessary, contacting participants’ general practitioners. Outcomes 
were defined as major adverse cardiovascular event (MACE, defined hierarchically as 
all-cause death, non-fatal MI, non-fatal ischaemic cerebrovascular accident, stent 
thrombosis, new or worsened heart failure (HF) leading to hospital admission, and 
unplanned revascularisation) at one year. The definitions used for all-cause death, 
recurrent MI, HF and unplanned revascularisation (either PCI or CABG) were obtained 
from the 2013 American College of Cardiology Foundation (ACCF)/American Heart 
Association (AHA) Clinical Data Standards.200 Stent thrombosis was defined according 
to the Academic Research Consortium criteria and ischaemic cerebrovascular accident 




2.2.2 Data collection 
Patients’ physical notes and hospital electronic records were used to collect 
demographic data, time of symptom onset, time of blood collection and WBC subtype 
counts (neutrophil, lymphocyte and monocyte counts) obtained from the earliest full 
blood count record after symptom onset that we could access. Table 2.1 outlines the 
definitions of the clinical risk factors used in this study.200 Time of symptom onset was 
divided into quartiles, with quartile one (Q1) being from midnight to 5:59am, quartile 
two (Q2) from 6:00am to 11:59am, quartile three (Q3) from midday to 5:59pm, and 
quartile four (Q4) from 6:00pm to 11:59pm. Time of blood collection was also divided 
into quartiles in the same way. NLR and LMR were calculated from the relevant subtypes 
of the WBC results. 
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Table 2.1   Definitions of clinical risk factors 
Risk factor Definition 
Prior MI 
At least one recorded previous MI between birth and current 
presentation.200 The definition of MI should be based on the third 
universal definition of MI.199 
HTN 
Having either a history of HTN that has been managed with 
medications, diet and/or exercise; a documented diagnosis of HTN; or 
a current prescription for anti-hypertensive medication.200  
Diabetes 
A previous history of diabetes that has been diagnosed and/or 
treated by a health professional.200  
Dyslipidaemia 
A previous history of dyslipidaemia that has been diagnosed and/or 
treated by a medical doctor.200 
Family history of 
CAD 
If any direct blood-related family members (parents, siblings or 
children) have had cardiac-related conditions (angina, AMI, sudden 
death with unknown cause, PCI or CABG) prematurely (<55 years old 
for males and <65 years old for females).200 
HF (Killip Class 2) 
Documentation of HF prior to current admission that meets the 
criteria for Killip Class 2 (rales heard in over 50% of the lung fields or 
presence of an S3 heart sound heard on auscultation).200 
AF Whether AF was present within two weeks prior to admission.200 
Stroke/TIA 
A previous history of stroke or TIA, defined as an acute episode of 
neurological dysfunction due to haemorrhagic or ischaemic injury of 
the brain, spinal cord or retinal vasculature.200 
Current smoker Current regular use of tobacco products.200 
Former smoker Previous regular use of tobacco products,200 where they have stopped 
regularly using the products for at least 28 days.202 
Never smoked Has never regularly used tobacco products in the patient’s lifetime.200 
This table displays the definitions of clinical risk factors used to identify study 
participants with or without these factors, based on the 2013 ACCF/AHA Clinical Data 
Standards and the Ministry of Health, New Zealand.200,202  
AF - atrial fibrillation; CABG - coronary artery bypass graft; CAD - coronary artery 
disease; HF - heart failure; HTN - hypertension; MI - myocardial infarction; PCI - 
percutaneous coronary intervention; TIA - transient ischaemic attack. 
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2.2.3 Statistical analysis 
Tests for normality (the D’Agostino and Pearson, and Shapiro-Wilk normality tests) 
were conducted on all variables prior to statistical analysis to determine if parametric 
or non-parametric tests should be used. This was conducted with GraphPad Prism 
software v.7 (GraphPad Software Inc.; CA, USA). Baseline demographic data was 
recorded as median (with 25th and 75th percentiles) for non-parametric, continuous 
variables and as frequencies and percentages for categorical variables. A non-
parametric independent-samples median test was used to compare the medians for 
continuous variables between those with and without MACE, while a Chi-square test 
was used to compare the categorical variables.  
A one-sample Chi-square test was used to compare the proportion of symptom 
onsets and blood collection times across the quartiles and the proportion of MACE in 
each quartile. The median levels of WBC subtypes in each symptom onset quartile and 
blood collection quartile were compared with the independent-samples median test. 
The same test was also used to analyse the differences between patients with and 
without MACE for each WBC subtype. A post-hoc power calculation was conducted 
using a student’s t-test to compare the means and standard deviations of the cytokine 
score in patients who did and did not develop MACE (G*Power v.3.0.10, University of 
Düsseldorf; Germany). Receiver operator characteristics (ROC) curves of WBC subtypes 
that were statistically significant on univariate analysis were produced to provide an 
indication of the usefulness of WBC subtypes as predictors of MACE. To assess whether 
the WBC subtypes were independent predictors of MACE, the subtypes that were found 
to be statistically significant between patients with and without MACE at univariate 
analysis were incorporated into a multivariate model with demographic variables that 
were significantly associated with MACE. However, the demographic variables that 
were significant but did not have many patients affected by the variable were not 
included in the multinomial logistic regression to minimise the effect of small sample 
size on the results. Unless specified, all statistical analyses were completed using SPSS 
v.24 (IBM; Armonk, NY). All statistical graphs, with the exception of the ROC curves, 
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2.3.1 Baseline demographics 
From the biobank of 1340 AMI patients, 480 patients (35.8%) did not meet the 
study criteria, with 459 (95.6%) being excluded because there was no fixed symptom 
onset time recorded, and a further 21 (4.4%) due to the unavailability of blood test 
results in Wellington Hospital’s electronic records that were prior to angiography. This 
left 860 patients who met the study criteria, with 130 (15.1%) of them developing MACE 
within one year of follow-up. These MACE outcomes were composed of 23 deaths, 47 
MIs, 15 ischaemic strokes, two stent thromboses, 27 HF and 16 unplanned 
revascularisations. A total of 340 patients (40%) were transferred from outside of the 
Wellington region and the median number of days from symptom onset to blood 
collection was zero (IQR 0-2). Table 2.2 summarises the patients’ baseline demographics 
and clinical characteristics. In this study cohort, 72% of patients were male and 84% 
were European, with a median age of 64. There were statistically significant differences 
between MACE and no-MACE patients for age, prior MI, hypertension, diabetes, 
dyslipidaemia, estimated glomerular filtration rate (eGFR) below 45mL/min/1.73m2, HF 




Table 2.2   Baseline demographics 






Male, n (%) 618 (71.9) 94 (72.3) 524 (71.8) 0.916 
















Ethnicity, n (%):     
European 725 (84.3) 103 (79.2) 622 (85.2) 
0.163 Maori and PI 92 (10.7) 20 (15.4) 72 (9.90) 
Other 43 (5.00) 7 (5.40) 36 (4.90) 
Risk factors     
Prior MI, n (%) 187 (21.7) 53 (40.8) 134 (18.4) <0.001 
HTN, n (%) 529 (61.5) 99 (76.2) 430 (58.9) <0.001 
Diabetes, n (%) 167 (19.4) 49 (37.7) 118 (16.2) <0.001 
Dyslipidaemia, n (%) 567 (65.9) 99 (76.2) 468 (64.1) 0.009 
Family history of CAD,  
n (%) 
281 (32.7) 35 (26.9) 246 (33.7) 0.155 
eGFR <45mL/min/1.73m2, 
n (%) 
49 (5.70) 25 (19.2) 24 (3.30) <0.001 
HF (Killip Class 2), n (%) 21 (2.44) 14 (10.8) 7 (1.00) <0.001 
AF, n (%) 51 (5.93) 16 (12.3) 35 (4.80) 0.002 
Stroke/TIA, n (%) 47 (5.47) 16 (12.3) 31 (4.20) 0.001 
Smoking, n (%):     
Current 198 (23.0) 25 (19.2) 173 (23.7) 
0.242 Former 329 (38.3) 58 (44.6) 271 (37.1) 
Never 333 (38.7) 47 (36.2) 286 (39.2) 
Clinical presentation     
STEMI, n (%) 164 (19.1) 20 (15.4) 144 (19.7) 
0.277 
NSTEMI, n (%) 696 (80.9) 110 (84.6) 586 (80.3) 
This table displays the baseline demographics, clinical risk factors and clinical 
presentation of the whole cohort, the MACE group and the non-MACE group. 
Continuous variables are expressed as median (Q1, Q3) and categorical variables are 
expressed as frequency (percentage). Differences between the MACE and non-MACE 
groups were determined by the independent-samples median test for continuous 
variables, and the Chi-square test for categorical variables. Statistically significant p-
values (<0.05) are bolded. 
AF – atrial fibrillation; BMI – body mass index; CAD – coronary artery disease; HF – 
heart failure; HTN – hypertension; MACE – major adverse cardiovascular events; MI – 
myocardial infarction; n – number; NSTEMI – non-ST elevation myocardial infarction; PI 
– Pacific Islander; Q1 – 25th percentile; Q3 – 75th percentile; STEMI – ST elevation 
myocardial infarction; TIA – transient ischaemic attack; TnT – troponin T. 




2.3.2 Time of symptom onset and MACE 
Using a one-sample Chi-square test, the proportions of symptom onset differed 
significantly across the quartiles (p-value <0.001). A third (33.0%) of patients 
experienced symptom onset in the morning (Q2) and only 19.0% of patients had 
symptom onset in Q1 (Figure 2.1). The proportion of patients with MACE in each 
symptom onset quartile were also calculated, ranging from 13.1% (Q3) to 17.2% (Q1). 
However, MACE proportions were not significantly different by time of symptom onset 
(p-value = 0.755). 
 
Figure 2.1  Proportion of symptom onset and MACE per symptom onset 
quartile 
The dark blue columns represent the percentage of the total cohort in each 
symptom onset quartile and the light blue columns represent the percentage of major 
adverse cardiovascular events (MACE) in each symptom onset quartile.  The differences 
in proportion of patients per symptom onset quartile were significant (p<0.001) but the 
differences in proportion of MACE were not (p=0.755). Data was analysed from all 860 




2.3.3 Time of blood collection and MACE 
On average (median), the blood samples were collected on the day of symptom 
onset (IQR = 2). Similar to symptom onset, the one-sample Chi-square test showed that 
proportions of blood collection times significantly differed across the quartiles (p-value 
<0.001), with 32.7% of patients having their earliest blood sample collected in the 
morning (Q2) and only 12.7% of them collected in Q1 (Figure 2.2). The majority of 
patients seemed to have their first blood test soon after their symptom onset, as the 
circadian pattern for time of blood collection was similar to that of time of symptom 
onset. 
 
Figure 2.2  Proportion of initial blood samples collected per quartile 
This figure displays the percentage of the total cohort in each symptom onset 
quartile. The differences in proportion of patients per symptom onset quartile was 





2.3.4 Time of symptom onset and WBC subtypes 
Table 2.3 presents the descriptive statistics (medians and IQRs) for each WBC 
subtype per symptom onset quartile. There was no evidence of higher neutrophil or 
monocyte levels associated with Q2. Using the independent-samples median test, only 
the medians for lymphocyte and monocyte counts were found to be significantly 
different over time (p-value = 0.002 and 0.034, respectively), with both having their 
lowest medians in Q2.  
Table 2.3   Descriptive statistics of WBC subtypes per symptom onset quartile 
WBC subtype 









Neutrophil count  5.39 (2.81) 4.91 (2.91) 5.15 (2.67) 5.00 (3.20) 0.430 
Lymphocyte count  2.00 (1.12) 1.80 (0.79) 1.90 (1.04) 2.00 (1.12) 0.002 
Monocyte count  0.70 (0.39) 0.60 (0.30) 0.70 (0.29) 0.70 (0.38) 0.034 
NLR 2.50 (2.03) 2.83 (2.25) 2.70 (2.47) 2.48 (2.36) 0.192 
LMR 2.89 (1.68) 2.81 (1.77) 2.83 (1.85) 3.11 (1.92) 0.129 
All of the white blood cell (WBC) subtypes in the table are expressed as median 
(interquartile range, IQR) for each symptom onset quartile. P-values from the 
independent-samples median test were bolded if they were statistically significant 
(p<0.05). 
LMR - lymphocyte-monocyte ratio; NLR - neutrophil-lymphocyte ratio; Q(number) 




2.3.5 Time of blood collection and WBC subtypes 
Table 2.4 presents the descriptive statistics (medians and IQRs) for each WBC 
subtype per blood collection quartile. Using the independent-samples median test, only 
the medians for neutrophil count, lymphocyte count and NLR were found to be 
significantly different over time, and none of these peaked in Q2.  
Table 2.4   Descriptive statistics of WBC subtypes per blood collection quartile 
WBC subtype 









Neutrophil count  4.80 (2.75) 4.70 (2.50) 5.40 (3.00) 5.20 (3.37) 0.001 
Lymphocyte count  2.10 (1.50) 1.80 (0.80) 1.90 (0.93) 2.00 (1.18) <0.001 
Monocyte count  0.70 (0.40) 0.60 (0.30) 0.70 (0.35) 0.70 (0.34) 0.100 
NLR 2.27 (1.88) 2.67 (1.79) 3.05 (2.73) 2.43 (2.70) <0.001 
LMR 3.10 (1.95) 2.86 (1.72) 2.76 (1.75) 3.16 (1.99) 0.182 
All of the white blood cell (WBC) subtypes in the table are expressed as median 
(interquartile range, IQR) for each blood collection quartile. P-values from the 
independent-samples median test were bolded if statistically significant (p<0.05). 
LMR - lymphocyte-monocyte ratio; NLR - neutrophil-lymphocyte ratio; Q(number) 
- quartile (number). 
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2.3.6 WBC subtypes and MACE 
Medians and IQRs for each WBC subtype were also calculated for patients with and 
without MACE (Table 2.5). On univariate analysis (independent-samples median test), 
patients with MACE were found to have a significantly higher median NLR and a 
significantly lower median LMR than those without MACE (p-value = 0.006 and 0.005, 
respectively). Figures 2.3 and 2.4 highlight the different distributions of NLR and LMR 
between those with and without MACE. A post-hoc power calculation revealed that the 
cohort had 80.0% power to detect a significant difference in NLR levels between 
patients with and without MACE, and 68.6% power to detect a significant difference in 
LMR levels (significance determined by α=0.05). 




MACE (n=130) No MACE (n=730) 
Neutrophil count  5.53 (3.30) 5.00 (2.80) 0.164 
Lymphocyte count  1.76 (1.01) 1.90 (0.90) 0.075 
Monocyte count  0.70 (0.32) 0.66 (0.34) 0.070 
NLR 2.93(2.97) 2.55 (2.15) 0.006 
LMR 2.56 (1.57) 2.93 (1.89) 0.005 
The medians (interquartile ranges, IQRs) of each white blood cell (WBC) subtype 
for the major adverse cardiovascular events (MACE) and non-MACE groups are 
displayed. P-values from the independent-samples median test were bolded if 






Figure 2.3  Distribution of NLR in MACE and no-MACE groups 
The neutrophil-lymphocyte ratios (NLRs) for patient in both the major adverse 
cardiovascular events (MACE) and non-MACE groups are represented by dots. The bars 
represent the medians and interquartile ranges (IQRs). The majority of those without 
MACE had lower NLR levels, resulting in a lower median and IQR than those who 





Figure 2.4   Distribution of LMR in MACE and no-MACE groups 
The lymphocyte-monocyte ratios (LMRs) for patients in both the major adverse 
cardiovascular events (MACE) and non-MACE groups are represented by dots. The bars 
represent the medians and interquartile ranges (IQRs). Patients without MACE had 




2.3.7 ROC curve of WBC ratios in patients with and without MACE 
ROC curves were graphed for NLR and LMR in patients who did and did not develop 
MACE (Figure 2.5). For both curves, the area under the curves (AUCs) of 0.586 (p=0.002) 
and 0.588 (p=0.001), respectively, showed that there was a weak ability to differentiate 
the levels of these WBC ratios in patients with or without MACE. As the AUCs were poor 
and we had sufficient power to measure NLR and LMR as continuous variables, we 
chose to analyse the ratios as continuous variables for the multivariate analysis, rather 
than dichotomise the ratios based on a threshold value obtained from the ROC curves. 
 
Figure 2.5  ROC curves of NLR and LMR 
The receiver operator characteristic (ROC) curves display the sensitivity (y-axis) and 
1-specificity (x-axis) of neutrophil-lymphocyte ratio, NLR (left), and lymphocyte-





2.3.8 Multivariate analysis of WBC ratios and MACE 
Multivariate analysis of NLR and LMR in patients with and without MACE was 
conducted using multinomial logistic regression. Baseline demographics and clinical 
characteristics included in this multivariate model were age, prior MI, hypertension, 
diabetes and dyslipidaemia. Although eGFR <45mL/min/1.73m2, HF diagnosed on 
admission, atrial fibrillation and stroke/TIA were also significantly different between 
those with and without MACE, we excluded them due to a small proportion (less than 
6%) of the cohort having these clinical characteristics. Increased NLR and decreased 
LMR were significantly associated with MACE at univariate analysis, but our results 
showed that they were not independent predictors of MACE at the multivariate level. 
Table 2.6 presents the odds ratios (ORs) of the multinomial regression, where age, prior 
MI and diabetes were all predictive of MACE. 
Table 2.6   Multivariate analysis of WBC ratios in patients with and without 
MACE 
Factor OR (95% CI) P-value 
Age 1.022 (1.001-1.042) 0.037 
Prior MI 2.421 (1.562-3.750) <0.001 
Dyslipidaemia 1.043 (0.634-1.715) 0.870 
Hypertension 1.478 (0.912-2.396) 0.120 
Diabetes 2.481 (1.602-3.842) <0.001 
NLR 1.058 (0.996-1.125) 0.069 
LMR 0.966 (0.844-1.105) 0.612 
The odds ratios (ORs) for NLR, LMR and potential confounders that were significant 
on univariate analysis were calculated with no MACE as the reference category. 
Significant p-values (<0.05) are bolded. Results were calculated from all 860 patients 
with multinomial logistic regression. 
CI - confidence interval; LMR - lymphocyte-monocyte ratio; MI - myocardial 




In our cohort of 860 AMI patients, we found that higher levels of NLR and lower 
levels of LMR were significantly associated with MACE at one year on univariate 
analysis, but not on multivariate analysis (adjusted for age, prior MI, dyslipidaemia, 
hypertension, and diabetes). The frequency of symptom onset and blood collection 
both peaked in the morning (06:00-11:59am) and were least frequent at night 
(12:00am-05:59am). Although some circadian variation was observed in the WBC 
subtypes, the peaks did not coincide with when symptom onset was most frequent. 
Additionally, the time of symptom onset was not found to be significantly associated 
with MACE.  
While median NLR was slightly higher in the MACE group than those without MACE, 
the overlap between the two groups was considerable. In the multivariate model the 
OR for NLR was 1.058, with a 95% confidence interval of 0.996-1.125. While it is possible 
that a study with greater power would have found this association to be statistically 
significant, the effect size would remain very modest. In contrast to this, a recent meta-
analysis conducted on studies investigating the prognostic utility of NLR for MACE 
reported a combined OR of 1.26, with 89.0% of the weighting placed on three studies 
with ORs of 1.09, 1.10 and 1.24 and cohort sizes ranging from 400 to 1050.26 Two of 
these studies had substantially longer follow-up periods than our study (48 and 60 
months) which may have contributed to their observations. Our point estimate of effect 
size is slightly lower than that reported in any of the seven studies included with the 
meta-analysis, all of which reported significant association between NLR and MACE.26 
However, outside of this meta-analysis, we have found two studies that found a similar 
conclusion to our study, where NLR was not an independent predictor of MACE.203,204 
LMR has been less frequently examined as a predictor of MACE following AMI. We 
observed a slightly lower median LMR in those with MACE than in those without, again 
with considerable overlap between the groups. The multivariate OR of 0.966, with 95% 
confidence interval of 0.844-1.105 suggests that it is unlikely that LMR was associated 
with MACE in our study. LMR has previously been an independent predictor of outcome 
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in both NSTEMI and STEMI populations.54,55,205,206 These studies have had longer follow-
up periods than we used (median follow-up of 21-36 months), and this resulted in 
higher overall MACE rates that may have contributed to their observations.  
As discussed in Chapter 1, inflammation in AMI is mediated by a range of biological 
markers in a complex response, including WBCs, cytokines, chemokines and platelets.118 
Therefore, assessing only WBC subtypes may be insufficient to represent a patient’s 
inflammatory state and the subsequent risk for outcomes.207 This is another possible 
reason for our findings. With our results, we do not believe that NLR or LMR alone can 
be used to predict MACE in AMI patients in New Zealand. A combination of 
inflammatory markers that represent the various inflammatory pathways may better 
predict MACE. This will need to be confirmed in a future study. 
The factors that were associated with MACE in our multivariate model were age, 
diabetes and prior MI. None of these are in any way surprising, as the association 
between all three and adverse outcome are well established. In addition, both diabetes 
and age are associated with inflammation,208,209 and may have been confounders 
contributing to the results seen in univariate analysis that were not replicated in 
multivariate analysis for NLR and LMR.  
We found 33.0% of AMI events in our cohort occurred between 6am and midday. 
This pattern was consistent with what was described in a literature review published by 
Mistry et al.193 They reported studies conducted from 1963 to 2015 that investigated 
time of symptom onset of AMI. Their review showed that the majority of the studies 
(35 of the 41, 85%) found symptom onset was most frequent in the morning, which is 
consistent with our findings. Out of nine studies, seven (78%) stated that the least 
common time of symptom onset found was at night. However, two studies found this 
time quarter was the most common. Seven out of nine studies (78%) found a second 




We did not find an association between symptom onset time and MACE. There are 
mixed findings on the association between time of symptom onset of AMI and MACE, 
individual adverse events, or surrogate endpoints for MACE. A study by Nakashima et 
al. found that the risk of MACE (defined as death, recurrent ACS, including unstable 
angina, and new or worsened HF) and recurrent ACS alone was greatest in patients with 
morning symptom onset (06:00-11:59am), while no significant differences were found 
between symptom onset times for death or rehospitalisation due to heart failure.195 
However, a study by Bae et al. found that a greater proportion of AMI patients who died 
within six to 12 months had symptom onset most frequently in the evening.210 In 10 
studies observed by Mistry et al., five found that greater infarct size or greater injury 
was associated with symptom onset at night, while three found greater infarct size with 
symptom onset in the morning.193 If we include our study, the differences in findings 
may be due to a number of factors, including different patient criteria (NSTEMI versus 
STEMI versus ACS), different follow-up lengths and different endpoints used.  
We hypothesised that peak leukocyte levels would be in the morning, coinciding 
with peak symptom onset time, and would be associated with greater risk of MACE. 
However, our results showed that only lymphocyte and monocyte counts had a 
potential circadian rhythm, with a significantly higher lymphocyte count median in Q1 
and Q4, and a significantly lower monocyte count median in Q2. Also, the peaks in WBC 
subtype levels did not occur in the same quartile as peak symptom onset frequency. 
Schloss et al. found that in mice, a lower ejection fraction and increased left ventricular 
end systolic and end-diastolic volumes occurred when symptom onset coincided with 
the time at which migration of neutrophils into the myocardium peaked, which was at 
8:30pm in this animal model.197 Ly6Chigh monocytes also peaked at this time.198 To our 
knowledge, no prior study had associated MACE with circadian rhythm of lymphocytes 
in AMI patients, but Druzd et al. found that lymphocyte count in the circulation of mice 
was highest during the day.211 Based on our results, it seems that the circadian pattern 
found in the mouse model does not reflect what may occur in humans. Any associations 
between peak levels of WBC subtypes and risk of MACE did not correlate with peak 
symptom onset frequency in our study. Unlike humans, mice are nocturnal and are 
therefore likely to have different times for peak leukocyte activity.197 A literature review 
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of leukocytes and circadian rhythm found that levels of all WBC subtypes peaked close 
to midnight in normal human physiology.212 The measured endpoints also differed 
between our study (MACE) and Schloss et al.’s (who used indicators of myocardial 
damage, such as decreased ejection fraction), which was another factor to consider why 
our findings differed.197   
A limitation of this study was that we were unable to control when blood was taken 
for analysis relative to presentation to hospital, because the analysis was retrospective. 
We tried to reduce this variation in time by using the earliest recorded WBC counts. 
However, this cohort included patients who had been transferred from hospitals 
outside of the Wellington region. Without a national electronic health record, we had 
to rely on the printed health records from the transferring hospital, and WBC counts 
were not included in the printed records for some patients. For those patients, the 
earliest WBC result recorded was from Wellington Hospital. It is unknown how sampling 
time affects WBC levels and their associations with MACE. He et al. found that 
neutrophil counts peaked on admission in STEMI patients, while lymphocyte counts 
troughed at 24 hours following admission.213 With delays in sampling time, some of the 
WBC counts recorded might have returned to baseline levels. This then would not be 
reflective of excessive inflammation and could weaken the association between WBCs 
and MACE. We cannot rule out the possibility that the variations in blood sampling time 
might have affected our findings. However, the approach we have taken for measuring 
the WBC counts is similar to other studies that frequently use the WBC counts measured 
on admission.206,213-216 
Because the damage from the MI could lead to changes in blood levels of 
neutrophils, monocytes and lymphocytes, it might have masked any circadian variation 
in these cell types. This might also have limited our ability to examine any correlation 
between circulating levels of cell types at the time of MI onset and adverse outcome. In 
addition, we did not take serial measurements of WBC to examine the changes in these 
markers over time. We relied on patients’ recollection of symptom onset time, and this 
data was not recorded for over a third of the patients recruited into our biobank. The 
accuracy of this information for the remainder of the patients cannot be determined. 
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However, this is the standard approach taken in examining the time of MI. Although a 
few studies have investigated the prognostic utility of eosinophils,59,60 we were unable 
to include eosinophils in our study because data on eosinophil counts was not collected 
for the biobank. Finally, although our cohort had sufficient statistical power to analyse 
a significant difference in NLR levels between patients who did and did not develop 
MACE, it was less sufficient for analysing LMR levels. This might have contributed to our 




In conclusion, NLR and LMR were found to be significant predictors of MACE in AMI 
patients, but only at univariate analysis. Symptom onset was most frequent in the 
morning, but was not associated with risk of MACE. Peak levels of leukocyte counts did 
not coincide with peak symptom onset time, and only lymphocyte and monocyte counts 
had significant circadian variation. As the WBC ratios were not independent predictors 
of MACE, it is unlikely that they are sufficient to characterise pathological inflammation 
alone. Further investigations on WBC subtypes as predictors of individual adverse 
outcomes, LMR as a prognostic marker in NSTEMI patients, and other inflammatory 
markers as predictors of MACE, may be useful for a better understanding of 
inflammation post-AMI. However, we relied on clinical samples for the WBC counts, 
which were measured at different times following symptom onset. It will be better to 
measure inflammatory markers, of which we can collect the samples for ourselves at a 
standardised time and measure them in our own laboratory. Therefore, for the 
remainder of this thesis, we will focus on other inflammatory markers that may be able 




Chapter 3 C-reactive protein, interleukin-6 and tumour necrosis 





In the previous chapter, it was observed that WBC subtypes, inflammatory 
biomarkers that were routinely measured in clinical practice, were insufficient to 
predict adverse outcomes in AMI patients alone. Although NLR and LMR were weakly 
predictive on univariate analysis with MACE, the multivariate model showed that they 
were not independent predictors. In addition, as WBC subtypes are measured in a 
clinical setting, we have less control over when they are measured following symptom 
onset. WBC subtypes are only one subset of inflammatory markers that exist. Therefore, 
in this chapter, we chose to explore other inflammatory markers that have been 
associated with MACE in AMI. 
Other inflammatory markers that have been studied in the ACS context as 
indicators of pathological inflammation include CRP and cytokines, such as IL-6 and 
TNFα. CRP is already established in clinical practice as an indicator of systemic 
inflammation, so it will be beneficial if it can be used as a predictive marker of MACE. 
IL-6 and TNFα are two of the most commonly measured cytokines in ACS patients. 
Previous observational studies have presented mixed results for the prognostic value 
that CRP, IL-6 and TNFα have in determining adverse ischaemic events after ACS. Kang 
et al. and Schaan et al. found that CRP was associated with ischaemic cardiovascular 
events such as cardiac death, MI and repeat revascularisation,68,69 while Dominguez-
Rodriguez et al. and Ribeiro et al. found no significant association between CRP and 
MACE, which was defined as a composite of ischaemic and non-ischaemic events.71,72 
Mixed findings were also found for IL-6 and TNFα.20,85,96,142 
These markers may also work together during the inflammatory process and be 
correlated. IL-6 has a variety of roles, such as being the main promoter of CRP 
production through hepatocyte stimulation.131 Due to its upstream effects on CRP, IL-6 
has been suggested as a surrogate prognostic marker.81 However, IL-6 has a shorter 
half-life than CRP,217 so there may be a smaller correlation between the two markers. 
Although TNFα has a different activation pathway to IL-6,218,219 it has been shown that 
IL-6 inhibits the production of TNFα,131 so there may be a weak negative correlation 
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between the two cytokines. Investigating the degree of correlation between these 
markers allows us to understand whether there is sufficient correlation for one marker 
to represent all three markers, or whether they are distinct and can provide different 
information about the inflammatory process. 
As mentioned in Chapter 1, there is no gold standard definition of MACE for ACS 
research, so it will be advantageous to explore which composite of MACE is best 
associated with pathological inflammation. In Chapter 2, we chose a broad definition of 
MACE that encompassed all-cause death, non-fatal MI, ischaemic stroke, stent 
thrombosis, hospitalisation due to new or worsened HF, and unplanned 
revascularisation. Within Type 2 diabetes research, the MACE definition that is 
commonly used is the “three-point MACE”, which is comprised of cardiac death, non-
fatal MI and non-fatal stroke.220 The reason why three-point MACE became popular in 
this field was because when researchers added other adverse outcomes that had little 
association with diabetes to the MACE definition, more non-significant results were 
found.220 Inflammation plays a significant roles in Type 2 diabetes,221 and the 
observations made by diabetes researchers may be relevant to those studying 
pathological inflammation in AMI. Using a three-point MACE definition in the AMI 
context may lead to stronger associations between inflammatory markers and MACE. 
Depending on the level of correlation between the markers, examining a 
combination of markers may improve the predictive score for ischaemic outcomes. This 
was seen in Chapter 2, where the individual WBC subtypes were not associated with 
MACE, but the NLR and LMR were. A few studies showed that significant associations 
with MACE were made when cytokines were combined into ratios or added into a 
combined score.29,32 Therefore, the aims of this case-control study were to: 
1) Determine whether multiple markers (CRP, IL-6 and TNFα) allowed for better 
separation of cases (patients with three-point MACE) from controls, 
74 
 
2) Investigate the relationships between the three markers – whether they had a 
high degree of correlation that allowed us to use just one marker to represent 
them or whether they were all distinct, and 
3) Examine whether a combined multi-marker approach altered our classification 




3.2.1 Study population 
All patients that were included as part of this observational, case-control study 
were selected from the same biobank that was used in Chapter 2 (see section 2.2.1).  
From this population, cases were selected if they had a MACE of ischaemic nature, 
which was defined as a composite of cardiac death, non-fatal MI, and non-fatal CVA, at 
one year. Cardiac death was defined according to the 2013 ACCF/AHA Task Force 
Clinical Data Standards report, i.e. death resulting from AMI, sudden cardiac death, 
heart failure, stroke, cardiac procedures, cardiovascular bleeding, or other cardiac-
related causes.200 CVA was diagnosed by imaging studies.201 The two controls paired 
with each case were matched hierarchically for sex, age (±5 years), clinical presentation 
(STEMI or NSTEMI) and diabetes mellitus. However, four case-control pairs could not be 
matched for diabetes, three could not be matched for clinical presentation, and one 
could not be matched for age (eight-year difference). In total, there were 138 patients 
selected for this case-control study, of which 46 were cases. 
 
3.2.2 Data collection and sampling methods 
Data on patient demographics, clinical characteristics, current medications and 
clinical management were collected at the time of recruitment from the hospital 
medical records and cardiac catheterisation database. The clinical characteristics were 
defined as in Table 2.1. Renal insufficiency was defined as eGFR below 
45mL/min/1.73m2 or as stated in the patients’ clinical records. Procedural data and in-
hospital outcomes were recorded by cardiology registrars. One year follow-up data 
were collected by cardiac research nurses via telephone. If the clinical outcomes could 
not be fully obtained by these methods, a cardiologist would review the case notes and 
the general practitioner would be contacted. 
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With a median of four days after hospital admission (IQR, three to six days), whole 
blood samples were collected in tubes with sodium citrate (10mL BD Vacutainer, New 
Jersey, USA) from the peripheral vein before angiography or from the arterial sheath 
just before heparin administration during the angiography. The blood was put into a 
tube with sodium citrate to separate the plasma from the whole blood. All samples were 
processed using a standard protocol, where the tubes were left to coagulate for a 
minimum of 15 minutes and centrifuged 60 minutes or less after collection at 1500g for 
12 minutes. Once the plasma was separated from the other blood components, six 
500μL plasma aliquots were made and stored at -80oC until analysis. 
 
3.2.3 CRP analysis 
CRP concentrations were analysed using Human CRP Quantikine® ELISA kit (R&D 
Systems, Inc., MN, USA). The samples were analysed in duplicate using a 1:200 dilution 
with 1x calibrator diluent. Any concentrations above the maximum were re-analysed 
using 1:400 or 1:800 dilutions. Recombinant human CRP standard in a protein buffered 
base was reconstituted with 1x calibrator diluent in a two-fold serial dilution to create 
an eight-point standard curve (0-50ng/mL). The 96-well microplate (provided in the kit) 
was pre-coated with a monoclonal antibody specific for CRP by the manufacturer. To 
maximise binding of the sample or standard to the antibodies, assay diluent (100µL) 
along with 50µL of standard or diluted sample was pipetted into the wells. After a two-
hour incubation at room temperature, the solution was removed and the plate was 
washed four times using 1x wash buffer to remove any unbound sample or standard. 
To be able to detect the bound CRP, CRP conjugate antibody (200µL) was added to each 
well and incubation occurred for two hours at room temperature. The plate solution 
was removed and the plate was washed as previously described to remove unbound 
conjugate antibody. Substrate solution (200µL) was pipetted into each well to begin the 
photometric reaction and the plate was incubated for a further 30 minutes. The reaction 
was discontinued using 50µL of stop solution and the plate was read using a plate reader 
(MultiskanTM GO microplate spectrophotometer v.1.01.10, Thermo Fisher Scientific, 
Vantaa, Finland) at 450nm and 540nm, with the results subtracted from each 
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wavelength to correct for variable plate absorption across the plates. Intra-assay 
coefficient of variation was 4.65% and inter-assay coefficient of variation was 6.40%. 
  
3.2.4 IL-6 analysis 
IL-6 concentrations were analysed using the Human IL-6 Ready-Set-Go ELISA kit 
(Invitrogen, Thermo Fisher Scientific, CA, USA). The samples were analysed in duplicate 
in a 1:2 dilution using 1x ELISA diluent. Human IL-6 lypholised standard was 
reconstituted with deionised water and mixed with ELISA diluent in a 2-fold serial 
dilution to create a 9-point standard curve (0-200pg/mL). Before the samples were 
analysed, the spike and recovery was assessed and found to be within 70-130% and the 
linearity of dilution was also within this range. A 96-well microplate (Corning Costar 
9018, bought with kit) was coated overnight at 4oC with the anti-human IL-6 capture 
antibody in coating buffer that was prepared according to the certificate of analysis. The 
plate was washed three times with 1x wash buffer to remove any unbound capture 
antibody. ELISA diluent (200μL) was pipetted into each well and the plate was incubated 
at room temperature for one hour to minimise non-specific binding. Excess diluent was 
discarded physically and by washing the plate twice with wash buffer. The standard or 
sample (100µL) was added to the wells and the plate was incubated overnight at 4oC to 
allow for binding to the capture antibody. Again, contents were discarded and the plate 
was washed five times to remove unbound standard or sample. To be able to detect the 
bound IL-6, anti-human IL-6 detection antibody (100μL) was pipetted into each well and 
the plate was incubated at room temperature for an hour. After a further five washes, 
100μL of Avidin-HRP solution, which amplified the photometric reaction in an ELISA, 
was pipetted into each well. Following a 30-minute incubation period, excess Avidin-
HRP was removed from the plate by wash buffer (seven washes) and 100μL of 
tetramethylbenzidine (TMB) ELISA substrate solution was added to begin the 
photometric reaction. Stop solution (50μL) was added to discontinue the reaction after 
the plate had been incubated for another 15 minutes. The plate was read using a plate 
reader (MultiskanTM GO microplate spectrophotometer v.1.01.10, Thermo Fisher 
Scientific, Vantaa, Finland) at 450nm, with correction at 570nm to account for variable 
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plate absorption across plates. The intra-assay coefficient of variation was 8.32% and 
inter-assay coefficient of variation was 4.31%. 
 
3.2.5 TNFα analysis 
TNFα concentrations were analysed using the Human TNFα Ready-Set-Go ELISA kit 
(Invitrogen, Thermo Fisher Scientific, CA, USA). The method used was similar to IL-6 
analysis (see section 3.2.4). Differences in the methods were that the antibodies used 
were specific for TNFα, that a 10-point standard curve (0-500pg/mL) was generated 
instead of a nine-point curve, and that at each washing step an additional wash was 
done. Before analysing the samples, the spike and recovery was found to be within 80-
120% and the linearity of dilution was also found within this range. The intra-assay 
coefficient of variation was 3.8% and inter-assay coefficient of variation was 3.2%. 
 
3.2.6 Statistical analysis 
For baseline characteristics, continuous variables were reported as the mean ± 
standard deviation (SD) if they passed the Shapiro-Wilk and D’Agostino and Pearson 
normality tests, or as the median, 25th percentile (Q1) and 75th percentile (Q3) if they 
were non-parametric. These normality tests were conducted using GraphPad Prism 
software v.7 (GraphPad Software Inc.; CA, USA). Categorical variables were reported as 
frequencies and percentages. A student’s unpaired t-test was used to compare the 
normally-distributed continuous variables between the cases and controls and a Mann-
Whitney U test was used for the non-parametric continuous variables. A Chi-square test 
was used to compare the categorical variables. These statistical tests were completed 
using SPSS v.24 (IBM; Armonk, NY, USA). 
CRP, IL-6 and TNFα concentrations were calculated from the absorbances using 
GraphPad Prism v.7, using a 4PL fitted standard curve for CRP and a 5PL standard curve 
for IL-6 and TNFα. The CRP concentrations were converted from ng/mL to mg/L on 
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Microsoft Excel 2013 (Microsoft Corporation; WA, USA). For IL-6 and TNFα, samples that 
had absorbances below the lowest standard, and therefore had undetermined 
concentrations when fitted with the 5PL curve, were extrapolated using linear 
regression down to the lower limit of detection (LLOD). The LLOD concentration was 
derived from the LLOD absorbance, which was calculated as three times the standard 
deviation of the blank absorbance. Samples values that were below the blank were 
defined as “undetectable” and were given the mean LLOD across the plates, which was 
0.452pg/mL for IL-6 and 1.31pg/mL for TNFα. Samples with CRP absorbance values 
above the upper limit of detection that could not be extrapolated were given one 
concentration that was higher than the upper limit of detection, and this was arbitrarily 
chosen as 120mg/L. 
Using GraphPad Prism v.7, the D’Agostino and Pearson normality test and the 
Shapiro-Wilk normality test were conducted to determine if our data was parametrically 
or non-parametrically distributed. Concentrations between cases and controls were 
compared using the Mann-Whitney U test (IBM SPSS v.24). Correlations between 
markers, and between individual markers and clinical risk factors, were analysed using 
the Spearman’s rank correlation test for continuous variables, the Mann-Whitney U test 
for dichotomous categorical variables, and the Kruskal-Wallis test for categorical risk 
factors with more than two categories (IBM SPSS v.24). The concentrations of each 
biomarker were divided into quartiles. The number of markers each patient had in the 
highest quartile (Quartile Four, Q4) was added. With the cohort divided by the number 
of markers in Q4, the proportions of patients with clinical risk factors were calculated 
and compared across the groups using a Chi-square test (IBM SPSS v.24). This Chi-square 
test was also used to compare the proportion of cases versus controls with zero, one or 
at least two markers in Q4, and zero or at least one marker in Q4. These statistical tests 




3.3.1 Patient outcomes and baseline demographics 
Information on the baseline demographic data and clinical characteristics of the 
138 patients (46 cases, 92 controls) are summarised in Table 3.1. Of the 46 cases who 
developed MACE at one year, 17 (37.0%) died from cardiac causes, 18 (39.1%) had a 
non-fatal MI, and 11 (23.9%) had a non-fatal CVA. The study cohort had 84 (60.9%) male 
participants, a median age of 71 years and a mean BMI of 29.4. For the clinical 
characteristics, 81.2% of the cohort (112 patients) were diagnosed with NSTEMI and 
18.8% (26 patients) were diagnosed with STEMI. Only dyslipidaemia was found to be 
significantly different between cases and controls (87.0% of cases versus 68.5% of 
controls with dyslipidaemia, p = 0.022).   
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Table 3.1   Baseline demographics and characteristics  
Demographics 
Total  
(N = 138) 
Cases  
(n = 46) 
Controls  
(n = 92) 
P-value 
Male, n (%) 84 (60.9) 28 (60.9) 56 (60.9) 1.00a 








BMI, mean (SD) 29.4 (5.63) 28.8 (5.63) 29.6 (5.57) 0.429c 
Ethnicity, n (%):   
  
European 115 (83.3) 37 (80.4) 78 (84.8) 
0.142a Maori and PI 19 (13.8) 9 (19.6) 10 (10.9) 
Other 4 (2.90) 0 (0.00) 4 (4.30) 
Risk factors     
Prior MI, n (%) 46 (33.3) 20 (43.5) 26 (28.3) 0.086a 
HTN, n (%) 105 (76.1) 38 (82.6) 67 (72.8) 0.290a 
Diabetes, n (%) 49 (35.5) 18 (39.1) 31 (33.7) 0.574a 
Dyslipidaemia, n (%) 103 (74.6) 40 (87.0) 63 (68.5) 0.022a 
Family history of CAD, n (%) 44 (31.9) 13 (28.3) 31 (33.7) 0.566a 
Renal insufficiency, n (%) 18 (13.0) 9 (19.6) 9 (9.80) 0.178a 
CHF (Killip Class 2), n (%) 9 (6.50) 6 (13.0) 3 (3.30) 0.060a 
AF, n (%) 12 (8.70) 2 (4.30) 10 (10.9) 0.337a 
Stroke/TIA, n (%) 18 (13.0) 5 (10.9) 13 (14.1) 0.790a 
Smoking, n (%):   
  
Current 22 (15.9) 9 (19.6) 13 (14.1) 
0.482a Former 55 (39.9) 20 (43.5) 35 (38.0) 
Never 61 (44.2) 17 (37.0) 44 (47.8) 
Clinical presentation     
STEMI, n (%) 26 (18.8) 8 (17.4) 18 (19.6) 
0.821a 
NSTEMI, n (%) 112 (81.2) 38 (82.6) 74 (80.4) 
Number of days from 
symptom onset to blood 








This table displays the baseline demographics, clinical risk factors and clinical 
presentation of the whole cohort, the MACE group and the no-MACE group. Age and 
time from symptom onset to blood collection are expressed as median (Q1, Q3), BMI is 
expressed as mean (SD) and categorical variables are expressed as frequency 
(percentages). Significant differences between cases and controls are bolded (p<0.05). 
AF – atrial fibrillation; BMI – body mass index; CAD – coronary artery disease; CHF 
– congestive heart failure; HTN – hypertension; MI – myocardial infarction; n – number; 
NSTEMI – non-ST elevation myocardial infarction; PI – Pacific Islander; Q1 – 25th 
percentile; Q3 – 75th percentile; SD – standard deviation; STEMI – ST elevation 
myocardial infarction; TIA – transient ischaemic attack; TnT – troponin T. 
a Chi-square test, b Mann-Whitney U test, c Student’s unpaired t-test.  
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3.3.2 Inflammatory markers in cases and controls 
The D’Agostino and Pearson, and Shapiro-Wilk normality tests for CRP, IL-6 and 
TNFα showed that the data was non-parametric (p<0.001). Figure 3.1 displays the 
concentrations of each biomarker for cases and controls. Variation of the biomarker 
concentrations was observed, with the IQR being 2.71-fold of the median for CRP, 1.56-
fold for IL-6 and 3.85-fold for TNFα. For CRP and TNFα, the medians of the cases were 
numerically higher than for the controls. However, using the Mann-Whitney U test, the 
distributions of all three biomarkers were not statistically significant between cases and 






Figure 3.1  Distributions of biomarker concentrations between cases and controls 
The concentrations for each biomarker are displayed in the scatterplots above, with the median and interquartile ranges indicated by the 
black lines. The Mann-Whitney U test showed that any differences in distribution between cases and controls were not statistically significant 
(p>0.05). CRP - C-reactive protein; IL-6 - interleukin-6; TNFα - tumour necrosis factor-alpha.
84 
 
3.3.3 Correlations between individual biomarkers and risk factors 
The correlations between the individual biomarkers, and clinical risk factors were 
analysed using either the Spearman’s rank correlation test for continuous clinical risk 
factors, Mann-Whitney U test for categorical risk factors with only two groups, or the 
Kruskal-Wallis test for categorical risk factors with three or more groups (Table 3.2). CRP 
was significantly associated with hypertension (p = 0.006), smoking status (p = 0.016) 
and clinical presentation (p = 0.024). IL-6 was significantly associated with renal 
insufficiency (p = 0.049) and smoking status (p<0.001). TNFα was only associated with 
atrial fibrillation (p = 0.008). 
 
Table 3.2  Correlations between clinical risk factors and inflammatory 
biomarkers 
Clinical risk factor CRP IL-6 TNFα 
Age, rs (p-value)a 0.011 (0.898) 0.130 (0.127) -0.090 (0.294) 
BMI, rs (p-value)a 0.116 (0.175) 0.124 (0.146) -0.003 (0.976) 
Sex, p-valueb 0.631 0.778 0.803 
Ethnicity, p-valuec 0.254 0.054 0.623 
Prior MI, p-valueb 0.381 0.153 0.823 
HTN, p-valueb 0.006 0.144 0.150 
Diabetes, p-valueb 0.847 0.729 0.672 
Dyslipidaemia, p-valueb 0.426 0.180 0.728 
Family history of CAD, p-valueb 0.895 0.432 0.864 
Renal insufficiency, p-valueb 0.523 0.049 0.244 
CHF (Kilip Class 2), p-valueb 0.714 0.990 0.691 
AF, p-valueb 0.066 0.913 0.008 
Stroke/TIA, p-valueb 0.536 0.354 0.664 
Smoking status, p-valuec 0.016 <0.001 0.522 
Clinical presentation, p-valueb 0.024 0.547 0.842 
The table displays the correlations between clinical risk factors and individual 
inflammatory biomarkers. The full names of the abbreviations in this table can be found 
in the Abbreviations section. 
a = Spearman’s rank correlation was used for continuous risk factors, with the 
correlation (rs) and p-value displayed.  
b = Mann-Whitney U test was used for categorical risk factors with only two 
categories, and the p-values are displayed.  
c = Kruskal-Wallis test was used for categorical risk factors with three or more 




3.3.4 Correlation between inflammatory markers and distribution between cases 
and controls 
Figures 3.2 to 3.4 each shows the correlation between two markers and the 
distribution of concentrations between cases (in dark blue) and controls (in light blue). 
Using the Spearman’s rank correlation test, no correlations were found between the 
inflammatory markers except for between CRP and IL-6, where the correlation was 
moderate (rs = 0.597, p<0.001). The data was separated into quartiles to rank patients 
on their inflammatory state based on each individual marker. Quartile One (Q1) 
indicated the lowest levels of inflammation, and Q4 indicated the highest levels. When 
comparing the quartile rankings for each marker, less than half of the patients had at 
least two markers with the same quartile rankings (46.7% for CRP and IL-6, 22.6% for IL-
6 and TNFα and 27.0% for CRP and TNFα). These results were consistent with the 
correlations found between the markers. The distribution of concentrations between 
cases and controls did not appear different. There was a combination of cases and 
controls across all concentration levels.  
 
Figure 3.2  Correlation between CRP and IL-6 
The data on the graph have been divided into quartiles (indicated by the dashed 
lines), allowing us to observe the frequency of patients with both CRP and IL-6 in the 
same quartile. The Spearman’s rank correlation test showed that there was a moderate 




Figure 3.3  Correlation between CRP and TNFα 
The data on the graph have been divided into quartiles (indicated by the dashed 
lines), allowing us to observe the frequency of patients with both CRP and TNFα in the 
same quartile. The Spearman’s rank correlation test showed that there was no 
correlation between CRP and TNFα concentrations (rs = 0.011, p = 0.895).  
 
 
Figure 3.4  Correlation between IL-6 and TNFα 
The data on the graph have been divided into quartiles (indicated by the dashed 
lines), allowing us to observe the frequency of patients with both IL-6 and TNFα in the 
same quartile. The Spearman’s rank correlation test showed that there was no 
correlation between levels of IL-6 and TNFα (rs = 0.031, p = 0.716).   
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3.3.5 Correlations between clinical risk factors and number of biomarkers in 
Quartile Four 
Clinical risk factors were compared with the number of markers in Q4 to analyse if 
they may have influenced the proportion of patients with markers in this quartile. Using 
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Figure 3.5  Proportion of patients with markers in Quartile Four and clinical risk 
factors 
The percentage of patients who had zero to three markers in Q4 and also had one 
of the clinical risk factors are displayed. A Chi-square test was used to determine 
significant differences in proportions of patients with clinical risk factors across each 
group of patients with a certain number of markers in Q4. MI - myocardial infarction; 




3.3.6 Quartile rankings of inflammatory biomarkers 
The concentrations of biomarkers were divided into quartiles, with Q4 containing 
the highest concentrations. The number of biomarkers each patient had in Q4 were 
added together. The proportion of cases or controls with either two or three markers 
in Q4 were combined together to increase its statistical power. When comparing cases 
and controls with zero marker, one marker and at least two markers in Quartile Four 
(Figure 3.6), the differences were not statistically significant (Chi-square test, p-value = 
0.199). When the cases and controls were dichotomised to either having at least one 
marker in Quartile Four or having no marker in this quartile, although a numerically 
greater proportion of cases had at least one marker in Q4 (63.0% compared with 48.9%), 
the difference was not statistically significant (Chi-square test, p = 0.117).  
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Figure 3.6  Proportion of cases versus controls with markers in Quartile Four 
This figure displays the number of inflammatory markers in Q4 (between two to 
three markers, one marker, or no marker), as observed by the proportion of cases and 




This case-control study found that there was some variance in CRP, IL-6 and TNFα 
levels within the patient cohort, of which TNFα displayed the greatest variation (IQR 
3.85-fold of the median). Individually, the biomarkers did not significantly differ 
between cases and controls. The individual biomarkers were associated with several 
clinical factors, but only one risk factor was associated with more than one biomarker 
(smoking status with CRP and IL-6). When we looked at the correlations between each 
biomarker, only CRP and IL-6 had a moderate, positive correlation. This signifies that 
patients with “high” levels of inflammation using one biomarker may have “low” levels 
when using another biomarker. When we looked at patients with multiple elevated 
inflammatory biomarkers, this did not correlate with three-point MACE, either. Finally, 
the clinical risk factors were not associated with the number of elevated inflammatory 
markers a patient had. 
There are AMI patients with varying levels of inflammation, such as high or low 
levels of CRP, but this was not associated with MACE. Some of this variation could be 
explained by clinical risk factors. CRP was significantly associated with hypertension, 
smoking status and clinical presentation (STEMI or NSTEMI). IL-6 was significantly 
correlated with renal insufficiency and smoking status, while TNFα was associated with 
AF. These risk factors have been associated with inflammation in previous studies.222-226 
However, it is unlikely that the variation observed can solely be accounted for by the 
clinical risk factors. For example, TNFα had the greatest amount of variation out of the 
three biomarkers, yet the only risk factor associated with this cytokine was AF, which 
only 18 patients (13.0%) were diagnosed with. It is unknown what other factors might 
have influenced this variation. One possible factor is the time of blood collection relative 
to symptom onset. The blood samples used in this study were all collected prior to 
invasive management, at a median of four days following symptom onset. With the 
pathogenesis of AMI that was explained in section 1.1.2.2,15,17 patients who had 
samples collected prior to four days would still be within the inflammatory phase and 
would be more likely to have elevated levels of inflammatory markers. Further 
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investigation is required to determine other drivers of inflammatory biomarker 
variation outside of the traditional risk factors. 
Using a combination of three inflammatory markers to assess a patient’s 
inflammatory state revealed that the markers were not elevated in similar proportions. 
The Spearman’s rank correlations also showed that the CRP and TNFα, and IL-6 and 
TNFα were not significantly correlated, which is consistent with a previous study.227 
However, Guo et al. found a weak correlation between TNFα and IL-6 in AMI patients.228 
Although a small subset of IL-6 molecules are activated by TNFα and IL-6 can inhibit 
TNFα production,131 they are largely activated by different pathways. IL-6 is released 
from many cells, including macrophages, neutrophils, fibroblasts, T-cells, B-cells, and 
cells at the area of damage, while TNFα is mostly released from monocytes and 
macrophages.80,228 CRP also has a different activation pathway to TNFα.131,228 Therefore, 
it is not surprising that our study found no significant correlation between these pairs 
of markers.  
As mentioned briefly in the introduction, CRP is mainly activated by IL-6, which 
explains the correlation between these two markers. However, CRP has a longer half-
life than IL-6.217 CRP levels start to rise within six hours after symptom onset, peaking 
at about 48 hours, and has a half-life of 19 hours.62,63 CRP levels may continue to remain 
elevated if there is ongoing damage.62 CRP has been found to be a relatively stable 
marker of inflammation, with similar consistency year to year as systolic blood pressure 
and total cholesterol.64 In comparison, IL-6 is a more dynamic marker. In a mechanistic 
study of acute inflammation, IL-6 levels peaked at 12 hours and also fell more quickly.229 
To accurately reflect acute inflammatory changes in an AMI population, it will be better 
to use IL-6 instead of CRP. 
The poor correlations between the three markers suggests that using an individual 
marker to represent a patient’s inflammatory state may lead to a different conclusion, 
depending on which marker was used. Measuring multiple markers may provide a 
better understanding of a patient’s level of inflammation than using a single marker, as 
our three markers seemed to provide slightly different information for each patient. A 
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larger number of biomarkers would be required to confirm our conclusion. The 
exception to this is the moderate correlation between CRP and IL-6 – it may be sufficient 
to analyse only IL-6 in future studies. The time at which we collected these blood 
samples (median of four days) may have contributed to the correlation between these 
markers being only moderate. 
When analysed individually, none of the biomarkers were significantly different 
between the cases and controls. As mentioned in the Introduction, all three markers 
have been previously investigated as a prognostic marker for MACE, with mixed 
results.20,68,69,71,72,85,96,142 We hypothesised that some of the negative findings may have 
been attributed to defining MACE as a composite of both non-ischaemic and ischaemic 
events. For example, Ribeiro et al. found that CRP was not associated with MACE, which 
was defined as all-cause death, heart failure, re-infarction or revascularisation at 30 
days.72 However, even though our study only included events related to ischaemia in 
the outcome, we did not find any significant associations. There may be several factors 
that influence whether or not an individual marker is significantly associated with 
adverse outcome, such as cohort size and time of blood collection. Overall, our results 
show that individual markers are insufficient to predict three-point MACE. 
This study also found no significant association between three-point MACE and the 
combination of the three markers. We used an additive scoring method, which was a 
successful method used by Novo et al.29 Two differences between our study and Novo 
et al.’s are that we were only able to measure three markers with our methods (Novo 
et al. determined that the addition of at least 14 elevated cytokines was associated with 
MACE) and one of our markers was not a cytokine.29 We would require many more 
cytokines to produce similar results to Novo et al. However, a limitation of this simple 
addition method is that the biomarkers may not be independent of each other, and so 
adding two collinear markers with similar functions may result in unequal weightings, 
as evidenced by the moderate correlation with CRP and IL-6. A more complex 




 Another possible reason for why we were unable to detect the three biomarkers 
is that we did not measure them at their peak concentrations. For example, TNFα has 
previously been shown to peak at times outside of Day 2.116,230-232 Other markers, 
including IL-6, MCP-1 and IFN-γ, have been shown to have dynamic changes in 
concentration over time.116,232 Further investigation is required regarding the temporal 
changes in concentrations for all cytokines and how that might affect a cytokine score. 
It may be that we must include cytokine measurements from several time points to 
create a more accurate cytokine score, or we need to determine the optimal time point 
for measuring peak levels of cytokines so that we can incorporate more cytokines into 
the score.  
A further limitation was that although we were successful in controlling for the 
confounding risk factors that we included in our matching criteria (age, sex, diabetes 
and clinical presentation), there was a significantly greater proportion of cases who had 
dyslipidaemia. However, dyslipidaemia was not significantly associated with the 
number of markers a patient had in Q4. Interestingly, although this finding was not 
statistically significant, no diabetic patient had all three markers in Q4. This is surprising 
because inflammatory biomarkers have been known to be elevated in diabetes.208 It 
may be that because the majority of our patients had blood samples collected at least 
three days (25th percentile) after symptom onset, these diabetic patients had a quicker 
rise in biomarker concentrations that also returned to lower levels at a faster rate. 
Other limitations include how our cohort size of 138 patients meant that the effects 
of small differences in inflammation could be missed. However, we tried to increase the 
power of our study by using a case-control study design. Conducting a retrospective 
analysis of this data can also affect the quality of the study results if the records used 
are not made for the study or if there are missing data. This case-control study had no 
missing data for any of the clinical factors analysed. A final limitation is that we had to 
conduct laboratory analyses of the markers individually by ELISA. Measuring each 
biomarker individually is more time consuming and costly. Hence, only three 
biomarkers were analysed in this study. It would be beneficial to try other multiplex 
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methods, such as cytometric bead array, to allow us to investigate a wider range of 




In conclusion, analysing a combination of CRP, IL-6 and TNFα has shown that 
individually, these markers are likely to present dissimilar information about 
inflammatory state. While there is a general consensus that elevated levels of 
inflammation is associated with adverse outcomes, how we choose which marker(s) to 
represent excess inflammation is not necessarily clear. Using multiple markers may 
allow for a more holistic picture of the inflammatory state, but which markers to 
measure requires further investigation. This will be explored in Chapter 4. A 
combination of CRP, IL-6 and TNFα was not significantly associated with three-point 
MACE at one year. Although CRP is a systemic marker of acute inflammation, its 
concentrations are relatively stable over time compared to cytokines such as IL-6. 
Therefore, the following studies in this thesis will investigate cytokines alone. The non-
significant correlations between our three markers and MACE may have been due to 
time as a potential confounder. A study investigating the dynamic changes in biomarker 




Chapter 4 Association between inflammatory cytokines and long-





As seen in the previous two chapters, clinical markers derived from WBCs were 
weakly associated with the risk of MACE, while our case-control study looking at CRP 
and two cytokines found that these markers were not predictive of MACE, both 
individually and as a combination of markers. In Chapter 3, we stated that although the 
most widely studied biomarker of inflammation is CRP,233,234 CRP is a relatively stable 
marker of inflammation compared with IL-6. A large number of studies have also 
examined the relationship between circulating levels of individual cytokines measured 
after the onset of ACS and MACE, partly due to the fact that cytokines have a more 
direct relationship with atherosclerosis than CRP.235 Therefore, cytokines may be better 
markers to investigate than CRP. We decided to turn to the literature to investigate 
cytokines that had been used in previous studies to predict MACE.  
Inflammation is a complex network response of multiple different cell types to an 
injury, such as AMI, that involves an altered expression of cell surface markers and 
secretion of a large numbers of cytokines and chemokines.21 Therefore, it is likely that 
measurement of a non-specific, single marker to characterise “inflammation” in this 
complex setting is an over-simplified approach. A chronic HF cohort study found 
assessment of multiple inflammatory biomarkers to be a stronger predictor of the long-
term risk of adverse events when compared to a single marker approach.236 This has 
also been reported in other disease states such as colorectal cancer and hepatocellular 
carcinoma.237,238 
Many studies have focussed on the significance of individual cytokines as 
prognostic markers of MACE.239 However, these cytokines are not cardiac-specific; they 
have been associated with other diseases such as colorectal cancer and autoimmune 
diseases.240,241 Inflammatory comorbidities may also appear in ACS patients and 
therefore, a single cytokine may not reflect cardiac-driven inflammation. This is 
reflected in the mixed findings in the literature.85,96 As mentioned in Chapter 3, even 
the most widely studied inflammatory marker, CRP, has some studies presenting an 
association with MACE,68,242 and some others presenting no association.71,72 A similar 
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pattern can be seen with other singular markers. Multiple inflammatory biomarkers 
investigated in HF and abdominal aortic aneurysm cohorts were found to be strong 
predictors for assessing risk of MACE.243-245 We hypothesise that this may also be true 
for ACS patients.   
Therefore, the aim of this systematic review is to investigate whether multi-marker 
approaches for predicting long-term MACE is superior to single-marker approaches in 




4.2.1 Search strategy 
We searched for publications online using Ovid Medline(R), EMBASE, EMBASE 
Classic, and Cochrane Library databases. The results found on Medline were from 1946 
to 31 December 2017 and the MeSH terms and keywords used were: (“myocardial 
infarction/ or non-st elevation myocardial infarction/ or st elevation myocardial 
infarction/” OR “acute myocardial infarction.mp.” OR “AMI.mp.”) AND (“exp 
Cytokines/” OR “cytokine*.mp.”) AND (“Prognosis/” OR “prognos*.mp.” OR “Risk 
Assessment/” OR “risk stratification*.mp.” OR “predict*.mp.”). The results were limited 
to English language. The publications found on EMBASE and EMBASE Classic were from 
1947 to 31 December 2017. Similar MeSH terms and keywords were used, but an 
additional limitation for article-in-press status, EMBASE status or in-process status was 
included along with English language. The results found on Cochrane Library were from 
1945 to 31 December 2017. Similar keywords and MeSH terms were used as with 
Medline, but the search strategy was limited to the following collections: Cochrane 
Reviews, Trials, Clinical Answers, Editorials and Special Collections. 
 
4.2.2 Inclusion and exclusion criteria 
All results were imported into EndNote X7 (Clarivate Analytics, PA, USA) and 
assessed for eligibility. Studies were included if they met the following criteria: 1) 
baseline blood samples collected and results conducted for an ACS-only cohort; 2) at 
least two inflammatory cytokines and chemokines measured and associated with MACE 
outcomes that occurred at least a year after symptom onset; and 3) study design was 
either observational study, RCT or systematic review. Cytokines and chemokines were 
defined as proteins released by one cell to act on another cell, either to aid in 
communication, chemotactic activity, or have another effect,77 and MACE was defined 
as one of the following: death, recurrent MI, stroke, stent thrombosis, revascularisation, 
recurrent angina, and/or HF. Studies that measured the cytokines from cells in vitro 
were excluded.  
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4.2.3 Quality assessment and data extraction 
Titles, abstracts and keywords were first screened to assess for eligibility. The full 
text of all potentially eligible studies were then assessed using a screening form adapted 
from Boland et al. (Figure 4.1).246 Two students using cohort and case-control checklists 
adapted from the Scottish Intercollegiate Guidelines Network (SIGN) independently 
evaluated studies that were confirmed to meet the eligibility criteria for quality and 
bias.247 Any disagreements were firstly resolved by discussion, and then if necessary, 
with the primary research supervisor. Study characteristics and outcomes were also 
collected from the full text and supplementary documents. 
Univariate and multivariate analyses of the association between cytokines and 
MACE were extracted from the studies. Seven corresponding authors were emailed for 
missing data, of which one was able to provide the data required and two responded 
but were unable to provide the missing data.  Heterogeneity of the studies, in terms of 
study methods and reporting methods for the results, was observed to determine 
feasibility of a meta-analysis. A forest plot was drawn for cytokines where at least two 
studies had reported similar types of point estimates, e.g. hazard ratios (HRs). This 




Figure 4.1 Eligibility screening form  
This form, adapted from Boland et al,246 was used to screen full papers when 
deciding whether to include or exclude studies for the systematic review. The full names 




4.3.1 Study characteristics 
The search strategy resulted in 1159 records, of which 252 were duplicates. From 
the 907 abstracts screened, 108 full-text articles were assessed for eligibility, and 10 
observational studies with a combined population of 3,287 ACS patients were found to 
meet the inclusion criteria (Figure 4.2).22,29,31-33,132,141,143,248,249 There was heterogeneity 
between the studies in terms of the cytokines analysed, clinical endpoints, population 
and follow-up length (Table 4.1). Heterogeneity was also observed for blood collection 
times, ranging from a strict time of less than six hours from symptom onset to within 10 
days of symptom onset.248,249 The variation in the definitions of MACE and follow-up 
lengths between the studies resulted in different rates of MACE between the studies. 
For example, Skau et al. excluded all other cardiovascular outcomes other than death, 
but had a high mortality rate of 24%.22 This was largely due to a long follow-up of 6.9 
years (median).22 Conversely, Kilic et al. had a MACE rate of 29% within one year of 
follow-up, but their definition of MACE was less stringent and included several 
outcomes such as recurrent rest angina.143 Novo et al. also had a high MACE rate of 
67%, but also had a looser definition of MACE combined with a follow-up length of six 
years.29 
In total, there were 25 different cytokines analysed by the 10 studies, with nine of 
them measuring IL-6,22,29,31,33,132,141,143,248,249 seven measuring IL-10,29,32,132,141,143,248,249 
four measuring MCP-1,22,29,33,249 three measuring IL-1ra,22,29,141 three measuring IL-
18,22,32,132 and three measuring TNFα.29,141,143 Six of the studies were cohort by design 
and four were case-control, though all were prospective. The size of the ACS group in 
each study ranged from 33 to 981, and follow-up length ranged from one to 6.9 years. 





Figure 4.2  PRISMA flow diagram of selection process  
A flow diagram depicting how studies from the systematic searches were included 
or excluded to result in the final selection of studies for the systematic review. Flow 
chart adapted from the Preferred Reporting Items for Systematic Reviews and Meta-
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Table 4.1   Study characteristics 
Author 
(Year) 






Endpoints; follow-up Data sources 
Skau et al. 
(2018)22 a 
AMI ± invasive procedure 
(847); 24%  
<72h from admission; 
plasma 
13 cytokines, including IL-6, IL-
18, & MCP-1; PEA chip 
All-cause death; median 6.9 
years 
Medical records & 
patient reporting 
Novo et al. 
(2015)29 a 
AMI ± invasive procedure 
(33); 67% 
<24h from symptom 
onset; serum 
23 cytokines, including IL-6, IL-
10, MCP-1, & TNFα; Luminex 
MACE; 6 years Not stated 
Yu et al. 
(2013)248 b  
STEMI ± invasive 
procedure (40); 30% 
<6h from symptom 
onset; plasma 
IL-6, IL-10; ELISA  MACE; 4 years Not stated 
Simon et al. 
(2013)31 a 
AMI ± invasive procedure 
(n = 981); 18% 
<48h from symptom 
onset; serum 
IL-6, IL-17; flow cytometry* MACE; 2 years Not stated 
Kaski et al. 
(2010)132 a 
NSTE-ACS ± invasive 
procedure (610); 9.8% 
<48h from symptom 
onset; serum 
IL-6, IL-10, IL-18; ELISA MACE; 1 year Outpatient clinics 
Chalikias et 
al. (2007)32 a 
ACS ± invasive procedure 
(186); 26% 
<1h from admission; 
serum 
IL-10, IL-18; ELISA MACE; median 15 months Outpatient clinics, 
telephone & 
hospital records 
Kilic et al. 
(2006)143 a 
NSTE-ACS w. invasive 
procedure (80); 29% 
On admission; serum IL-6, IL-1β, IL-10 & TNFα; ELISA MACE; 1 year Not stated 
Hung et al. 
(2006)33 b 
ACS + angiogram (92); 
21% all-cause death, 7.6% 
cardiac death, 0% MI, 




IL-6, MCP-1; ELISA Death (cardiac vs non-
cardiac), MI & recurrent 





al. (2005)141 b 
AMI ± invasive procedure 
(184); 18% 
14 ± 9h after symptom 
onset; serum 
IL-6, IL-10, IL-1ra & TNFα; 
ELISA 
MACE; median 406 days Outpatient clinics 
& telephone 
Ueland et al. 
(2005)249 b 
AMI + acute HF (234); % 
not stated 
<10 days of symptom 
onset;251 plasma 
IL-6, IL-10, MCP-1; ELISA Cardiac death, all-cause 
death, MI & angina; 2 years 
Not stated 
This table summarises the methodology of the studies included in the systematic review.  
*Detection assay only for IL-17; assay for IL-6 not stated; a study is a cohort; b study is a case-control 
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4.3.2 Methodological quality 
The evaluation of the quality of the studies have been summarised in Tables 4.2 
and 4.3. Internal validity was determined by the risk of bias and completeness of 
adjustments for confounding, with six papers having acceptable internal validity, and 
four having poor quality. No studies had a high internal validity, due to the absence of 
case-control studies of high quality. In addition, by definition according to SIGN, no 
single cohort study designs should be scored as high quality as they have an increased 
risk for bias.247 The investigators also believed that overall, none of the studies had 
robust methodology. For example, the majority of the papers did not clearly state as to 
why certain cytokines were chosen over others. The rationales inferred from the 
manuscripts seemed to be the results from previous studies and availability of 
commercial kits for analysing combinations of cytokines in a relatively inexpensive and 
efficient manner. Only one study validated their cohort size using a power calculation 
for one of the biomarkers they analysed, but found that their cohort might still have 
been underpowered for the other biomarkers.132 Only one study mentioned a 
participation rate,22 and only two studies blinded their researchers from MACE 





Table 4.2   Cohort quality assessment 
This table summarises the quality assessment findings of the six cohort studies 
included in this systematic review. 
Y = Yes, N = No, NA = Not applicable, CS = Can’t say, ++ = High quality, + = Acceptable 
quality, 0 = Poor quality 
‡ Internal validity assessed by risk of bias and completeness of adjustments made 






























1.1 Appropriate and focussed 
study question 
Y Y Y Y Y Y 
1.2 Groups selected from 
comparable source populations 
NA NA NA NA NA NA 
1.3 Participation rate (%) 94.4 CS CS CS CS CS 
1.4 Subjects having outcome 
during enrolment 
NA NA NA NA NA NA 
1.5 Lost to follow-up (%) 0.24 CS <2 10 2.6 CS 
1.6 Comparison between full 
participants and lost to follow-
up 
NA N CS Y CS N 
1.7 Defined outcomes Y Y Y Y Y Y 
1.8 Outcome assessment made 
blind to cytokine measurements 
N N Y Y N N 
1.9 Recognition that knowledge 
of cytokine levels could 
influence outcome assessment 
N N Y Y N N 
1.10 Methodology of cytokine 
measurement 
Y Y Y Y Y Y 
1.11 Methodology of outcome 
assessment 
Y Y Y Y Y Y 
1.12 Repeated cytokine 
measurements 
CS CS CS CS CS CS 
1.13 Adjustment for 
confounding 
Y Y Y Y Y Y 
1.14 Confidence intervals 
provided 
Y Y Y Y Y Y 
2.1 Internal validity of study‡ + + + 0 + 0 
2.2 Association between 
cytokines and outcome 
CS CS Y Y Y CS 
2.3 Study results applicable to NZ 
population 
Y Y Y Y Y CS 
106 
 
Table 4.3   Case-control quality assessment 
Quality factor 












1.1 Appropriate and focussed study 
question 
Y Y Y Y 
1.2 Cases and controls selected from 
comparable source populations 
Y Y Y CS 
1.3 Same exclusion criteria for cases 
and controls 
CS Y Y CS 
1.4 Participation rate per group (%) CS CS CS CS 
1.5 Baseline comparison between 
cases and controls 
Y Y Y N 
1.6 Cases defined and differentiated 
from controls 
Y Y Y Y 
1.7 Controls established as non-cases Y Y Y Y 
1.8 Measures to prevent knowledge of 
primary exposure influencing case 
ascertainment 
NA N N N 
1.9 Methodology for cytokine and 
outcome measurement 
Y Y Y Y 
1.10 Adjustment for confounding Y Y Y Y 
1.11 Confidence intervals provided Y Y Y Y 
2.1 Internal validity of study + 0 + 0 
2.2 Association between cytokines 
and outcome 
CS CS Y CS 
2.3 Study results applicable to NZ 
population 
CS CS Y CS 
This table summarises the quality assessment findings of the four case-control 
studies included in this systematic review. 
Y = Yes, N = No, NA = Not applicable, CS = Can’t say, ++ = High quality, + = Acceptable 
quality, 0 = Poor quality 
‡ Internal validity assessed by risk of bias and completeness of adjustments made 
for potential confounders 
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4.3.3 MACE outcomes and forest plot 
Table 4.4 summarises the statistically significant findings found for the clinical 
endpoints of the studies. Six of the studies found a significant association between 
individual cytokines and MACE, either by univariate or multivariate 
analysis.22,29,31,32,141,248 Figure 4.3 shows a forest plot summarising the point estimates 
calculated for IL-6, IL-10 and IL-18. Four of the six studies that produced an HR for IL-6 
had values above 1.0022,29,31,132,141,248 and three of those HRs were statistically 
significant,22,31,141 indicating that IL-6 may be a risk factor for MACE. There were mixed 
findings for IL-10, with two of the studies with statistically significant findings showing 
that the biomarker was protective for MACE, 32,248 and one study showing the 
opposite.141 Kaski et al. found IL-18 to be a risk factor for MACE (defined as a composite 
of death, MI, UA, percutaneous coronary intervention and coronary artery bypass graft) 
but the same cytokine had an HR below 1.00 for death and MI alone (the secondary 
endpoint).132 The other two studies that assessed IL-18 found an odds ratio (OR) and an 
HR per unit change above 1.00.22,32 No point estimate was given for IL-6 by three 
studies,33,143,249 and for IL-10 by two studies.143,249 Valgimigli et al. only gave an “analysis 
of continuous variables” HR and an “above versus below median” HR, which were not 
comparable to the other HRs calculated, so it was separated in the forest plot.141 For 
TNFα, one study did not give a point estimate,143 one gave an HR,141 and another gave 
an OR,29 so they were unable to be combined into a forest plot. Similar to TNFα, two 
studies did not give point estimates for MCP-1,33,249 and the other two studies had 
different point estimates.22,29 All of the three studies that measured IL-1ra gave 
different point estimates (HR per unit change, HR for analysis of continuous variables, 
and OR).22,29,141 
The eight studies that conducted a multivariate analysis made adjustments for a 
variety of potential confounders, based on what was found to be statistically significant 
in the univariate analysis. All studies that measured individual cytokines on multivariate 
analysis found that a portion of those cytokines were not significantly associated with 
MACE, except for Kilic et al., who found all individual cytokines in their multivariate 
model to not have significant correlations.143 Skau et al. and Chalikias et al. used several 
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models adjusted for different groups of confounders.22,32 Skau et al. had four models: 
one for age and sex alone; one for traditional risk factors for MACE; one for age, sex and 
biomarkers including growth differentiation factor-15 (GDF-15), and TNF-related 
apoptosis-inducing ligand receptor-2 (TRAIL-R2); and a final model including traditional 
risk factors and the selected biomarkers.22 All four models produced high AUCs from 
ROC curves ranging from 0.79 for the model adjusting for only age and sex, to 0.88 for 
the model adjusting for both traditional risk factors and the selected biomarkers.22 
Chalikias et al. had four models based on clinical factors that were significant on 
univariate analysis, lipid-related risk factors, MACE-related risk factors and 
medications.32 Out of these four models, IL-10 and IL-18 individually were only 
significantly associated with MACE in one or two of these models, while a combined IL-
18/IL-10 ratio was significantly associated with MACE in all models.32 
Four studies analysed the association between MACE and the combined effect of 
multiple cytokines.22,29,32,143 Skau et al. used L1 penalised regression analysis to 
determine the optimal set of cytokines needed for predicting all-cause death.22 Initially 
they found that 32 biomarkers gave a ROC AUC of 0.85, but reducing this set of markers 
to only GDF-15 and TRAIL-R2 produced the same AUC.22 Combining these two markers 
with traditional risk factors for MACE in multivariate analysis resulted in a ROC AUC of 
0.89, with a net reclassification improvement of 0.09 (p = 0.001).22 Out of the 27 
cytokines analysed, Novo et al. found that an additive score of greater than 13, with a 
point given for each cytokine concentration above the median, resulted in an AUC of 
0.72.29 Chalikias et al. and Kilic et al. analysed a pro-inflammatory cytokine and an anti-
inflammatory cytokine as ratios (such as IL-6/IL-10) and found that they were significant 
predictors of MACE.32,143 For Chalikias et al., the ORs were greater for all four models of 
the ratios compared with the individual cytokines.32 For Kilic et al., the ratio OR for IL-




Table 4.4   Significant outcomes 
Author 
(year) 
Endpoints Univariate analysis Adjusted multivariate analysis Combined cytokine 
analyses Primary endpoint Primary endpoint Factors adjusted for 
Skau et al. 
(2017) 22 
All-cause death Results not given IL-1ra = 1.36 (1.21-
1.52)1 
IL-6 = 1.31 (1.17-1.47)1 
IL-8 = 1.48 (1.34-1.64)1 
IL-16 = 1.35 (1.19-1.54)1 
IL-18 = 1.27 (1.13-1.43)1 
IL-27A = 1.66 (1.48-
1.85)1 
MCP-1 = 1.20 (1.07-
1.36)1 
MIP-1α = 1.55 (1.39-
1.72)1 
MIP-1β = 1.24 (1.12-
1.38)1 
MIP-3α = 1.41 (1.28-
1.56)1  
CXCL16 = 1.30 (1.15-
1.47)1 
Age and sex Penalised regression 
analysis showed that 32 
markers (incl. IL27A, MIP-
3α & CXCL16) and GDF-15 
+ TRAIL-R2 alone had ROC 
AUCs of 0.85. In 
combination with 
traditional risk factors, the 
AUC was 0.89 with NRI 
0.09 
Novo et al. 
(2015) 29 
Composite of 




IL-8 OR = 1.13 (1.00-
1.28) 
IL-10 OR = 1.14 (0.99-
1.30) 
MIP-1β OR = 1.01 (1.00-
1.03) 
Stated no statistically 
significant ORs were 
found 
Not stated Logistic regression; 
Higher rank score (with all 
27 biomarkers): F = 5.07; 
ROC curve analysis: Score 
of >13 cytokine levels 
above the median was a 
better predictor of MACE, 





Endpoints Univariate analysis Adjusted multivariate analysis Combined cytokine 
analyses Primary endpoint Primary endpoint Factors adjusted for 
Yu et al. 
(2013) 248 
Composite of all-cause 
death, MI, stroke 
(unspecified) & TLR 
IL-10 HR = 0.935 (0.902-
0.969) 
No multivariate analysis 
conducted 
No multivariate analysis 
conducted 
No combined analysis 
conducted 
Simon et 
al. (2013) 31 
Composite of all-cause 
death + MI 
IL-17 HR  = 1.44 (1.07-
1.95) 
IL-17 HR = 1.40 (1.03-
1.91) 
IL-17 = 0.88 (0.79-0.99)1 
IL-6 = 1.20 (1.05-1.37)1 
Sex; age; smoking; BMI; family 
history of CAD; history of HTN, 
AMI, HF, renal failure, or DM; 
HR at admission; Killip class, 
LVEF; hospital management; & 
log CRP 
No combined analysis 
conducted 
Kaski et al. 
(2010) 132 
Primary endpoint: 
Composite of all-cause 
death, MI, UA, PCI, & 
CABG 
Secondary endpoint: 
Composite of death & 
MI 
Stated no statistically 
significant HRs were 
found 
No statistically 
significant HRs were 
found 
TIMI risk score, HF and 
previous CAD 
No combined analysis 
conducted 
Chalikias et 
al. (2007) 32 
Composite of cardiac 
death, MI, UA 
requiring meds & 
urgent 
revascularisation 
No data from univariate 
analysis included in 
paper 
Model 1: 
IL-18 OR = 1.59 (1.11-
2.27) 
Model 3: 
IL-10 OR = 0.6 (0.42-
0.87) 
Model 1: CRP, TnT, diagnosis 
on admission, 
revascularisation, β-blocker & 
EF<40% 
Model 2: Total cholesterol, 
LDL, HDL & triglycerides 
Model 3: Age, sex, DM, HTN, 
smoking, creatinine, LDL, HDL 
& prior CAD 
Model 4: β-blocker, statin, 
ACEi & revascularisation 
Logistic regression of IL-
18:IL-10 cytokine ratio:  
Unadjusted:  
OR = 1.91 (1.37-2.65) 
Model 1:  
OR = 2.31 (1.55-3.42) 
Model 2:  
OR = 1.86 (1.33-2.61) 
Model 3:  
OR = 2.33 (1.58-3.45) 
Model 4:  





Endpoints Univariate analysis Adjusted multivariate analysis Combined cytokine 
analyses Primary endpoint Primary endpoint Factors adjusted for 
Kilic et al. 
(2006) 143 
Composite of cardiac 
death, new-onset MI 
and recurrent rest 
angina. 
No data from univariate 
analysis included in 
paper 
Stated IL-1β, IL-6 and IL-
10 ORs were not 
significant 
hsCRP IL-6:IL-10 OR = 2.2 (1.2-
3.9) 
Stated IL-1β:IL-10 OR 
wasn’t significant 
Hung et al. 
(2006) 33 
Death (classified into 
cardiac & non-
cardiac), MI and 
recurrent angina. 
No data from univariate 
analysis included in 
paper 
Stated no independent 
predictors were found 
Smoking, WBC, monocyte 
count, log CRP 





Composite of all-cause 
death & HF 
TNFα HR = 1.4 (1.5-1.3)2 
IL-6 HR = 1.16 (1.2-
1.15)2 
IL-10 HR = 1.09 (1.15-
1.07)2 
No multivariate analysis 
conducted 
No multivariate analysis 
conducted 






cause death, MI & 
angina 
No non-significant RRs 
were stated for baseline 
measurements 
No non-significant HRs 
were stated for baseline 
measurements 
Smoking, prior MI, DM, 
medication, age, sex, 
creatinine clearance, NYHA 
functional class, NT-proBNP & 
hsCRP 
No combined analysis 
conducted 
The significant findings related to the primary endpoints of the studies are summarised in this table. All values are statistically significant (p 
≤ 0.05). Values that are not statistically significant are not included.  AUC - area under the curve; CXCL16 - C-X-C motif chemokine ligand; DM - 
diabetes mellitus; EF - ejection fraction; GDF-15 - growth differentiation factor-15; HR - hazard ratio; hsCRP - high sensitivity C-reactive protein; 
IL - interleukin; MCP-1 - monocyte chemoattractant protein-1; MIP - macrophage inflammatory protein; NRI - net reclassification index; NT-
proBNP - N terminal pro hormone B-type natriuretic peptide; NYHA - New York Heart Association; OR - odds ratio; ROC - receiver operator 
characteristic; TIMI - thrombolysis in myocardial infarction; TLR - target lesion revascularisation; TNFα - tumour necrosis factor-alpha; TRAIL-R2 
- tumour necrosis factor-related apoptosis inducing ligand-receptor 2; WBC - white blood cell. 
1 HRs were calculated for per unit change; 2 HRs were calculated by comparing patients with biomarker levels above the median to those 




Figure 4.3  Forest Plot for IL-6, IL-10 and IL-18 
Hazards ratios (HRs) and odds ratios (ORs) from each study were based on the 
difference in biomarker (IL-6, IL-10 or IL-18) levels between patients who developed 
MACE and patients who did not, unless specified otherwise. Point estimates that are 
statistically significant have 95% CIs that do not encompass 1.0. Studies with point 
estimates above 1.0 demonstrate that the biomarker has an increased risk for MACE, 
while point estimates below 1.0 demonstrate a protective factor for MACE.  
Kaski 2010 a presents the point estimate for the primary endpoint, while b presents 
the point estimate for the secondary endpoint. 
1HR was calculated for a 1 unit change in the biomarker; 2HR was calculated for an 




In the 10 studies analysed in this systematic review, a large heterogeneity was 
observed for methodology, length of follow-up and blood collection. All studies had 
either acceptable or poor internal validity, with no clear rationale behind the cytokines 
chosen for the studies and a general poor reporting on the validation of cohort size. 
There were mixed associations when considering any individual cytokine as predictors 
of MACE, but out of the four studies that did a multi-marker analysis, all showed a 
significant statistical association. 
To answer the primary study aim, a systematic review was chosen because a 
systematic search would ensure an inclusion of most, if not all, relevant studies. 
However, this study type also allowed us to compare the methodologies across studies. 
This review highlighted the heterogeneity in methodology for studies assessing the 
prognostic value of inflammatory cytokines in ACS patients with at least one year follow-
up for MACE. This heterogeneity included the cytokines selected for analysis. One of 
the main reasons why it was not appropriate to conduct a meta-analysis was that many 
of the cytokines were investigated in two studies or less. Many of the studies mentioned 
that previous studies had found some or all of the cytokines of focus to be significant in 
ACS.29,32,132,141,143,248,249 Investigating the reproducibility of previous findings is 
important, but there was no explanation as to why certain cytokines were chosen in 
each study over others that have also been proven to correlate with MACE following 
ACS. However, it is recognised that analysing all cytokines and chemokines that have 
been associated with ACS would be extremely time consuming and expensive to do. 
Skau et al. implied that the decision on which cytokines to measure was based on the 
assay kits available.22 It is common for limited resources to be a barrier to optimal 
methodologies.  Only Simon et al. clearly explained their interest in exploring the role 
of IL-17 and other markers related to the IL-17 biological pathway with MACE.31 With 
greater availabilities of affordable assay kits and further studies clarifying which 
markers are most promising for predicting MACE, this may lead to improved rationale 
for choosing which cytokines to analyse.  
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Cytokines investigated for its association with MACE have traditionally been 
measured after the onset of AMI due to accessibility of samples in this period. However, 
another factor that caused heterogeneity between the studies was the time blood 
samples were collected. Three of the studies mentioned that measuring cytokine levels 
from only one time point could be a limitation because the levels were dynamic within 
the acute phase and the blood samples might not have been collected at the peak 
cytokine levels.31-33 Skau et al. also mentioned that their study could not determine to 
what extent the biomarkers remained elevated in the acute phase, as they only 
collected one sample within 72 hours.22 The few studies that have collected serial blood 
samples have consistently shown that cytokine levels fluctuate significantly in the acute 
phase after an AMI.230,232,252 Many cytokines have not been assessed for its levels across 
time, so it is unknown whether some may have steady-state levels across the acute 
phase of AMI, and what the significance of fluctuating or steady cytokine levels may be 
for predicting MACE. Further research is required to investigate this. While it is relatively 
straightforward to collect single samples from patients at some time point during a 
hospital admission, the complexity of any study increases considerably when the time 
point is more precisely defined relative to symptom onset, or when multiple time points 
are selected. However, despite the increased complexity, moving away from an 
opportunistic sampling approach to sampling at deliberately chosen time points within 
the evolution of myocardial infarction may produce results that are more consistent, 
sensitive and specific. 
These 10 studies also showed variation in cohort size, ranging from 33 to 981 
patients, with only one mentioning a power calculation to validate their cohort size in 
their paper.132 Power calculation is a common method to determine cohort size.253 
However, Kaski et al. found it difficult to ascertain that the cytokine chosen for the 
power calculation was sufficient to represent the other cytokines.132 The rate of MACE 
in a study will be dependent on the risk of the population enrolled, the definition of 
MACE used (endpoints included in the composite) and the length of follow-up. The 
definition of MACE used can also lead to bias if more subjective endpoints, such as 
recurrent angina, are included. In this review, the MACE rates ranged from 9.8% to 67%, 
which is likely to reflect the differences in the factors mentioned. Statistically, a certain 
115 
 
number of events should be added per variable included in a regression model, 
although this number being widely debated.254 However, it is unlikely that Novo et al.’s 
study had enough events for the 46 variables included in the logistic regression analysis, 
with only 11 patients in the MACE group.29 Overall, improvement is needed for 
validating sample sizes in these studies.  
The current paradigm is individuals with elevated levels of pro-inflammatory 
cytokines and low levels of anti-inflammatory cytokines are at increased risk of MACE 
following AMI. However, only six of the studies included in this review found a 
statistically significant association between certain individual cytokines and MACE via 
univariate or multivariate analyses (Table 4.4).22,29,31,32,141,248 Figure 4.3 showed that 
although the majority of the point estimates for IL-6 demonstrated that elevated levels 
might be predictive for MACE,22,31,132,141 and half of the point estimates for IL-10 
demonstrated that elevated levels might be protective,32,132,248 some of these point 
estimates did not reach statistical significance and some studies had point estimates 
that did not contribute to this conclusion. Liu et al. conducted a meta-analysis of 12 
studies on IL-10 in ACS patients and found that an elevated level of IL-10 was associated 
with a slight increase in risk of MACE during a follow-up of at least 30 days (relative risk 
= 1.009, 95% CI 1.005-1.013, p<0.001),255 which is a surprising result for an anti-
inflammatory cytokine. Variations in the methodologies of these studies are likely to 
contribute to these inconsistent findings, reflecting a need for a more robust and 
homogeneous methodology.  
There is clear evidence that cytokines work together in a complex inflammatory 
network, where an imbalance of pro-inflammatory and anti-inflammatory cytokines 
may lead to adverse outcomes.256 As mentioned in Chapters 2 and 3, examining 
individual biomarkers that are non-specific to ACS may be insufficient to capture a 
snapshot of this inflammatory network and how it relates to MACE.257,258 Observations 
from our systematic review showed that results for individual cytokines were 
inconsistent and of the four studies that conducted a combined biomarker analysis, all 
had statistically significant results.22,29,32,143 Therefore, a combined biomarker approach 
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may be a better option for future studies to better reflect underlying inflammatory 
changes that could cause MACE.  
The four studies all used different methods to combine their markers, with no 
obvious rationale for the method chosen in each study. The methods included creating 
ratio of pro-inflammatory to anti-inflammatory cytokines,143 logistic regression,29,32 
creating a rank score,29 and penalised regression analysis.22 A limitation of these 
methods is that because cytokines have overlapping functions,256 there is a risk that 
these studies may have over-counted their effects of each cytokine by analysing each 
one as an independent risk factor. A complex inflammatory network cannot be 
represented by a simple analysis of multiple cytokines. Three studies have investigated 
over 10 cytokines in ACS patients,22,29,95 with one providing no analysis between the 
cytokine scores and MACE after at least one year of follow-up.95 The inflammatory 
cytokines included in Skau et al. and Novo et al.’s studies served as a good foundation 
for examining a combined inflammatory panel to predict risk of MACE.22,29 However, 
further investigation is needed to determine which set of cytokines creates the optimal 
inflammatory panel and how best to combine these markers into a composite score.  
The initial promise of targeting inflammation as a therapeutic intervention has not 
yet led to improved clinical outcomes.259,260 However, the idea that those with 
pathologically elevated inflammation might be effectively targeted with anti-
inflammatory therapy has received new impetus due to the results of the CANTOS 
trial.158 Improved methodologies to characterise pathological inflammation in both the 
acute and chronic stages of myocardial infarction may allow this promise to be achieved 
to a greater completion. We would suggest that a multi-marker approach is sufficiently 
promising to warrant further investigation, despite the limitations discussed above in 
the existing literature.    
The selection process required to answer our systematic review question caused 
our literature search to be limited to papers looking specifically at combined versus 
single marker measures and comparing them in the paper analyses. This represents 
potential selection bias in Table 4.4, as the small number of single cytokine results may 
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not be representative of the totality of the literature. The specific selection criteria also 
resulted in our forest plot displaying only a small subset of three cytokines for a visual 
representation of our observations. As mentioned earlier, one of the limitations of this 
study was being unable to conduct a meta-analysis, largely due to the heterogeneity of 
the methodologies. Statistically, it would also be incorrect to combine the different 
summary statistics, such as HRs and ORs, for meta-analysis.261 This reflects a limitation 
in the current literature. However, we were still able to design a forest plot for three of 
the cytokines as a visual representation of our observations. This review has only 
focussed on the prognostic ability of cytokines and chemokines, but other inflammatory 
biomarkers may also be important to consider, such as white blood cell subtypes.47,50 
We were also interested in long-term outcomes, which is why we excluded follow-up 
lengths less than an average of one year. However, this caused a large number of studies 
to be excluded from our review. Lastly, we chose to include studies that had ACS 
populations, i.e. unstable angina as well as AMI, to be able to have a sufficient number 




Although some studies have reported significant associations between individual 
cytokines and MACE, we found mixed associations from the 10 studies included in this 
review. However, a combined analysis of multiple cytokines appears to have a greater 
association with MACE. This review highlights some gaps in the current body of 
evidence on the relationship between inflammatory cytokines and MACE in ACS 
patients, showing that there is a considerable heterogeneity in methods and results, 
such as cytokine selection, blood collection times and cohort sizes. We would 
recommend that future studies provide a rationale for their cytokine selection and be 
adequately powered to detect a clinically significant difference in appropriately defined 
MACE outcomes. It was observed that these 10 studies used opportunistic sampling and 
did not try to control the sampling time. Our question from Chapter 3 about time as a 
potential confounder could not be answered by these studies. Further investigation is 
required to determine the importance of time of blood collection, which will be 
explored in Chapter 5. Finally, a multi-marker approach is promising and may be a future 
target for research. Further investigation is required to determine which set of markers 
creates an optimal panel and which method(s) can be used to combine the markers 
while accounting for collinearity. Chapters 6 and 7 will aim to provide further insight 
into this question with a larger cytokine panel and a more comprehensive mathematical 








In Chapter 3, no significant association was found between three biomarkers (CRP, 
IL-6 and TNFα) and MACE. It was hypothesised that the time the blood samples were 
collected from symptom onset might have been a potential confounder affecting the 
associations between these biomarkers and MACE. If the biomarkers were measured 
outside of the time window that their concentrations were elevated and detectable, 
pathological inflammation would not be well-characterised by these markers and no 
association would be found with MACE on statistical analysis. In Chapter 4, the 
systematic review was unable to answer whether time was a potential confounder. It 
did, however, show that measuring a combination of cytokines might be a superior 
approach to measuring individual cytokines as predictors of MACE. So far, the only 
cytokines that have been investigated in this thesis are IL-6 and TNFα, as they are two 
predominant cytokines in this field. However, there are many other cytokines that may 
be investigated as predictors of MACE (see section 1.2.3), and there has been no 
systemic investigation into which cytokines are promising to investigate pathological 
inflammation in AMI patients.  
Although time is an important factor in characterising pathological inflammation, 
the literature showed differences in peaks and trends observed between 
studies.20,115,262-264 Santoro et al. measured 12 cytokines at Day 1 and Day 5 after 
hospital admission in ACS.262 Some cytokines (such as IL-6) had higher means on Day 1 
compared with Day 5, some (such as TNFα) had higher means on Day 5, and the 
remainder (such as MCP-1) had similar means on the two days.262 Qin et al. found similar 
results to Santoro et al. for IL-6, where levels peaked at admission in AMI patients.230 
However, they found TNFα peaked at admission, which differed to Santoro et al.230 
Differing results were also found between Kobusiak-Prokopowicz et al. and Korybalska 
et al. for MCP-1.115,265 The differences in the peaks and trends observed over time 
reflect that further investigation around the dynamic changes in cytokine levels is 
required. Investigating the changes in concentrations of many cytokines in AMI patients 
over time and finding the optimal acute timepoint for measuring cytokines will be 
informative for characterising excessive inflammation. It will aid in determining the best 
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time to measure cytokines in a clinical setting to assess their prognostic abilities for 
adverse outcome. It will also be beneficial to ascertain whether time is a confounding 
factor for future biomarker studies. 
To better understand how cytokines may affect pathological inflammation in AMI, 
it is important to determine what the potential drivers of changes in cytokine 
concentrations over time may be. Korybalska et al. found that the MCP-1 levels were 
inversely correlated with time from symptom onset to reperfusion.265 No other baseline 
or clinical parameter was found to be associated with the MCP-1 levels,265 leaving it 
unknown as to what could be the underlying drivers of the variation in the observed 
MCP-1 levels. In Chapter 3 some variation was also observed for TNFα concentrations 
with interquartile ranges being 2.78-fold that of the median for the cases (AMI patients 
who developed MACE within one year) and 4.12-fold for the controls (AMI patients who 
did not develop MACE). Again, potential causes of the variation could not be found in 
the case-control study. To have a deeper understanding of the inflammatory processes 
that occur post-AMI, it will be interesting to investigate which baseline or clinical 
parameters are associated with peak cytokine levels. 
Therefore, the aims of this study were to 1) investigate the change in cytokine 
concentrations over time, 2) determine an optimal sampling timepoint within the acute 





5.2.1 Study population 
The Measurement of Inflammation in Myocardial Infarction over Time (MIMIT) 
study was designed as an observational cohort study. Patients admitted to Wellington 
Regional Hospital were recruited within 24 hours of ischaemic symptom onset between 
March and December 2018. These patients met the study criteria if they had a diagnosis 
of AMI (STEMI or NSTEMI) with a planned invasive approach (coronary angiography with 
or without percutaneous coronary intervention); were living in the domicile for 
Wellington Hospital; were not on any immune-modulating therapy or dialysis; had no 
significant inflammatory conditions that could affect cytokine levels or cytokine 
clearance from the system (such as active malignancy237 or renal insufficiency266); had 
left ventricular ejection fraction (LVEF) >30%; did not require cardiac defibrillation; and 
did not have atrial fibrillation or cardiogenic shock. AMI was defined using the third 
universal definition of ACS as explained in section 2.2.1.199 All patients gave voluntary 
written consent for their participation in this study and the study was approved by the 
Central Health and Disability Ethics Committee (17/CEN/212). 
To be able to detect trends in cytokine levels over time and observe variations, we 
aimed to recruit between 20 and 30 AMI patients. In Chapter 3, the AMI study 
population (138 patients in total) was stratified according to when the blood sample 
was collected. Out of the patients who had their blood samples collected within the first 
four days from symptom onset, the coefficient of variation for TNFα ranged from 112% 
on Day 4 in 23 patients, to 286.8% on Day 3 in 22 patients (data not shown). We 
expected to be able to detect a similar amount of variation in this study.  
 
5.2.2 Data collection and sampling methods 
Data on patients’ demographics, clinical characteristics, current medications, 
procedural data, clinical management and in-hospital outcomes were collected at the 
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time of recruitment from the hospital medical records and cardiac catheterisation 
database. The clinical characteristics were defined as in Table 2.1. 
Cytokine concentrations have been shown to vary across the acute phase following 
symptom onset of AMI, with studies reporting an average of 139% change from hospital 
admission up to six months later.20,101,115,116,230-232,262-265 The sampling timepoints were 
chosen to allow us to capture the most information but also balance it with viability of 
patients’ consent and feasibility to obtain serial blood samples in the clinical setting of 
Wellington Regional Hospital. Hence, blood samples were collected daily during the 
patients’ hospital admission until discharge at Day 3 or Day 4, as well as at the next one 
or two follow-up appointments (six weeks ± two weeks and six months ± one month). 
In six patients, the first follow-up appointments did not fall in the six weeks ± two weeks’ 
time window, so not all of the patients had samples for this time point. At each time 
point, whole blood samples were collected in tubes coagulated with sodium EDTA 
(10mL BD Vacutainer, New Jersey, USA) from the peripheral vein or from the arterial 
sheath just before heparin administration during the angiography. The plasma was 
separated from the other blood components by centrifugation at 1500g for 20 minutes. 
Once this was done, the samples were stored at -80oC until analysis. 
 
5.2.3 Cytokine analysis 
A total of 12 cytokines were analysed: IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-
γ, MCP-1, RANTES, TNFα, and VEGF. These cytokines were selected because there was 
some evidence in the literature that they might be associated with pathological 
inflammation and adverse outcome, and because of the ease in which they were able 
to be grouped into panels for laboratory analysis. The inflammatory roles of these 
cytokines have been discussed in section 1.2.3 and Table 5.1 presents the rationales for 
the chosen cytokines. These cytokines were analysed with cytometric bead array (CBA) 
and ELISA kits. The concentrations of the lowest standards for each cytokine were 
included in Table 5.1. The CBA kits were multiplexed in the following configurations: 
One assay consisted of seven cytokines, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ and TNFα 
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(Enhanced Sensitivity Human Soluble Protein CBA Flex Set, BD Biosciences; CA, USA), 
another consisted of four cytokines, GM-CSF, MCP-1, RANTES and VEGF (Human Soluble 
Protein CBA, BD Biosciences; CA, USA), and the third one consisted of a commercially 
available ELISA kit used to quantify levels of IL-1β in the plasma (Human IL-1β Ready-
Set-Go ELISA, Invitrogen, Thermo Fisher Scientific; CA, USA).  
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Table 5.1   Overview of cytokines selected for analysis 
Cytokine Assay Lowest 
standard 
Rationale 
IL-1β ELISA 0.586 Indicated as a prognostic marker for in-hospital outcomes in AMI and associated with LV dysfunction in AMI.20,97,267 
The CANTOS trial showed inhibition of IL-1β with canakinumab showed reduced MACE (non-fatal MI, cardiovascular 
death or stroke) in stable CAD.158 
IL-2 CBA 0.274 IL-2 therapy in experimental studies resulted in less adverse cardiac repair post-MI.268 
IL-4 CBA 0.274 Indicated as a prognostic marker for severe LV dysfunction in STEMI.264 
IL-6 CBA 0.274 Indicated as a prognostic marker for MACE, death or HF in ACS.91,94,95 
IL-8 CBA 0.274 Indicated as a prognostic marker for MACE and restenosis in AMI.263,269 
IL-10 CBA 0.274 Associated with MACE and impaired LVEF in AMI, and death in STEMI.29,95,270 
GM-CSF CBA 10.0 Indicated as a prognostic marker for LV dysfunction.271 However, GM-CSF treatment in STEMI patients was associated 
with improved LVEF.90,272 
IFNγ CBA 0.274 Indicated as a prognostic marker for restenosis in AMI and severe LV dysfunction in STEMI.264,269 
MCP-1 CBA 10.0 Indicated as a prognostic marker for MACE, death and non-fatal MI in ACS.112,273 
RANTES CBA 10.0 Indicated as a prognostic marker for mortality and progressive atherosclerosis in ACS.113,274 
TNFα CBA 0.274 Indicated as a prognostic marker for MACE in STEMI and ACS.85,96 
VEGF CBA 10.0 Indicated as a prognostic marker for MACE in ACS.127,275 
The assays used to detect the cytokines, the concentrations of the lowest standard that could be detected on the standard curves and the 
rationale behind the cytokines chosen for this study are listed above. All concentrations are in pg/mL and are rounded to three significant figures.  
ACS – acute coronary syndrome; AMI – acute myocardial infarction; CAD – coronary artery disease; CANTOS – Canakinumab Anti-
Inflammatory Thrombosis Outcome Study; CBA – cytometric bead array; ELISA – enzyme-linked immunosorbent assay; GM-CSF – granulocyte-
macrophage colony stimulating factor; IFNγ – interferon-gamma; IL – interleukin; LV – left ventricular; LVEF – left ventricular ejection fraction; 
MACE – major adverse cardiovascular events; MCP-1 – monocyte chemoattractant protein-1; MI – myocardial infarction; RANTES – regulated 
upon activation; normal T cell expressed and secreted; STEMI – ST-elevation myocardial infarction; TNFα – tumour necrosis factor-alpha; VEGF 
– vascular endothelial growth factor. 
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5.2.3.1 Cytometric bead arrays  
The CBA microparticle beads and detection agents were diluted in a 1:5 ratio prior 
to the cytokines being quantified according to manufacturer’s instructions. Each well in 
the plate had microparticle bead populations according to the number of different 
cytokines being analysed, and the beads in each population were pre-coated with 
capture antibodies specific for the respective cytokine of interest. These beads were 
combined with 50µL/well samples or lyophilised standards in a 1:1 ratio with a final 
volume of 100µL/well in the 96-well microplate. To ensure the contents were well-
mixed, the plate was placed on an orbital plate shaker for five minutes. After a two-hour 
incubation, the plate was centrifuged for five minutes at 200 x g and washed twice with 
wash buffer, followed by aspiration of the supernatant. This was done to remove any 
excess sample or standard that had not bound to the capture antibodies on the beads. 
To be able to differentiate between cytokine-bound beads and unbound beads, 
phycoerythrin (PE)-conjugated cytokine-specific detection antibodies were added after 
the plate was washed in two parts. Between the addition of the primary and secondary 
antibody solutions, washing and centrifugation occurred to ensure unbound antibody 
was removed. Wash buffer was added to resuspend the beads, and the plate was placed 
on the plate shaker. Finally, the plate was incubated overnight at 4oC. Each plate was 
read on the FACSCanto™ II flow cytometer (BD Biosciences; CA, USA). The bead 
populations had distinct fluorescent intensities that, with allophycocyanin (APC) and 
allophycocyanin-cyanine dye Cy7 (APC-Cy™7), could be detected by the red laser of the 
flow cytometer. The PE fluorescence intensity from the detection antibodies were 
detected by the yellow-green laser and this was used to determine the cytokine 
concentrations, using the range produced by the 10-point standard curve.  
5.2.3.2 ELISA  
The samples for IL-1β detection were analysed in duplicate in a 1:2 dilution using 
1x ELISA diluent. Human IL-1β lypholised standard was reconstituted with deionised 
water and mixed with ELISA diluent in a 2-fold serial dilution to create an eight-point 
standard curve (0-105pg/mL). A 96-well microplate (Corning Costar 9018) was coated 
overnight at 4oC with the anti-human IL-1β capture antibody according to 
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manufacturer’s protocol. Using 1x wash buffer, the plate was washed three times to 
remove any unbound capture antibody. ELISA diluent (200μL) was pipetted into each 
well and the plate was incubated at room temperature for one hour to minimise non-
specific binding. Excess diluent was removed by physically discarding the remaining 
diluent in the wells and by washing the plate twice. The standard or sample (100µL) was 
added to the wells and the plate was incubated overnight at 4oC to allow it to bind to 
the capture antibody. Again, contents were discarded and the plate was washed five 
times to remove unbound sample or standard. To be able to detect the bound IL-1β, 
anti-human IL-1β detection antibody (100μL) was pipetted into each well and the plate 
was incubated at room temperature for an hour. After a further five washes, 100μL of 
Avidin-HRP solution, which amplified the photometric reaction in an ELISA, was pipetted 
into each well. Following a 30-minute incubation period, excess Avidin-HRP was 
removed from the plate via wash buffer (seven washes) and 100μL of 
tetramethylbenzidine (TMB) ELISA substrate solution was added to begin the 
photometric reaction. Stop solution (50μL) was added to discontinue the reaction after 
the plate had been incubated for another 15 minutes. The plate was read using a plate 
reader (MultiskanTM GO microplate spectrophotometer v.1.01.10, Thermo Fisher 
Scientific, Vantaa, Finland) at 450nm, with correction at 570nm, to account for variable 
absorption across the plate. The intra-assay coefficient of variation was 5.60% and inter-
assay coefficient of variation was 3.20%.  
 
5.2.4 Statistical analysis 
For the CBA plates, data collected from the flow cytometer was analysed on 
FlowJo® (FlowJo, LLC; OR, USA) and FCAP Array Software v3.0 (BD Biosciences; CA USA) 
to obtain a mean fluorescence intensity (MFI). The concentrations of each cytokine 
were calculated using a 5PL fitted standard curve. For the ELISA, IL-1β concentrations 
were calculated from the absorbances using a fitted 5PL standard curve. Due to the 
limited sample volume, any samples with concentrations above or below the lower limit 
of detection (LLOD) were not repeated. Instead, samples with MFIs above the limit of 
detection were all given one concentration that was greater than the highest detected 
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concentration. Samples that had MFIs or absorbances below the lowest standard and 
therefore had undetermined concentrations when fitted with the 5PL curve, but were 
above the LLOD, were extrapolated using linear regression. Unless specified, these 
analyses were conducted on GraphPad Prism v.7 (GraphPad Software Inc.; CA, USA). 
The methods in section 3.2.6 were used, where all samples with undetectable levels of 
cytokines (i.e. below the LLOD) were given the respective LLOD values, which were 
0.0148pg/mL for IFN-γ, 0.384pg/mL for IL-1β, 0.0890pg/mL for IL-2, 0.144pg/mL for IL-
4, 0.0684pg/mL for IL-6, 0.0700pg/mL for IL-8, 0.0137pg/mL for IL-10, 0.200pg/mL for 
GM-CSF, 1.30pg/mL for MCP-1, 0.00200pg/mL for RANTES, 0.0674pg/mL for TNFα, and 
4.50pg/mL for VEGF. Any cytokines where over half of the patients had to be given the 
LLOD concentration for the majority (over 50%) of the timepoints were excluded from 
further statistical analyses to minimise skew of the results. 
Tests of normality (Shapiro-Wilk and D’Agostino), descriptive statistics for baseline 
demographics, and Dunn’s multiple comparisons test to assess any significant 
differences in median rank concentrations across the timepoints were generated using 
GraphPad Prism v.7 (GraphPad Software Inc.; CA, USA). The proportion of patients with 
peak cytokine levels at each timepoint was calculated and a Chi-square test was 
conducted to determine if the difference in proportions across time was significant 
(GraphPad Prism v.7). For each cytokine, the concentrations were divided into deciles 
(one to 10), with decile one containing the lowest concentrations and decile 10 
containing the highest. A heat map for each timepoint was generated to visually display 
the cytokine concentrations each patient had per timepoint (GraphPad Prism v.7). The 
proportion of low cytokine concentrations (deciles one to five) at each timepoint was 
calculated on Microsoft Excel 2016 (Microsoft Corporation; WA, USA). A Chi-square test 
was conducted to examine whether there was a significant difference in proportion of 
low cytokine concentrations across the timepoints (Graphpad Prism v.7). Spearman’s 
rank correlation tests were used to assess the relationships between cytokines per 
single timepoint. This same test was used to assess the correlations between peak 
cytokine levels for each patient and continuous clinical risk factors. Mann-Whitney U 
tests were used to examine the relationships between peak cytokine levels and 
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categorical risk factors. These tests were conducted using SPSS v.24 (IBM; Armonk, NY, 




5.3.1 Baseline demographics 
A total of 23 patients were prospectively recruited for this cohort. Table 5.2 
presents the patient demographics collected at baseline. In this cohort, 73.9% of the 
patients were male, 69.6% were diagnosed with STEMI and were of European ethnicity, 
and the mean age was 59.6 years. 
Table 5.2   Baseline demographics 
Demographics Total (N = 23) 
Male, n (%) 17 (73.9) 
Age, mean years (SD) 59.6 (11.0) 
BMI, median (Q1, Q3) 27.5 (25.5, 30.5) 
Ethnicity, n (%): 
 
European 16 (69.6) 
Maori and PI 4 (17.4) 
Other 3 (13.0) 
Risk factors  
Prior MI, n (%) 3 (13.0) 
HTN, n (%) 9 (39.1) 
Diabetes, n (%) 2 (8.70) 
Dyslipidaemia, n (%) 16 (69.6) 
Family history of CAD, n (%) 1 (4.35) 
CHF (Killip Class 2 or 3) 1 (4.35) 
Smoking, n (%):  
Current 8 (34.8) 
Former 6 (26.1) 
Never 9 (39.1) 
Clinical presentation  
STEMI, n (%) 16 (69.6) 
NSTEMI, n (%) 7 (30.4) 
This table displays the baseline demographics, clinical risk factors and clinical 
presentation of the whole cohort. Continuous, parametric variables of the total cohort 
are expressed as mean (SD) whereas continuous, non-parametric variables are 
expressed as median (25th percentile, 75th percentile). Categorical variables are 
expressed as frequency (percentage). BMI – body mass index; CAD – coronary artery 
disease; CHF – congestive heart failure; HTN – hypertension; MI – myocardial infarction; 
n – number; NSTEMI – non-ST elevation myocardial infarction; PI – Pacific Islander; Q1 
– 25th percentile; Q3 – 75th percentile; SD – standard deviation; STEMI – ST elevation 
myocardial infarction; TnT – troponin T.  
131 
 
5.3.2 Cytokine concentrations across time 
In total, there were 117 samples across the timepoints (23 samples each for Days 
1-3 and at 6 Months, 17 samples at 6 Weeks, and eight samples at Day 4). Out of the 12 
cytokines that were measured, only six had at least half of the samples with 
concentrations above the LLOD in the majority of timepoints, which were IL-1β, IL-6, IL-
8, IL-10, MCP-1, and RANTES. The remaining six cytokines were excluded from further 
analyses as IL-2, IFNγ and TNFα had no samples with detectable concentrations (0%), 
IL-4 had one out of 117 (0.855%), GM-CSF had 17 (14.5%), and VEGF had 47 (40.2%). 
Figure 5.1 presents the concentrations of the six detectable cytokines across each 
timepoint. Seventeen patients had blood samples collected at the first follow-up clinic 
that was within our time window of six ± two weeks and only eight patients remained 
in hospital for four days. A large amount of variation in concentrations across time 
between patients can be seen for all cytokines, and the median shows no clear trend 
for most of the cytokines. The exception is IL-6, where there are significantly lower 
concentrations at the chronic timepoints compared with the acute, according to the 




Figure 5.1  Concentration of cytokines over time 
Concentrations of each cytokine (pg/mL) at each measured timepoint (Days 1 to 4, 6 Weeks and 6 Months). The median concentration at 
each timepoint has been plotted (dark blue). N=23 for Days 1 to 3 and for 6 months, N=17 for 6 weeks and N=8 for Day 4. 
133 
 
The proportion of patients with peak levels of each cytokine per timepoint is 
displayed on Figure 5.2. The Day 4 timepoint was excluded from this analysis due to 
only eight patients having samples collected at this timepoint. Four patients were 
excluded from the graph for IL-1β and one patient was excluded for IL-10, because they 
had the same LLOD concentration across all timepoints. For one patient, the peak MCP-
1 concentrations were identical at six weeks and at six months, so this patient was 
included twice (once at each timepoint). What is interesting to note is that although the 
trend for IL-6 levels in Figure 5.1 showed that IL-6 peaked on Day 1, only 52% of patients 
had their IL-6 levels peak at this timepoint. The remaining 48% of patients had peak IL-
6 concentrations on either Day 2 or 3. Chi-square tests showed that the differences in 
proportions across time were significant for IL-6 (p <0.001), IL-10 (p = 0.013) and MCP-
1 (p = 0.024). 
 
Figure 5.2  Proportion of patients with peak cytokine levels per timepoint 
The proportion (%) of patients with peak concentrations for each cytokine per 
timepoint was calculated. Day 4 was excluded from this figure. Four patients were 
excluded from the IL-1β proportions and one patient was excluded from the IL-10 
proportion as no peak level was observed. Absent bars for a timepoint indicate that no 
patients (0%) had their peak for that cytokine in that timepoint. Chi-square tests 
revealed significant differences in proportions of patients with peak IL-6, IL-10 and MCP-
1 across time (p<0.05). IL – interleukin; MCP-1 – monocyte chemoattractant protein-1; 





 Figure 5.3 displays the heat maps of cytokine concentrations at each timepoint. It 
is observed that there are variations in cytokine levels within patients. Most patients 
have a combination of high and low deciles for the six cytokines, and for each patient 
there is no obvious pattern regarding which cytokines have high levels and vice versa. 
The proportion of low cytokine levels (deciles one to five) out of 138 patient-cytokine 
samples at each timepoint have been calculated and are stated on the figure. An 
increasing proportion of low-level deciles was observed. Day 1 had the lowest 
proportion (39.9%), while the 6-Month timepoint had the highest proportion (64.5%). 
This trend of more patients having low cytokine levels across the timepoints was 




Figure 5.3  Heat maps of cytokine levels at each timepoint 
The cytokine concentrations for each patient per timepoint is visually displayed on the heat maps. The concentrations have been grouped 
into deciles, with decile one (dark blue) demonstrating the lowest concentrations and decile 10 (red) demonstrating the highest concentrations. 
The proportion of low concentrations (deciles one to five) at each timepoint is stated below the respective heat maps. Chi-square test shows 
that the proportions of low concentrations across the timepoints are significantly different (p = 0.048). N = 23 for Days 1-3 and 6 Months; N = 17 




A sub-analysis of acute versus chronic concentrations and Day 1 versus Day 3 
concentrations was conducted using Dunn’s multiple comparisons. When comparing 
the concentrations at Day 1 vs Day 3, no significant differences were found (p>0.05). 
Day 4 was excluded from this acute phase sub-analysis as only eight of the 23 patients 
stayed in the hospital until Day 4. Figure 5.4 displays the ratios of Day 1 vs Day 3 
concentrations for all cytokines. For ease of visualisation, patients whose cytokine 
concentrations increased on Day 3 (ratio below 1) have points in the shaded area.  
Similar comparisons were analysed for concentrations at all acute timepoints 
versus concentrations at six weeks and six months. Only IL-6 was found to have 
significantly higher concentrations at all acute timepoints compared with the chronic 
timepoints with the Dunn’s multiple comparisons test (at six weeks or six months, p 
<0.01). Figures 5.5 and 5.6 display the ratios of the concentrations of each acute 
timepoint over concentrations at six weeks and six months, respectively. 
  
Figure 5.4  Ratios of cytokine concentrations from Day 1 to Day 3 
This figure displays the ratios for each patient that were calculated as Day 1 over 
Day 3 concentrations. Values less than one, represented by the shaded area, signify 
patients whose cytokine concentration increased on Day 3 relative to Day 1. No 
differences in concentrations between Day 1 versus Day 3 were statistically significant 




Figure 5.5  Acute versus 6-Week ratios 
Ratios of concentrations at each acute timepoint (Days 1-3) versus 6 Weeks are displayed for each cytokine. The shaded area represents 
patients whose cytokine concentrations increased at the chronic timepoint (ratio <1). IL – interleukin; MCP-1 – monocyte chemoattractant 
protein-1; RANTES – regulated upon activation, normal T cell expressed and secreted. 









Figure 5.6  Acute versus 6-Month ratios 
Ratios of concentrations at each acute timepoint (Days 1-3) versus 6 Months are displayed for each cytokine. The shaded area represents 
patients whose cytokine concentrations increased at the chronic timepoint (ratio <1). IL – interleukin; MCP-1 – monocyte chemoattractant 
protein-1; RANTES – regulated upon activation, normal T cell expressed and secreted. 
* Statistically significant differences in concentrations between two timepoints (p<0.05), calculated using Dunn’s multiple comparisons test.  
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5.3.3 Correlations between cytokines 
Spearman’s rank correlations were conducted between all six cytokines across 
five timepoints (Days 1-3, six weeks and six months). Out of the 105 possible 
combinations, there were only eight correlations between two cytokines at a single 
timepoint that were statistically significant: IL-8 versus (vs) IL-10 at Day 1, IL-10 vs 
MCP-1 at Day 1, IL-6 vs IL-10 at Day 3, IL-1β vs IL-6 at six weeks, IL-1β vs IL-10 at six 
weeks, IL-8 vs IL-10 at six weeks, RANTES vs MCP-1 at six weeks, and IL-8 vs IL-10 at six 
months. These correlations were weak to moderate, with Spearman’s rhos between 
0.414 and 0.668 (p <0.05). The greatest number of correlations were between IL-8 and 




Figure 5.7  Correlations between cytokines per timepoint 
Statistically significant correlations (Spearman’s rho, r) between two cytokines at each timepoint, as calculated using Spearman’s rank 
correlation test, are displayed. The eight significant correlations were mostly weak. * p<0.05, ** p<0.01.
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5.3.4 Correlations with clinical risk factors 
Tests were conducted for correlations between peak cytokine concentrations, for 
each patient and AUC troponin T (TnT) or LVEF fraction calculated from 
echocardiogram. These parameters were used as surrogate endpoints, because the 
cohort was not designed to look at MACE. None of the observed Spearman’s rank 
correlations were statistically significant (p >0.05), as shown in Table 5.3 below. 
Table 5.3   Correlations between clinical factors and peak cytokine 
concentrations or scores 
 
 
Peak cytokine levels 
IL-1β IL-6 IL-8 IL-10 MCP-1 RANTES 
AUC TnT -0.025 0.315 0.204 0.355 -0.156 -0.104 
P-value 0.911 0.143 0.352 0.097 0.478 0.638 
LVEF -0.031 0.291 -0.127 0.116 -0.278 -0.069 
P-value 0.895 0.201 0.582 0.618 0.222 0.767 
Age 0.27 -0.071 0.214 0.131 0.304 -0.012 
P-value 0.213 0.747 0.328 0.553 0.159 0.955 
BMI -0.15 -0.086 0.105 -0.062 0.27 0.029 
P-value 0.494 0.695 0.633 0.778 0.213 0.897 
Spearman’s rank correlation was used to correlate peak cytokine concentrations 
with area under the curve (AUC) troponin T (TnT), left ventricular ejection fraction 
(LVEF), age and body mass index (BMI). IL – interleukin; MCP-1 – monocyte 
chemoattractant protein-1; RANTES – regulated upon activation, normal T cell 
expressed and secreted. Statistical significance is set at p<0.05.
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Finally, Mann-Whitney U tests of categorical risk factors and peak cytokine 
concentrations or scores were conducted to determine potential causes of variation in 
levels (Table 5.4). Categorical risk factors with fewer than five patients in one of the 
subgroups were excluded from the analysis to reduce the risk of error, so the assessed 
factors were sex, ethnicity, smoking status, clinical presentation (STEMI or NSTEMI), 
hypertension, and dyslipidaemia. Only smoking status was significantly associated with 
peak IL-6 levels at a median of 14.0pg/mL (p = 0.028). 
 
Table 5.4   Associations between categorical risk factors and peak cytokine 
concentrations or scores 
  
Peak cytokine levels 
IL-1β IL-6 IL-8 IL-10 MCP-1 RANTES 
Sex 0.354 0.286 0.431 0.759 0.759 0.062 
Ethnicity 0.72 0.376 0.624 0.376 1.00 0.769 
Smoking status 0.681 0.028 0.428 0.101 0.101 0.681 
STEMI 0.82 0.452 0.769 0.871 0.624 0.154 
Hypertension 0.159 0.369 1.00 0.975 0.926 0.369 
Dyslipidaemia 0.922 0.452 0.624 0.769 0.341 0.72 
This table presents the p-values from Mann-Whitney U tests assessing categorical 
risk factors versus peak cytokine levels. Significant associations are bolded (p<0.05). IL 
– interleukin; MCP-1 – monocyte chemoattractant protein-1; RANTES – received upon 





This study aimed to investigate the temporal changes in cytokine concentrations, 
determine an optimal sampling timepoint for measuring pathological inflammation 
within the acute phase, and explore the potential factors associated with dynamic 
changes in cytokine concentrations. The results demonstrated large variation in 
individual cytokine concentrations over time, both between and within patients. No 
consistent trend was observed between patients except for IL-6, where concentrations 
decreased from Day 1 to the chronic phase. However, this trend was largely driven by 
52% of the patients with peak IL-6 levels on Day 1. The data for the other cytokines 
suggested that there was no single optimal timepoint for measuring them to best 
capture pathological inflammation. Finally, the only clinical factor associated with IL-6 
was smoking status, signifying that traditional clinical factors were unlikely to drive the 
variation seen in this cohort.  
Most of the measured cytokines showed large variation in individual levels over 
time, which was consistent with studies that have presented the individual patient 
levels in their graphs. The results in this study were consistent with Korybalska et al.’s 
study, where they looked at serum MCP-1 levels in 81 AMI patients at baseline versus 
six months and found a non-significant 8.8% decrease in MCP-1 levels over this 
period.265 Their non-significant result might be because there was no consistent trend 
between patients.265 In this study, we also found it difficult to ascertain particular trends 
or patterns between patients. Our study reported an increase of 65.2% in MCP-1 levels 
from Day 1 to 6 Months that was non-significant, likely because of the lack of consistent 
trend across patients. Deng et al. also found high individual variation of macrophage 
inhibitory factor (MIF) levels which were measured from admission to nine days after 
admission.276 Although many patients peaked at about 18 hours from admission, there 
was significant variation in individual concentrations after Day 1.276 It is unknown 
whether other previous studies that had investigated serial changes in cytokine 
concentration over time found a similar amount of variation, as they only reported the 
average concentration and measure of spread at each timepoint.20,115,262-264,277  
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In Chapter 3, the IL-6 and TNFα cytokines which were measured in AMI patients at 
a median of four days (IQR three to six days) showed no correlation with MACE. It was 
hypothesised that the variability in sampling collection time might have influenced the 
results. This led to the design of the MIMIT study. The results of this study showed that 
IL-6 had a decreasing trend from Day 1, so time might have affected the results for IL-6 
in Chapter 3. We are interested in determining when peak cytokine levels occur because 
this timepoint may be reflective of excessive inflammation. However, with only 52% of 
patients had peak levels of IL-6 on Day 1, future studies that wish to collect blood 
samples for IL-6 within 24 hours following symptom onset may miss the peak levels for 
a significant proportion of patients. As observed in Figure 5.1, the changes in 
concentrations over time for the remaining five cytokines (IL-1β, IL-8, IL-10, MCP-1 and 
RANTES) analysed were so varied between individual patients that no common peak or 
trend was able to be determined. Therefore, this study is unable to answer how time 
may affect the relationship between these five cytokines and MACE.  
The results of this study had both similarities and differences to previous studies 
that investigated dynamic changes in cytokine levels. Santoro et al. and Qin et al. both 
measured IL-6 levels in ACS patients over the acute phase and found that the levels 
were highest on the day of hospital admission.230,262 This is consistent with our findings. 
A difference is that we were unable to determine a clear trend or peak for most of the 
cytokines measured, which is both unexpected and interesting. Many studies that have 
investigated dynamic changes in cytokine concentrations over time were able to define 
a clear peak for various cytokines, such as IL-4, IL-8, IFNγ and MCP-1.115,262-264 Our results 
might have differed due to differences in population and/or the timepoint selected. For 
example, in 29 STEMI patients with normal to mildly-impaired ejection fraction, 
Kobusiak-Prokopowicz et al. found that the mean peak MCP-1 level occurred at three 
hours following admission.115 We did not collect blood samples at three hours following 
admission and Kobusiak-Prokopowicz et al. did not collect blood samples at six 
months,115 which is when the highest median MCP-1 concentration was observed for 
our study. Di Stefano et al. showed that STEMI patients have different patterns of 
dynamic change in cytokine concentration compared with NSTEMI patients.226 The fact 
that NSTEMI patients made up 30% of our cohort may have influenced the difference 
145 
 
observed in our findings with studies which only investigated temporal trends in STEMI 
patients. Meanwhile, two studies found no obvious peak cytokine levels for several 
cytokines that they measured. As mentioned earlier in this Discussion, Korybalska et al. 
found no significant change in serum MCP-1 levels at baseline concentrations compared 
with at six months.265 Santoro et al. also found no significant changes in IL-1β, IL-8 and 
MCP-1 levels between Days 1 and 5 in 32 ACS patients, with large standard deviations 
that were on an average of 97% that of the respective means.262 
Potential drivers of elevated cytokine levels were investigated by testing the 
relationships between peak cytokine levels and surrogate markers of cardiac damage 
(AUC hsTnT, LVEF) or clinical risk factors. No association was found between these 
parameters. Kobusiak-Prokopowicz et al. found no significant correlation between LVEF 
and peak MCP-1 or peak RANTES concentrations in a population of 40 STEMI patients, 
which was consistent with our findings.115 However, a few studies have found that 
cytokine concentrations at certain timepoints were associated with LVEF. Ørn et al. 
found that IL-1β measured at two months was associated with LVEF one year following 
the index STEMI event.20 Szkodzinski et al. found both IL-4 and IFNγ troughed prior to 
PCI in 10 STEMI patients with a low LVEF (<30%).264 IL-4 peaked 72 hours post-PCI, while 
IFNγ peaked immediately after PCI.264 We measured LVEF during hospital admission, 
but were unable to detect IL-4 and IFNγ in sufficient patients, which might have 
contributed to the differences in our findings. 
Smoking status was the only clinical factor that was significantly associated with 
peak IL-6 levels. This suggested that some of the variation observed in these cytokines 
could be attributed to patients being smokers or non-smokers. However, no other risk 
factor was able to account for the remaining variation. This might be because of other 
underlying factors contributing to the variation that were unable to be assessed in this 
cohort. Prior MI and diabetes were a few examples that this study was not powered to 
assess, because less than four patients had these factors. Further investigation is 




As mentioned in the Methods (section 5.2), the timepoints for this study were 
chosen to allow us to capture sufficient information to answer the aims of this study, 
and also due to their practicality. Many patients are admitted to hospital within 24 
hours of symptom onset and are likely to be discharged on Day 2 or Day 3. The follow-
up appointments scheduled at Wellington Regional Hospital are routinely made at six 
weeks and six months. A variety of timepoint combinations can be seen within the 
literature, which may reflect the different policies at each hospital. Santoro et al. 
measured IL-1β IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, MCP-1, TNFα and VEGF, at Day 1 and 
Day 5 after hospital admission in ACS.262 They found that IL-6 and IL-10 had higher 
means on Day 1 compared to Day 5, while IFNγ, TNFα & VEGF had higher means on Day 
5, and IL-1β, IL-2, IL-4, IL-8 and MCP-1 had similar means on both days.262 Perhaps if we 
were able to measure cytokine levels on Day 5 (we were unable to do this as the patients 
in Wellington Regional Hospital were usually discharged on Day 3 or earlier), we would 
be able to have sufficient detectable levels of VEGF and the other cytokines. However, 
the investigators did not measure levels on Days 2 to 4, so it was unknown whether the 
trends showed a consistent decrease or increase over the five days.262   
As mentioned earlier, a cohort of 23 patients did not provide sufficient power to 
assess all clinical risk factors in AMI patients, such as prior MI and diabetes. However, 
this study was designed to explore temporal patterns. Our cohort size was able to detect 
trends in cytokine levels over time, as evident with the peak observed in IL-6 levels on 
Day 1. Some of the studies that found statistically significant peaks also had a small 
population, between 10 and 43 patients.20,115,262,264 Therefore, the lack of trends 
observed for the remaining five cytokines which were analysed was unlikely to be due 
to the small sample size. 
A final limitation is that we were able to include only six cytokines in our cytokine 
score because less than half of the patients had detectable levels for the remaining six. 
CBA is a highly sensitive technique that allows us to measure multiple cytokines at a 
wide range of concentrations.278 Advantages of using a multiplex CBA assay are that it 
increases efficiency by allowing us to measure multiple cytokines at the same time, and 
allows us to measure more analytes with a smaller volume of plasma. It is also less 
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expensive to measure several analytes using one CBA kit than several single-plex assays. 
A review by Elshal et al. stated that strong correlations of cytokine concentrations 
derived from ELISA versus multiplexing assays were generally observed.279 These 
correlations were further strengthened if the ELISA and multiplexing assays used similar 
reagents or were made by the same company.279  In this study, none of the patients had 
detectable levels of IFNγ, although it had previously been detected in other studies 
looking at adverse outcomes in ACS.74,264 Similarly, no patient had detectable levels of 
TNFα, when we were able to measure this cytokine by ELISA in our previous case-control 
study (see Chapter 3). As shown by the systematic review in Chapter 4, there are 
inconsistent findings with individual cytokines when assessing them as prognostic 
markers in ACS, for reasons that have yet to be discovered. The underlying cause(s) of 
these inconsistencies might have affected our ability to detect some of the cytokines in 
this cohort. We made an exception to measure IL-1β separately with ELISA because the 
results of the CANTOS trial suggested it was an important marker to measure in AMI 
patients.158 However, only low concentrations of IL-1β ranging from 0.15 to 3.0pg/mL 
were detected, so it is possible that our patient cohort had very low levels of several 
other cytokines that we were unable to detect using CBA. It is unknown whether the 
cause of our inability to measure half of the cytokines by CBA was due to low cytokine 
levels, poor quality antibodies, or a combination of both. This is a limitation that may 
occur with any commercial assay used to measure proteins. Overall, the advantages of 
CBA as a sensitive yet less resource-intensive assay makes it appealing to continue to 




In conclusion, there are variations in cytokine levels over time for AMI patients. 
Although IL-6 demonstrated the clearest trend in AMI patients with over half of the 
patients exhibiting peak levels within 24 hours (Day 1) from symptom onset, no 
consistent pattern of change was observed for most cytokines. The optimal timepoint 
to measure peak cytokine levels that might reflect pathological inflammation could not 
be determined. The possibility of time as a potential confounding factor in cytokine 
studies with AMI patients can neither be confirmed nor denied by this study. For 
caution, it may be best to control the time samples are collected from symptom onset. 
We demonstrated that the sampling time was a factor that was associated with variance 
in cytokine levels, but this study was unable to provide guidance on how to manage this 
variance. The only clinical factor significantly associated with peak levels of IL-6 was 
smoking status; hence the underlying drivers of variation remain unknown. Further 
investigation in a larger cohort is required to investigate other clinical risk factors that 
may be driving the variations in cytokine concentrations. Due to the time constraints 
for completing this thesis, we are unable to explore it in the subsequent chapters. 
However, we plan to use the results of this study to control the sampling time when 
designing the study described across Chapters 6 and 7. 
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Chapter 6 Development of a cytokine score in patients with acute 




As discussed in Chapter 4, a systematic review of the literature showed that there 
was no clear rationale for why certain cytokines were chosen over other inflammatory 
cytokines. The systematic review also showed a heterogeneity of methods and results 
between studies. The review suggested that using a combination of cytokines could be 
better for predicting MACE than individual cytokines and might be more representative 
of a patient’s inflammatory state. However, past studies had only used simple methods 
for creating a cytokine score, such as combining a pro- and anti-inflammatory cytokine 
into a ratio and adding a point to a patient’s score for every cytokine elevated above 
the median.29,32,143 Using ratios only allows a maximum combination of two cytokines 
and all these methods assume that the cytokines are independent factors. This 
inherently places a greater weighting on correlated cytokines with overlapping 
functions, causing them to be over-represented in the score. There is a need to create 
a combined cytokine score using a mathematical approach that can counter these flaws. 
One mathematical approach is principal component analysis (PCA). PCA is a 
statistical method that reduces complex, multi-dimensional data while retaining 
maximal variance.280 It makes no assumption on the independence between variables, 
which is ideal for combining multi-collinear data into a score. Other benefits are that 
PCA can be conducted with small portions of missing data for individual patients, and 
that, by reducing the number of variables, a smaller cohort size can be used to measure 
outcomes using multivariate analysis in a statistically-meaningful way.281 PCA has been 
used in studies looking at adverse outcome in conditions such as subarachnoid 
haemorrhage and trauma, where the studies derived prognostic scores from the 
principal components and found them to be predictive of outcome.282,283  
The primary aim of this study was to create a PCA-derived score composed of 
cytokines associated with inflammation in AMI patients. Due to resource constraints, 
13 inflammatory cytokines were selected and measured at a fixed time point, two days 
after symptom onset. The results from Chapter 5 showed that IL-6 peaked within one 
day after symptom onset for 52% of patients and no clear trend could be elucidated for 
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the remaining cytokines. It could be advantageous to minimise the risk of time as a 
potential confounder in the study design, at least for IL-6. Two days (24 to 48 hours) 
post-symptom onset was the timepoint with the greatest number of patients in the 
biobank, which was why this timepoint was chosen instead of within one day after 
symptom onset. The chosen cytokines had individually been associated with adverse 
outcome in ACS patients in the literature.  
The secondary aim was to measure the association between clinical factors and the 
cytokine score, to assess how much additional information a patient’s inflammatory 




6.2.1 Study population 
All patients in this observational cohort study were selected from two existing 
acute coronary syndrome biobanks. Patients were recruited into the biobanks if they 
were admitted to Wellington Regional Hospital between January 2012 and April 2018. 
Please refer to section 2.2.1 for details of the biobanks’ selection criteria. All patients 
gave voluntary written consent for their participation in this study and the study was 
approved by the Lower South Ethics Committee (LRS/11/09/035) and the Central Health 
and Disability Ethics Committee (16/CEN/68). 
From this population, patients were selected for this study if they had not been 
thrombolysed with an anti-thrombolytic agent, had no renal insufficiency and had 
plasma samples collected two days after their ischemic symptom onset (between 48 
and 72 hours). 
6.2.2 Data collection and sampling methods 
Please refer to section 3.2.2 for details of the data collection and sampling 
methods.  
6.2.3 Cytokine analysis 
Please refer to section 5.2.3 for details of the cytokine analysis. There was a 
difference, in that the commercialised high sensitivity CBA kit contained IL-17A instead 
of IL-2 at the time of analysis. TGF-β1 was also analysed in a separate single-plex CBA 
panel (Human Soluble Protein CBA Flex Set, BD Biosciences; CA, USA). The methods for 
the TGF-β1 CBA analysis were identical to that of the CBA analysis in section 5.2.3.1, 
except that the TGF-β1 was activated in the samples prior to adding the bead mixture. 
Each sample had 1N hydrochloric acid added before a 10-minute incubation. The acid 
was then neutralised with 2.7N of sodium hydroxide in 1M of HEPES buffer, and the 
samples were again incubated for 10 minutes. This made the total number of cytokines 
analysed 13: IL-1β, IL-4, IL-6, IL-8, IL-10, IL-17A, GM-CSF, IFN-γ, MCP-1, RANTES, TGF-β1, 
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TNFα and VEGF. The inflammatory roles of these cytokines was discussed in section 
1.2.3 and the rationale for choosing these cytokines was described in Table 5.1. IL-17A 
has been indicated as a prognostic marker for MACE and restenosis in AMI,31,269 while 
TGF-β1 has been associated with LVEF in STEMI.284 The IL-1β ELISA’s intra-assay 
coefficient of variation was 5.60% and inter-assay coefficient of variation was 3.20%. 
6.2.4 Statistical analysis 
For the CBA plates, the data collected from the flow cytometer was analysed on 
FlowJo® (FlowJo, LLC; OR, USA) and FCAP Array Software v3.0 (BD Biosciences; CA USA) 
to obtain an MFI. The concentrations of each cytokine were calculated using a 5PL fitted 
standard curve. For the ELISA, IL-1β concentrations were calculated from the 
absorbances using a fitted 5PL standard curve. Due to limited samples, any samples with 
concentrations above or below the limit of detection were not repeated. Sample values 
below the blank were defined as “undetectable” and were given a value of 0pg/mL. 
Samples that had MFIs or absorbances below the lowest standard, and therefore had 
undetermined concentrations when fitted with the 5PL curve, were extrapolated using 
linear regression down to zero. Samples with MFIs for RANTES above the upper limit of 
detection were all given one concentration that was greater than the highest detected 
concentration, and this was arbitrarily chosen as 16,000pg/mL. Unless specified, these 
analyses were conducted on GraphPad Prism v.7 (GraphPad Software Inc.; CA, USA). 
Descriptive statistics for baseline demographics and cytokine concentrations, tests 
of normality (Shapiro-Wilk and D’Agostino and Pearson) for the cytokine concentrations 
and baseline demographics, and Spearman’s rank correlations between each cytokine 
were analysed on GraphPad Prism v.7. The cytokine concentrations were divided into 
deciles and a heat map of the deciles was generated using Microsoft Excel 2016 
(Microsoft Corporation; WA, USA).  
Cytokines where over half of the patients had detectable concentrations were used 
to create a combined cytokine score by the addition of significant component scores 
derived from PCA. Goodness of fit tests (Kaiser-Meyer-Olkin (KMO) measure of 
sampling adequacy and Bartlett’s test of sphericity) were conducted on the cytokines 
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to ensure PCA was an appropriate method to use on the dataset. Parallel analysis was 
used to determine the number of significant components. Regression component 
scores were generated without rotation and the component matrix was used to observe 
which cytokines contributed significantly to the loading of each component score 
(correlation >0.5). Finally, the component scores were added to create the cytokine 
score. All PCA-related statistics except for parallel analysis was conducted using SPSS 
v.24 (IBM; Armonk, NY, USA). An online engine was used for parallel analysis.285 To 
determine whether cytokines that were not included in PCA might have significantly 
influenced the cytokine score, the cytokine score was divided into deciles and a Fisher’s 
exact test was used to compare the proportion of patients with high cytokine score 
deciles (between eight and 10) against the expected proportion of patients (30%). The 
medians and interquartile ranges of these groups of patients for each cytokine were 
also calculated. GraphPad Prism v.7 was used to analyse these statistics. 
The relationships between individual categorical risk factors and either the 
individual cytokines, the component scores or the cytokine score were determined by 
Mann-Whitney U test (for dichotomous risk factors) and Kruskal-Wallis test (for factors 
with at least three categories). Correlations with continuous risk factors were analysed 





6.3.1 Baseline demographics 
From 1994 patients in the biobank, 320 patients met the study criteria. Reasons for 
exclusion included blood samples not collected on Day 2 (1581, 94.4%), thrombolysis 
(33, 1.97%), eGFR below 45mL/min/1.73m2 (26, 1.55%), a change in diagnosis from AMI 
after angiography (18, 1.08%), and other factors, such as no plasma samples 
collected/found and undetermined symptom onset (16, 0.96%). Table 6.1 presents the 
baseline demographics of the cohort. Of the 320 patients, 75.6% were male, 82.8% were 




Table 6.1   Baseline demographics 
Demographics Total (N = 320) 
Male, n (%) 242 (75.6) 
Age, mean years (SD) 62.5 (10.9) 
BMI, median (Q1, Q3) 28.8 (25.6, 31.6) 
Ethnicity, n (%):  
European 265 (82.8) 
Maori and PI 36 (11.3) 
Other 19 (5.94) 
Risk factors  
Prior MI, n (%) 81 (25.3) 
HTN, n (%) 180 (56.2) 
Diabetes, n (%) 57 (17.8) 
Dyslipidaemia, n (%) 181 (56.5) 
Family history of CAD, n (%) 121 (37.8) 
CHF (Killip Class 2 or 3) 5 (1.56) 
AF, n (%) 22 (6.88) 
Stroke/TIA, n (%) 19 (5.94) 
Smoking, n (%):  
Current 70 (21.9) 
Former 113 (35.3) 
Never 137 (42.8) 
Peak TnT, median (Q1, Q3) 511 (145, 1548) 
Clinical presentation  
STEMI, n (%) 68 (21.2) 
NSTEMI, n (%) 252 (78.8) 
This table displays the baseline demographics, clinical risk factors and clinical 
presentation of the whole cohort. Continuous, parametric variables of the total cohort 
are expressed as mean (SD) while continuous, non-parametric variables are expressed 
as median (25th percentile, 75th percentile). Categorical variables are expressed as 
frequency (percentage). Significant p-values (p <0.05) are bolded.  
AF – atrial fibrillation; BMI – body mass index; CAD – coronary artery disease; HF – 
heart failure; HTN – hypertension; MI – myocardial infarction; n – number; NSTEMI – 
non-ST elevation myocardial infarction; PI – Pacific Islander; Q1 – 25th percentile; Q3 – 
75th percentile; SD – standard deviation; STEMI – ST elevation myocardial infarction; TIA 
– transient ischaemic attack; TnT – troponin T. 
1 Calculated from n = 318, as 2 patients had missing BMI values. 




6.3.2 Descriptive statistics of individual cytokine concentrations 
The percentage of detectable levels of the 13 cytokines within the patient 
population ranged from 0% to 99.4%. As no concentration of IFNγ was obtained from 
the samples, it was excluded from the graph and all further analyses. The 
concentrations, medians and IQRs for the remaining 12 cytokines have been plotted in 
Figure 6.1. A wide range of concentrations can be observed. Figure 6.2 shows a clearer 
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Figure 6.1  Cytokine concentrations 
The concentrations of all cytokines are demonstrated on the left y-axis, except for RANTES, which is shown on the right. Patients with levels 
of cytokine below the blank were given a concentration of 0pg/mL, and values above the upper limit of detection were given a value of 








































































Figure 6.2  Cytokines with lower-ranged concentrations        
The distributions of these lower-ranged cytokine concentrations from Figure 6.1 have been enlarged in this plot using different ranges on 
the y-axes. Again, the concentrations of all cytokines are demonstrated on the left y-axis, except for IL-8, which is shown on the right. Patients 
with levels of cytokine below the blank were given a concentration of 0pg/mL, and values above the upper limit of detection were given a value 
of 16,000pg/mL. The bars represent the median and IQRs of each cytokine. IL – interleukin.                   
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Table 6.2 describes the frequency and percentage of patients with detectable 
levels of the 12 cytokines (excluding IFNy). Cytokines with less than 50% of the patients 
having detectable levels (IL-4, IL-17A, GM-CSF, TGF-β1, TNFα, and VEGF) were excluded 
from further analyses. The medians and 25th and 75th percentiles were calculated for 
cytokines where more than half of the patients had detectable levels (IL-1β, IL-6, IL-8, 
IL-10, MCP-1, and RANTES). Again, as observed in Figures 6.1 and 6.2, big differences 
between the 25th and 75th percentiles can be observed for these six cytokines, 
demonstrating large interquartile ranges i.e. considerable variations in concentrations. 
Table 6.2   Descriptive statistics of cytokines 
Cytokine n (%) Median (Q1, Q3) 
IL-1β 182 (56.9) 0.109 (0.00, 0.596) 
IL-6 307 (95.9) 2.34 (0.175, 6.86) 
IL-8 318 (99.4) 3.75 (2.53, 5.34) 
IL-10 272 (85.0) 0.264 (0.220, 0.444) 
MCP-1 219 (68.4) 56.6 (0.00, 89.9) 
RANTES 256 (80.0) 5178 (3696, 8619) 
IL-4 19 (5.94) - 
IL-17A 53 (16.6) - 
GM-CSF 17 (5.31) - 
TGF-β1 2 (0.625) - 
TNFα 10 (3.13) - 
VEGF 111 (34.7) - 
The frequency (n) and percentage of patients with detectable concentrations have 
been calculated for each cytokine. The medians of the cytokine concentrations, 25th 
percentiles (Q1) and 75th percentiles (Q3) (pg/mL) were unable to be calculated for 
cytokines where <50% of patients had detectable levels. N = 320. GM-CSF – granulocyte-
macrophage colony stimulating factor; IL – interleukin; MCP-1 – monocyte 
chemoattractant protein-1; n – number; RANTES – regulated upon activation, normal T 
cell expressed and secreted; TGF-β1 – transforming growth factor-beta 1; TNFα – 
tumour necrosis factor-alpha; VEGF – vascular endothelial growth factor. 
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6.3.3 Levels of individual cytokines within AMI patients 
A heat map of the level of each cytokine ranked by decile (zero for undetectable 
levels to 10 for the highest levels detected in the cohort) is presented in Figure 6.3. Each 
row represents one patient and the colours range from dark blue (decile zero, levels of 
the cytokine below the lower limit of detection) to white (decile five, moderate cytokine 
concentrations) to bright red (decile 10, greatest cytokine concentrations). It is 
observed that individual patients have a variety of high, moderate and low-decile 




Figure 6.3  Heat map of cytokine concentrations in individual patients 
The rows represent each patient and the columns represent the concentration of 
each cytokine. These concentrations have been grouped into deciles, with decile zero 
(blue) having undetectable levels, decile five (white) having medium levels, and decile 
10 (red) having the highest concentrations.  
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6.3.4 Correlations between individual cytokines 
As no cytokine passed the D’Agostino and Pearson, and Shapiro-Wilk normality 
tests (p-value <0.001), Spearman’s rank correlation was used to test the relationships 
between the 15 pairs of individual cytokines (Figure 6.4). Statistically significant 
correlations were observed between only six cytokine pairs (IL-6 and IL-8, IL-6 and IL-
10, IL-8 and IL-10, and IL-8 and MCP-1, IL-8 and RANTES, and MCP-1 and IL-1β). 
However, all these correlations were weak (ranging from rs = 0.146 to rs = 0.445). 
Interestingly, a wide range of values can be observed for one cytokine against 




Figure 6.4  Correlations between cytokines 
These scatterplots show the associations between two individual cytokines, measured using Spearman’s rank correlation tests. r = Spearman’s rho. * p-value <0.05.  
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6.3.5 Principal component analysis 
PCA was conducted to create the cytokine score. The KMO measure of sampling 
adequacy was 0.448, which failed to meet the minimum threshold of 0.500.286 However, 
Bartlett’s test of sphericity was statistically significant (p<0.001), indicating that the 
cytokines were sufficiently correlated for structure analyses such as PCA to be 
potentially useful.286 Parallel analysis revealed that only the first two principal 
components, with eigenvalues above 1.00 (1.562 and 1.156, respectively), were 
significant. These two components accounted for 45.3% of the variance in the data. The 
scores of the two components were added to create the cytokine score.  
Table 6.3 and Figure 6.5 describe the correlations of each cytokine in relation to 
the loading for each component. IL-6, IL-8 and IL-10 had large correlations for the first 
component (r = 0.768, 0.722 and 0.536, respectively), while MCP-1 and IL-10 had the 
greatest correlations for the second component (r = 0.638 and -0.534, respectively), 
suggesting they have the greatest contributions to the loading of the components. In 
Figure 5.6, the relationships between the cytokines can also be observed by the 
similarity of the correlations. For example, IL-6 and IL-10 appear to have a relatively 
close relationship with both positive correlations for the first component and negative 
correlations for the second. 
Table 6.3   Component matrix demonstrating correlations of the first and 






IL-1β -0.031 0.247 
IL-6 0.768 -0.358 
IL-8 0.722 0.378 
IL-10 0.536 -0.534 
MCP-1 0.371 0.638 
RANTES 0.160 0.364 
The correlations of the first and second components for each cytokine are 
summarised above. Correlations less than -0.5 or greater than 0.5 demonstrate a 
significant loading or contribution to the variance in the component. IL – interleukin; 
MCP-1 – monocyte chemoattractant protein-1; RANTES – regulated upon activation, 





Figure 6.5  Component plot 
The correlations of the cytokines for each component are visually represented in 
this figure. The greater the distance of a cytokine from 0.0, the greater the loading or 
correlation to principal components. The relationship between cytokines can also be 
determined by the distance between a pair of cytokines. IL – interleukin; MCP-1 – 
monocyte chemoattractant protein-1; RANTES – regulated upon activation, normal T 




6.3.6 Observations of patients with high cytokine scores and detectable levels of 
unanalysed cytokines  
To determine whether the cytokines that were unable to include for PCA may have 
made a significant contribution if there were enough patients with detectable levels, 
we ranked the cytokine score into deciles. In the different groups of patients for each 
cytokine, the frequency and percentage of those with deciles above seven (to represent 
a high inflammatory score) and the median, 25th percentile (Q1) and 75th percentile (Q3) 
of the deciles were calculated. If a cytokine was unrelated to the cytokine score, we 
would expect the median decile to be five and 30% of the patients to be in a decile 
above seven. Table 6.4 shows that over half (54.1%) of the patients with detectable 
levels of VEGF had a high cytokine score decile, which was significantly more than 
expected (p-value = 0.004). The median decile for VEGF, GM-CSF and TGF-β1 were also 
relatively high (eight for VEGF, 10 for TGF-β1 and seven for GM-CSF), although TGF-β1 
only had two patients with detectable levels. TNFα, IL-4 and IL-17A had percentages of 
patients with a high decile that were not significantly different from the expected 
proportion and medians close to five. Therefore, VEGF and GM-CSF were most likely to 




Table 6.4   Average component and cytokine score ranks for unanalysed 
cytokines 
 
n (%) of patients with 
detectable levels 
n (%) of patients with 
cytokine score decile 
>7 
Cytokine score decile 
- median (Q1, Q3) 
IL-4 19 (5.94) 6 (31.6) 6 (5) 
IL-17A 53 (16.6) 16 (30.2) 6 (5) 
GM-CSF 17 (5.31) 8 (47.1) 7 (5) 
TGF-β1 2 (0.625) 2 (100) 10 (0) 
TNFα 10 (3.13) 5 (50.0) 5.5 (7.75) 
VEGF 111 (34.7) 60 (54.1)* 8 (3) 
This table displays the frequency of patients with detectable levels of the cytokines 
that were not included in the statistical analyses, the percentage of those patients with 
cytokine scores in a high decile (>7) and the median, 25th percentile (Q1) and 75th 
percentile (Q3) of the decile.  
GM-CSF – granulocyte-macrophage colony stimulating factor; IL – interleukin; n – 
number; TGF-β1 – transforming growth factor-beta 1; TNFα – tumour necrosis factor-
alpha; VEGF – vascular endothelial growth factor. 
* Proportion of patients with high-deciled (>7) cytokine scores that were 
statistically significant (p<0.05), using Fisher’s exact test.
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6.3.7 Associations between cytokines and clinical risk factors 
The associations between the clinical risk factors and the individual cytokines are 
summarised in Table 6.5, while the association with the component and cytokine scores 
are summarised in Table 6.6. Using Mann-Whitney U or Kruskal-Wallis tests for 
categorical variables, hypertension was significantly associated with IL-1β, diabetes was 
associated with IL-8, sex was associated with IL-8, and clinical presentation was 
associated with IL-6 and IL-8 out of the individual cytokines. Diabetes was also 
significantly associated with Component score 1 and the combined cytokine score, 
while sex was significantly associated with all three PCA-derived scores. Spearman’s 
rank correlation was used for the continuous variables. Age had a weakly positive 
correlation with IL-8, and BMI had weakly positive correlations with IL-1β and IL-6. 
Meanwhile, peak TnT had a moderately strong correlation with IL-6, weakly positive 
correlations with IL-8 and IL-10, and a weakly negative correlation with MCP-1. Age was 
the only continuous factor that had a significant correlation with the combined cytokine 
score (rs = 0.234, p <0.001). The first principal component score had significant 
correlations with age, BMI and peak TnT (rs = 0.305, 0.112 and 0.216; p <0.001, 0.046 
and <0.001, respectively) while the second component score had significant 
correlations with age and peak TnT (rs = 0.143 and -0.156; p = 0.010 and 0.005, 
respectively). All of the correlations with the scores were weakly positive, except for the 
correlation between Component score 2 and peak TnT, which was weakly negative.
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Table 6.5   Relationship between clinical risk factors and individual cytokines 
Risk factors 
P-values or correlations 
IL-1β IL-6 IL-8 IL-10 MCP-1 RANTES 
Sex 0.255 0.182 0.009 0.793 0.523 0.217 
Ethnicity 0.408 0.924 0.778 0.052 0.279 0.055 
Prior MI 0.159 0.264 0.056 0.258 0.154 0.394 
HTN 0.018 0.357 0.069 0.732 0.574 0.318 
Diabetes 0.422 0.369 <0.001 0.941 0.184 0.905 




0.070 0.904 0.172 0.930 0.501 0.992 
Smoking 
status 
0.694 0.581 0.933 0.377 0.641 0.370 
Clinical 
presentation 
0.846 0.007 0.012 0.068 0.136 0.425 
Age -0.081 0.103 0.374*** 0.098 0.107 -0.028 
BMI 0.149** 0.158** 0.024 0.043 0.099 0.035 
Peak TnT <0.001 0.528*** 0.211*** 0.125* -0.130* 0.011 
Mann-Whitney U and Kruskal-Wallis tests were used to analyse the relationships 
between the individual cytokines and categorical risk factors, and the p-values are 
displayed in the table. Meanwhile, Spearman’s rank correlation was used to calculate 
the correlation with continuous risk factors and the Spearman’s rhos are displayed in 
the table. Significant associations are bolded (p<0.05). * p<0.05, ** p<0.01, *** 
p<0.001. BMI – body mass index; CAD – coronary artery disease; HTN – hypertension; 
IL – interleukin; MCP-1 – monocyte chemoattractant protein-1; MI – myocardial 
infarction; RANTES – regulated upon activation, normal T cell expressed and secreted; 
TnT – troponin T. 
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Table 6.6   Relationships between clinical risk factors and component or 
cytokine scores 
 P-values or correlation (p-value) 
Risk factors Cytokine score Component score 1 Component score 2 
Sex 0.013 0.010 0.029 
Ethnicity 0.203 0.520 0.338 
Prior MI 0.157 0.239 0.086 
HTN 0.720 0.574 0.519 
Diabetes 0.031 0.005 0.077 
Dyslipidaemia 0.523 0.634 0.619 
Family history of CAD 0.742 0.475 0.895 
Smoking status 0.457 0.869 0.246 
Clinical presentation 0.715 0.195 0.331 
Age 0.234 (<0.001) 0.305 (<0.001) 0.143 (0.010) 
BMI 0.103 (0.066) 0.112 (0.046) 0.063 (0.260) 
Peak TnT 0.038 (0.501) 0.216 (<0.001) -0.156 (0.005) 
Mann-Whitney U and Kruskal-Wallis tests were used to analyse the relationships 
between the cytokine score or principal component scores and individual categorical 
risk factors. The p-values from these tests are displayed above. Meanwhile, Spearman’s 
rank correlation was used to calculate the correlation with continuous risk factors and 
the Spearman’s rhos and p-values are displayed above. Significant relationships are 
bolded (p-value <0.05). BMI – body mass index; CAD – coronary artery disease; HTN – 




This study revealed a large variation of cytokine concentrations among AMI 
patients who had plasma samples collected two days after their symptom onset. 
Further exploration of the six cytokines, which more than half the cohort had detectable 
levels of, revealed that there was also a variety of combinations for cytokine levels in 
each person. Any significant correlations between pairs of cytokines were weak. The 
individual cytokines, component scores and cytokine score had a few significant 
associations with clinical factors, such as age, peak TnT and BMI, but most of the 
correlations with these continuous variables were weak. Using PCA, two component 
scores were found to be significant, and they were added to create the cytokine score.  
A large variation of cytokine levels was observed in this cohort. The variation was 
not explained by other cytokines or clinical risk factors, as only weak, positive 
correlations were observed between six out of 15 pairs of cytokine, and infarct size 
(measured by peak TnT), age, BMI and ethnicity were significantly associated with some 
but not all individual cytokines. Creating a heat map (Figure 6.3) allowed us to observe 
that there was no obvious pattern of combinations of cytokine concentrations. In 
addition, each patient appears to have a different combination of high, moderate and 
low-level cytokines. As shown in section 1.2.3, many studies have investigated the use 
of individual cytokines to represent a patient’s inflammatory state and determine their 
prognostic ability, with some of those studies found that elevated levels of 
inflammation were associated with increased risk of adverse events (Tables 1.1-1.3). 
However, our findings from this study and the IL-6 and TNFα cytokines studied in 
Chapter 3 show that our conclusions on a patient’s inflammatory state will differ 
depending on which individual cytokine is chosen to represent it. There appears to be a 
lack of correlations between cytokines, and limited correlations between cytokines and 
clinical risk factors. The lack of correlations suggests that each cytokine gives different 
information about the inflammatory state beyond the clinical factors. As discussed in 
Chapter 1, inflammation is a complex process involving many cytokines, and our results 
show that it is insufficient to use one or two cytokines to represent the inflammatory 
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network. It is therefore beneficial to use multiple cytokines to explore a patient’s 
inflammatory profile. 
Despite not all patients having detectable levels of the cytokines, we were able to 
use PCA to reduce our six non-independent cytokines and successfully create a 
combined cytokine score. PCA minimises the need to remove patients with missing data 
from a cohort and/or conduct repeat assays to obtain a complete set of measurements, 
which is advantageous when there is a limited amount of plasma samples. Our use of 
PCA was also justified by the fact that some correlations were observed between the 
cytokines. Simply adding cytokines together, as we attempted in Chapter 3 or as 
conducted by one study included in our systematic review,29 does not address the 
collinear relationships between cytokines. To our knowledge, this was the first study to 
combine principal component scores into a combined score in AMI patients. Calce et al. 
did a weighted summation of component scores to create a combined score that 
represented the different methods for assessing osteoarthritis severity.287 As each 
principal component score was made up of different loadings from each individual 
method, the combined osteoarthritis score allowed for a better representation of the 
different methods. In our study, the first component had significant loadings from IL-6, 
IL-8 and IL-10, while the second component had significant loadings from IL-10 and 
MCP-1. Our combined cytokine score allowed us to retain the significant loadings from 
both components, so it is likely to be more representative of the inflammatory network. 
Another advantage of combining the component scores is that the information is 
retained in one set of numbers instead of multiple sets of numbers. This makes it easier 
for the score to be used both clinically and in further statistical analyses, where a smaller 
cohort size may have enough power to assess for significant outcomes due to the 
reduced number of variables.  
The two PCA components made up of the six cytokines were able to account for 
45.3% of the variance in the data. Similar to the individual cytokines, this variance was 
not explained by clinical risk factors, as only a few weak correlations were found with 
the component scores, and only age was weakly correlated with the cytokine score. This 
suggests that the scores give us new information beyond what the clinical risk factors 
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tell us about AMI and may therefore be useful for predicting outcome. However, as less 
than half of the variance was explained by the cytokine score, it suggests that six 
cytokines may not be enough to characterise a patient’s inflammatory profile. The 
cytokine score created in this cohort serves as a proof-of-concept rather than a 
definitive score. To create a more definitive score, further investigations with an 
enlarged panel of cytokines, multiple timepoints for sample collection and an 
assessment of outcome to validate the cytokine score are required. Some of these ideas 
are explained in more detail in the following paragraphs. 
The same cytokines that were able to be assessed in Chapter 5 were also able to 
be analysed in this study. Although it is still possible that measuring these cytokines at 
times where they have not yet peaked may reduce our ability to detect the cytokines, 
it is more likely that there is an unknown factor that causes cytokines to not be detected 
in different cohorts that has yet to be determined.  
The cytokines that were not included in the cytokine score were analysed to 
determine their association with elevated inflammation. It was discovered that the 
median cytokine score from the subset of patients with detectable levels of VEGF was 
high, and the proportion of patients with high cytokine scores was significantly greater 
than expected (Table 6.5). Out of the seven cytokines, VEGF had the largest subset of 
patients with detectable levels (111 patients). With lower patient numbers for the 
remaining cytokines (ranging from zero to 53), the possibility of these cytokines having 
a significant influence on the cytokine score cannot be ruled out. As the current 
literature suggests that these cytokines are associated with outcome in ACS (Table 5.1 
and section 6.2.3), this study recommends that they be included in a combined cytokine 
score in future studies. However, alternative assays that are more sensitive than CBA 
may be required for it to be feasible to measure these cytokines in a clinical setting. 
With our current data, we do not have enough information to determine the 
number of cytokines needed to create a cytokine score. As discussed in Chapter 5, due 
to limited financial resources and time, it was most cost-effective to use a multiplex CBA 
kit to maximise the number of inflammatory cytokines that could be measured. The 
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cytokines chosen had all been associated with adverse outcome in ACS in previous 
studies (Table 5.1 and section 6.2.3). However, there were many other inflammatory 
cytokines and chemokines that had been proven as a promising marker in ACS, yet could 
not be measured due to logistical reasons, such as interleukins-27 and -33, and 
macrophage inflammatory proteins one-alpha and one-beta.19,107,113,116 Currently, it is 
not logistically feasible to measure all existing cytokines and chemokines related to 
adverse outcome in AMI. Further work is needed to create the optimal cytokine panel 
for a combined score.  
Limitations on the cytokine score and assay used have been mentioned in earlier 
paragraphs. A final limitation was that peak TnT was used as a surrogate marker for 
infarct size. However, patients had variable amounts of serial troponin measurements, 
with many patients having TnT measured for diagnosis and only a handful of patients 
receiving daily TnT measurements. Therefore, the peak TnT used in this study may not 
have captured the true “peak”. It will be more accurate to use the area under the curve 
of serial TnT measurements, echocardiogram parameters or cardiac MRI (cMRI) 




Using this cohort, we were able to create a cytokine score that might be more 
representative of a patient’s inflammatory state than individual cytokines. However, 
this score is yet to be tested as a prognostic tool for outcome, which we plan to do in 
Chapter 7 as a continuation of this study. Further investigation is required to determine 
which day is best for collecting samples and to be able to include more cytokines for an 
improved score. However, as mentioned in the Conclusion of Chapter 5, the time 
constraints of completing this thesis mean that these questions are outside the scope 
of this thesis.  
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Chapter 7 Using a cytokine score to predict outcome in acute 




In Chapter 2, WBC subtypes, which are inflammatory markers routinely measured 
in clinical practice, were weakly associated with MACE when combined into ratios, but 
were not independent predictors. In Chapter 3, CRP (another clinical marker of 
inflammation), and two commonly measured cytokines, IL-6 and TNFα, were not 
associated with three-point MACE, both as individual markers and when added 
together. After conducting a systematic review in Chapter 4, we found that a 
combination of cytokines could be more predictive of MACE than individual cytokines. 
To determine if time was a confounding factor affecting cytokine levels, we conducted 
the study in Chapter 5. Cytokine levels did change over time, but there were no obvious 
trends, making it difficult to interpret from the results how to manage time in future 
studies. The results of the studies in Chapters 2 to 5 led to the development of our final 
study, which has been divided into two parts. The first part, which was discussed in 
Chapter 6, demonstrated the use of PCA to create an inflammatory biomarker score 
that could combine multiple, collinear cytokines. Only AMI patients with blood samples 
collected two days following symptom onset were included to control the sampling 
time. The second part of this final study will be discussed in this chapter. 
We next sought to determine the prognostic utility that the PCA-derived scores 
could have in AMI patients. Studies that used PCA to create prognostic scores often 
employed the principal component scores and did not add the scores into a combined 
score.283,288 As discussed in the previous chapter, it has been hypothesised that adding 
the principal component scores together allows for better representation of the data 
than the individual scores.287 In Chapter 2, WBC ratios were only weakly associated with 
a broad definition of MACE that encompassed all-cause death, recurrent MI, CVA, stent 
thrombosis, HF and unplanned revascularisation. In Chapter 3, we tested the use of 
three-point MACE, a narrower definition of MACE that only included ischaemic-related 
events, and found that the three biomarkers we tested were not predictive of this 
outcome. The cohort used in Chapter 6 was originally designed not to investigate 
outcomes, but as a proof-of-concept study to determine if PCA was able to be used to 
create scores in AMI patients. To explore the prognostic ability of the PCA-derived 
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scores, a broader definition of MACE (identical to the one used in Chapter 2) had to be 
used to provide sufficient patients with an adverse outcome. Therefore, using the same 
cohort that was used to create the cytokine score in Chapter 6, we aimed to pilot the 




7.2.1 Study population, data collection, sampling methods and laboratory analysis 
of cytokines 
The study population, data collection, sampling methods and cytokine analysis 
have been described in sections 6.2.1, 6.2.2 and 6.2.3. One year follow-up data was 
collected as explained in section 3.2.2. A difference to the methods in Chapter 3 is that 
the definition of MACE used for this study was a composite of all-cause death, recurrent 
MI, non-fatal ischaemic CVA, stent thrombosis, new or worsened HF requiring 
hospitalisation and unplanned revascularisation. 
 
7.2.2 Statistical analysis 
Please refer to section 6.2.4 for the analysis of the cytokine results obtained by CBA 
and ELISA, the descriptive statistics, and the use of PCA to create the component and 
cytokine scores. As mentioned in section 6.2.4, only cytokines where over half of the 
AMI patients had detectable levels were included in the statistical analyses. Unless 
specified, the statistical analyses in the subsections below were conducted using SPSS 
v.24. 
7.2.2.1 Univariate analysis of predictors of MACE 
The tests of normality (Shapiro-Wilk and D’Agostino and Pearson) conducted in 
Chapter 6 demonstrated that the PCA-derived scores had a non-parametric distribution. 
Univariate predictors of MACE were analysed by Mann-Whitney U tests. These included 
individual cytokines, significant component scores, the cytokine score and continuous 
clinical risk factors. A Chi-square test was used for categorical risk factors. From this 
test, any individual cytokine concentrations that were significantly different between 
patients with and without MACE were combined into a subset score using principal 
component analysis. Similar to what was done with the other PCA-derived scores, a 
Mann-Whitney U test was used on this subset PCA-derived score, and relationships 
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between clinical risk factors and this subset score were assessed using the Spearman’s 
rank correlation test for continuous risk factors, and Mann-Whitney U test for 
categorical risk factors. 
7.2.2.2 ROC curve analysis for univariate predictors 
Any individual cytokines, principal components or cytokine scores that were 
statistically significant on univariate analysis had ROC curves generated. This allowed us 
to define a threshold value for classifying the individual cytokine concentrations and/or 
PCA-derived scores as high or low. The sensitivities and specificities of the thresholds 
were also calculated to give us an insight into how effective these scores might be for 
clinical practice.  
7.2.2.3 Multivariate modelling of predictors of MACE 
All results that were found to be statistically significant from the univariate 
analyses were combined into a multinomial logistic regression for multivariate analysis. 
This enabled us to account for confounding variables and investigate whether the 
cytokines or PCA-derived scores were independent predictors of MACE. The individual 
cytokines and PCA-derived scores included in the multivariate analyses were 
dichotomised into categorical variables, based on the threshold values generated from 
the ROC curves. Because multinomial logistic regression assumes independence 
between variables included in each multivariate model, any non-independent variables 
were analysed in separate multivariate models.  
7.2.2.4 Post-hoc power assessment 
Finally, to conduct a post-hoc power calculation, a student’s T test was used to 
compare the means and standard deviations of the cytokine scores in patients who did 
and did not develop MACE (G*Power v.3.0.10, University of Düsseldorf; Germany). The 
power calculation showed that the cohort had 62.6% power to detect a significant 
difference in means of cytokine scores between patients who did and did not develop 




Please refer to section 6.3 for details of the cohort demographics, statistics of the 
individual cytokine levels, principal component analysis, correlations between 
individual cytokines, and correlations between cytokines and clinical risk factors. 
7.3.1 Baseline demographics 
Three patients were lost to follow-up, so 317 were included to analyse outcomes. 
Out of these patients, 41 (12.9%) patients developed MACE within one year of follow-
up, which comprised of four deaths, 16 repeat MIs, seven ischaemic strokes, one stent 
thrombosis, eight hospitalisations for HF and five unplanned revascularisations.  
Table 7.1 presents the baseline demographics of the cohort. We observed that the 
patients who developed MACE were older (66.6 versus 61.9 years old, p-value = 0.022), 
more likely to present with STEMI (35.2% versus 18.6%, p-value = 0.010) and more likely 
to have a previous history of CVA (14.6% versus 4.70%, p-value = 0.024).  
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Table 7.1   Baseline demographics 
Demographics 
Total  
(N = 317) 
MACE  
(n = 41) 
No MACE  
(n = 276) 
P-value 
Male, n (%) 241 (76.0) 29 (70.7) 212 (76.8) 0.433 
Age, mean years (SD) 62.5 (11.0) 66.6 (11.0) 61.9 (10.9) 0.022 








Ethnicity, n (%):     
European 263 (83.0) 34 (82.9) 229 (83.0) 
0.887 Maori and PI 35 (11.0) 4 (9.80) 31 (11.2) 
Other 19 (6.00) 3 (7.30) 16 (5.80) 
Risk factors     
Prior MI, n (%) 80 (25.2) 11 (26.8) 69 (25.0) 0.848 
HTN, n (%) 177 (55.8) 24 (58.5) 153 (55.4) 0.739 
Diabetes, n (%) 55 (17.4) 10 (24.4) 45 (16.3) 0.267 
Dyslipidaemia, n (%) 179 (56.5) 24 (58.5) 155 (56.2) 0.866 
Family history of CAD, 
n (%) 
121 (38.2) 16 (39.0) 105 (38.0) 1.00 
HF (Killip Class 2 or 3) 4 (1.30) 0 (0.00) 4 (1.40) 0.656 
AF, n (%) 22 (6.90) 5 (12.2) 17 (6.20) 0.181 
Stroke/TIA, n (%) 19 (6.00) 6 (14.6) 13 (4.70) 0.024 
Smoking, n (%):     
Current 67 (21.1) 6 (14.6) 61 (22.1) 
0.585 Former 113 (35.6) 16 (39.0) 97 (35.1) 
Never 137 (43.2) 19 (46.3) 118 (42.8) 









Clinical presentation     
STEMI, n (%) 67 (21.1) 15 (36.6) 52 (18.8) 
0.014 
NSTEMI, n (%) 250 (78.9) 26 (63.4) 224 (81.2) 
This table displays the baseline demographics, clinical risk factors and clinical 
presentation of the whole cohort, MACE group and no-MACE group. Continuous, 
parametric variables of the total cohort are expressed as mean (SD) whereas 
continuous, non-parametric variables are expressed as median (25th percentile, 75th 
percentile). Categorical variables are expressed as frequency (percentage). Significant 
p-values (p <0.05), calculated using the Mann-Whitney U test or exact significance two-
sided Chi-square test, are bolded.  
AF - atrial fibrillation; BMI - body mass index; CAD - coronary artery disease; HF - 
heart failure; HTN - hypertension; MACE - major adverse cardiovascular events; MI - 
myocardial infarction; NSTEMI - non-ST elevation myocardial infarction; PI - Pacific 
Islander; Q1 - 25th percentile; Q3 - 75th percentile; SD - standard deviation; STEMI - ST 
elevation myocardial infarction; TIA - transient ischaemic attack; TnT - troponin T. 
1 Calculated from n = 274, as 2 patients had missing BMI values. 
2 Calculated from n = 273, as 3 patients’ troponin T results were not accessible.  
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7.3.2 Predictors of MACE: Univariate analysis 
As shown in the demographic table (Table 7.1), age, clinical presentation and 
stroke/TIA were significantly associated with MACE on univariate analysis.  
Table 7.2 presents the medians, 25th percentiles (Q1) and 75th percentiles (Q3) for 
the cytokine score, principal component scores and individual cytokines in patients who 
did and did not develop MACE at one year. The Mann-Whitney U test revealed that IL-
6, IL-8, Component score 1 and the combined cytokine score were significantly higher 
in patients who developed MACE. As IL-6 and IL-8 had statistical significance (p = 0.006 
and p = 0.004, respectively), PCA was used to create a subset score, i.e. the IL-6-IL-8 
score. The KMO measure of sampling adequacy was 0.500 and the Bartlett’s test of 
sphericity was statistically significant (p<0.001). Only one component was significant, 
with an eigenvalue of 1.347. This component accounted for 67.4% of the total variance 
of the two cytokines. The score of this component was used for the IL-6-IL-8 score. The 
medians, 25th percentiles, 75th percentiles, and p-values from the Mann-Whitney U test 
were added to Table 7.2. Figures 7.1 and 7.2 visually display the information in the table. 
The IL-6-IL-8 score also showed statistical significant difference between patients who 
did and did not develop MACE alongside IL-6, IL-8, Component score 1 and the 
combined cytokine score (p<0.05).
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 Table 7.2   Univariate analysis of inflammation and MACE 
Cytokine MACE No MACE P-value 
IL-1β 0.130 (-0.620-0.880) 0.093 (-0.507-0.693) 0.827 
IL-6 4.55 (-5.12-14.2) 2.08 (-3.78-7.94) 0.006 
IL-8 4.74 (0.375-8.74) 3.48 (0.665-6.29) 0.004 
IL-10 0.358 (-0.182-0.898) 0.263 (-0.147-0.673) 0.074 
MCP-1 76.2 (-20.7-173) 55.6 (-32.2-143) 0.104 
RANTES 4128 (-859-9115) 5355 (546-10,164) 0.207 
Component score 1 0.052 (-0.837-0.941) -0.249 (-0.793-0.295) 0.005 
Component score 2 0.077 (-0.854-1.01) -0.028 (-1.01-0.959) 0.402 
Cytokine score 0.156 (-1.53-1.85) -0.260 (-1.67-1.15) 0.029 
IL-6-IL-8 score -0.098 (-0.790-0.595) -0.267 (-0.782-0.248) 0.002 
Median (Q1, Q3) of individual cytokines, the two principal component scores and 
combined cytokine score are calculated in MACE and non-MACE patients. The p-values 
are generated from Mann-Whitney U tests and significant p-values (p <0.05) are bolded. 
IL – interleukin; MACE – major adverse cardiovascular events; MCP-1 – monocyte 
chemoattractant protein-1; Q1 – 25th percentile; Q3 – 75th percentile; RANTES – 




Figure 7.1  Distributions of individual cytokines in patients with and without MACE 
The concentrations, medians and IQRs of the six cytokines used to create the cytokine score were compared in patients with and without 
MACE using the Mann-Whitney U test. Only IL-6 and IL-8 concentrations were significantly higher in those who developed MACE. * = Significant 




Figure 7.2  Distributions of cytokine score and principal component scores in patients with and without MACE 
The concentrations, medians and IQRs of the cytokine score, Component score 1, Component score 2, and IL-6-IL-8 score were compared 
in patients with MACE and without MACE, using Mann-Whitney U test. The cytokine score, Component score 1, and IL-6-IL-8 score were 
significantly higher in those who developed MACE at one year. * = Significant p-values (p<0.05). IL-6 – interleukin-6; IL-8 – interleukin-8; MACE 
– major adverse cardiovascular events. 
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To evaluate the prognostic ability of IL-6, IL-8 and the various PCA-derived scores 
that were univariately associated with MACE, ROC curves were generated (Figures 7.3). 
IL-6, IL-8, Component score 1, the cytokine score, and IL-6-IL-8 score were found to be 
moderate predictors of MACE, with significant AUCs of 0.632 (p = 0.006), 0.639 (p = 
0.004), 0.606 (p = 0.048), 0.637 (p = 0.005) and 0.652 (p = 0.002), respectively. Table 7.3 
presents the threshold concentration or score of these cytokines or PCA-derived scores, 
which were obtained at maximal sensitivities and specificities.   
Table 7.3   Area under the curves generated from ROC curve analysis of MACE 
Cytokine/Score ROC AUC Cut-off value Sensitivity (%) Specificity (%) 
IL-6 0.632 3.11pg/mL 65.9 60.1 
IL-8 0.639 3.59pg/mL 75.6 52.5 
PC1 score 0.637 -0.148 63.4 58.7 
Cytokine score 0.606 0.0802 56.1 62.3 
IL-6-IL-8 score 0.652 -0.141 65.9 65.2 
This table displays the AUCs, cut-off values, sensitivities and specificities generated 
from ROC curves of the individual cytokines and PCA-derived scores. All significant AUCs 
are bolded (p<0.05). A cut-off value with optimal sensitivity and specificity has been 
determined from the ROC curve, with sensitivity being prioritised over specificity when 
deciding between two similar cut-offs.   
AUC – area under the curve; IL-6 – interleukin-6; IL-8 – interleukin-8; PC1 – principal 




Figure 7.3  ROC curve of PCA-derived scores and MACE 
The ROC curves demonstrate sensitivity (y-axis) and 1-specificity (x-axis) for IL-6 and IL-8 (left curve), Component score 1 (central curve), 
and the cytokine score and IL-6-IL-8 score (right curve) as predictors of MACE. IL-6 – interleukin-6; IL-8 – interleukin-8; PCA – principal component 
analysis; ROC – receiver operator characteristic. 
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7.3.3 Predictors of MACE: Multivariate analysis 
As the individual cytokines and Component score 1 were used to derive the 
cytokine score, and IL-6 and IL-8 individually were used to derive the IL-6-IL-8 score, 
they could not be combined into one multinomial logistic regression model. Therefore, 
age, clinical presentation, and the cytokine score above 0.0802 (the cut-off score 
derived from the ROC curve) were combined into one multivariate model (Model 1), 
Component score 1 above -0.148 and the clinical factors were combined into Model 2, 
IL-6-IL-8 scores above -0.141 and clinical factors were combined into Model 3, and IL-6 
above 3.11pg/mL, IL-8 above 3.59pg/mL and the clinical factors were combined into 
Model 4. With only 19 (5.99%) patients in the cohort having a previous history of stroke 
or TIA, it was underpowered to be included in the models. Clinical presentation 
remained significantly associated with MACE in all four models. Age was significantly 
associated with MACE in all models except Model 3 (with the IL-6-IL-8 score). IL-6 was 
significantly associated with MACE, with an OR and 95% CI of 2.18 (1.06-4.50), but IL-8 
was not. Out of all the PCA-derived scores, only the IL-6-IL-8 score was found to be an 
independent predictor of MACE at one year, with an OR and confidence interval of 2.77 
(1.32-5.81), p=0.007 (Table 7.4). 
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Table 7.4   Multivariate models of MACE 
Risk Factor 
Model 1  
OR (95% CI) 
P-value 
Model 2  
OR (95% CI) 
P-value 
Model 3  
OR (95% CI) 
P-value 
Model 4 




























Cytokine score  
> 0.0802 
3.18 (0.724-13.9) 0.126 - - - - - - 
Component 




0.052 - - - - 
IL-6-IL-8 score  
> -0.141 
- - - - 
2.77  
(1.32-5.81) 
0.007 - - 
IL-6  
> 3.11pg/mL 










This table displays the ORs and 95% CIs calculated from the multinomial logistic regression analyses of the four models. Each variable in the 
multivariate models was associated with MACE on univariate analysis. Model 1 = Age, STEMI and cytokine score, Model 2 = Age, STEMI and 
Component score 1, Model 3 = Age, STEMI and IL-6-IL-8 score greater than -0.141, and Model 4 = Age, STEMI, IL-6 and IL-8. Significant p-values 
(<0.05) are bolded. CI – confidence interval; IL-6 – interleukin-6; IL-8 – interleukin-8; OR – odds ratio; STEMI – ST-elevation myocardial infarction.
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7.3.4 Correlations between the IL-6-IL-8 score and clinical risk factors 
Table 7.5 displays the correlations between the IL-6-IL-8 score and clinical risk 
factors. Age, sex, diabetes, clinical presentation (STEMI or NSTEMI), and peak TnT were 
significantly associated with the IL-6-IL-8 score (p<0.05). 
Table 7.5   Relationships between clinical risk factors and the IL-6-IL-8 score 
Risk Factors 
IL-6-IL-8 score 
P-Value or correlation (p-value) 
Sex 0.024 
Ethnicity 0.912 




Family history of CAD 0.182 
Current smoker 0.916 
Clinical presentation 0.008 
Age 0.367 (<0.001) 
BMI 0.057 (0.311)  
Peak TnT 0.340 (<0.001) 
This table displays the relationships between the IL-6-IL-8 score and clinical risk 
factors. The Mann-Whitney U test was used to analyse the relationships between the 
IL-6-IL-8 score and binomial categorical risk factors. The Kruskal-Wallis test was used for 
categorical risk factors with more than two categories. The Spearman’s rank correlation 
was used to calculate the correlations with continuous risk factors. Significant 
relationships are bolded (p-value <0.05).  
BMI – body mass index; CAD – coronary artery disease; HTN – hypertension; IL-6 – 




This study found that IL-6, IL-8, the first principal component score, the cytokine 
score, the IL-6-IL-8 PCA-derived score, age and clinical presentation (STEMI or NSTEMI) 
were significantly associated with MACE on univariate analysis. After adjustment for 
confounding variables, elevated IL-6 levels above 3.11pg/mL and elevated IL-6-IL-8 
scores above -0.141 remained as independent predictors of MACE. Clinical presentation 
was statistically significant in all multivariate models, and age was significant in all 
models except for the model with the IL-6-IL-8 score. The IL-6-IL-8 score had significant 
associations with age, sex, diabetes, clinical presentation and peak TnT. 
It is interesting that the IL-6-IL-8 score was found to be an independent predictor 
of MACE but the cytokine score (made up of all six cytokines) and component score 1 
(which was predominantly derived from IL-6, IL-8 and IL-10) were not. From a 
theoretical point of view, the inclusion of multiple markers using a mathematical 
technique that deals with inter-correlations and is robust even in the presence of 
missing data-points is an appealing approach to characterise inflammation. Combining 
the six cytokines where concentrations could be calculated for over 50% of the 
population in the PCA model produced an AUC of 0.606 on ROC analysis (Table 7.3), 
suggesting a moderate ability to predict MACE. In the multivariate model, the OR for 
the combined cytokine score was 3.18, but the 95% CI crossed 1.0, such that this score 
was not an independent predictor of MACE. Although our systematic review in Chapter 
4 showed that the inclusion of multiple cytokines that were previously linked to MACE 
following ACS might have merit, this study showed that a selective combination of 
cytokines was independently associated with MACE. In this instance, the inclusion of IL-
6 and IL-8 alone generated a PCA score that had a greater AUC of 0.652 on ROC analysis 
than either cytokine individually or the combined cytokine score. In the multivariate 
model, the IL-6-IL-8 score had a greater OR than IL-6 alone. Skau et al. showed similar 
results in their study of AMI patients where selectively combining growth differentiation 
factor 15 (GDF-15) and tumour necrosis factor-related apoptosis-inducing ligand 
receptor 2 (TRAIL-R2) produced the same ROC AUC of 0.85 for MACE as the combination 
of 33 biomarkers.22 This suggests that although a combination of multiple cytokines is 
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superior to individual cytokines to predict MACE, we must be selective in the cytokines 
used to derive the score. Otherwise, the additional cytokines act as an additional 
“noise” that weakens the prognostic ability of the score.  
Few studies have investigated PCA-derived scores as predictors of MACE in the AMI 
population. In a conference abstract, Stankovic et al. analysed 12 biomarkers in 100 
STEMI patients and used exploratory factor analysis (EFA), a statistical method similar 
to PCA, to create factor scores and correlate them with 30-day MACE.289 Only two factor 
scores, one of which was composed of IL-6, IL-8 and MCP-1, were found to be 
independent predictors.289 A full article of this study could not be found. With our 
cohort, IL-6 and IL-8 contributed to the first component score, while MCP-1 contributed 
to the second component score. The differences in our findings may be due to the 
rotational component of EFA, which allows for improved clustering of variables than 
PCA.290 PCA and EFA are both mathematical techniques that reduce data, but while EFA 
prioritises optimal clustering of variables to determine the relationships between the 
variables, PCA prioritises retaining the maximal variation within the variables.290 In 
Chapter 5, we showed that the six cytokines measured had considerable variation that 
could not be explained by traditional risk factors. We believed it was important to retain 
this variance within the combined cytokine scores, which led us to using PCA instead of 
EFA.  
As mentioned in sections 1.2.3.1 and 3.1, IL-6 is expressed by many cell types and 
predominantly acts in a pro-inflammatory manner by mediating the acute phase 
response.78 It has been associated with MACE in patients with acute coronary 
syndrome.78 IL-8 is also expressed by various cells and has both pro- and anti-
inflammatory roles. It is activated during myocardial ischaemic-reperfusion injury but 
also helps with angiogenesis, which improves myocardial function after AMI.78 High 
levels of IL-8 have been associated with both increased and decreased risk of adverse 
outcomes in different studies.78 To the best of our knowledge, no previous studies have 
looked at combining IL-6 and IL-8 alone to predict MACE in AMI. Previous studies that 
combined two cytokines into ratios preferred to combine a cytokine where increased 
levels were associated with MACE with another cytokine where decreased levels were 
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associated with MACE.32,143 As previously mentioned in Chapter 6, PCA has several 
advantages over ratios in that it does not require variables to be independent and can 
combine at least two variables together.287,289 
Limitations of the methodology and cytokine score, such as being unable to define 
an optimal cytokine panel and using peak TnT as a surrogate marker of infarct size, were 
discussed in section 6.4. Another limitation of our study is that it is unknown whether 
the cut-off value of -0.141 for the IL-6-IL-8 score is reproducible in independent AMI 
populations. The sensitivity and specificity of the IL-6-IL-8 score must also be improved 
if it is to be applied in clinical practice, as a moderate sensitivity of 65.9% and specificity 
of 65.2% is too low for the score to be applied in clinical decision-making for AMI 
patients. It is recommended that clinically useful tests should have an added sensitivity 
and specificity of between 150% and 200%.291 In order for the IL-6-IL-8 score to be 
applied in clinical decision making, an increase in these parameters is important. Further 
validation of the IL-6-IL-8 score in future AMI cohorts will determine the reproducibility 
of our reported cut-off value of -0.141.  
A final limitation is that IL-6 was found to be an independent predictor of MACE in 
this cohort, but not in Chapter 3. One possible reason for this might be that in this 
cohort, we collected the blood samples on Day 2, whereas in Chapter 3 time was not 
controlled and the samples were collected at a mean of four days following symptom 
onset. As shown in Chapter 5, IL-6 levels peak acutely following AMI, and it may be that 
the IL-6 levels captured in Chapter 3 had already returned to lower non-pathological 
levels. However, as demonstrated by the studies in this thesis, pathological 
inflammation contains a complex network of inflammatory markers, and the 
inconsistent results found between IL-6 and MACE in our two studies could be due to 
other unknown reasons. If this was the case, it would make it difficult to pre-define an 
appropriate cytokine panel to create a meaningful score predictive of MACE. It could be 
that patients would require a more personalised cytokine score, created out of a subset 
of cytokines that were significant for the individual. As mentioned in the previous 
paragraph, the IL-6-IL-8 score requires validation to provide insight into the potential 




An IL-6-IL-8 PCA-derived score can independently predict MACE in AMI patients, 
with moderate sensitivity and specificity. In the future, this study requires validation in 
an independent cohort to assess the prognostic ability of the cytokine score and 
determine the clinical significance of the IL-6-IL-8 score.  
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Chapter 8 Summary and future directions 
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8.1 Summary of studies 
The overall aim of this thesis was to characterise “pathological” inflammation and 
predict which patients were at increased risk of MACE, as shown in Figure 8.1 on the 
following page. The first study in this thesis explored the use of routinely-measured 
clinical markers, WBC subtypes, as potential biomarkers of pathological inflammation. 
The aim was to determine how WBC subtypes correlate with MACE in AMI patients and 
determine the relationship between levels of WBC subtypes, time of symptom onset 
and risk of MACE. While individual levels of WBC subtypes (neutrophil, lymphocyte and 
monocyte counts) were not found to be associated with MACE, when we explored ratios 
of these subtypes, we found that raised neutrophil-lymphocyte ratios (NLR) and 
reduced lymphocyte monocyte ratios (LMR) were significantly associated with MACE.185 
MACE was defined as all-cause death, non-fatal MI, non-fatal ischaemic stroke, stent 
thrombosis, new or worsened HF leading to hospitalisation and unplanned 
revascularisation.185 However, once adjusted for potential confounders such as age, 
prior MI, dyslipidaemia, hypertension and diabetes, multivariate analysis showed that 
these markers were not independent predictors of MACE in this AMI cohort.185 These 
results indicated that WBC subtypes were not strong predictors of MACE and unlikely 
to represent pathological inflammation. Additionally, this chapter concluded that the 
time of day that symptom onset began (which peaked between 06:00 and 11:59am) did 
not affect circadian changes in WBC subtype levels or affect the ability of these WBC 




Figure 8.1  Simplified relationship between inflammatory response post-ACS and MACE 
A summary depicting how a “healthy” inflammatory response post-ACS will lead to optimal infarct expansion, while excess or “pathological” 
inflammation may lead to MACE. Characterising “pathological” inflammation and its relationship with MACE has been the main focus of this 
thesis. This figure was created using Biorender.com, Toronto, Ontario, Canada.
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With WBC subtypes, we had little control over when the markers were measured 
as the samples were collected and measured clinically. Hence, we decided to investigate 
other inflammatory markers that we could collect and measure in our own laboratory. 
This next study focussed on exploring the use of CRP, another routinely-measured 
clinical marker of systemic inflammation, and two commonly measured cytokines in 
order to characterise pathological inflammation in AMI patients. As the first study 
showed that combining two WBC subtypes into a ratio was more predictive of MACE 
than individual subtypes, the primary aim of this study was to investigate whether 
adding three inflammatory markers together would be able to independently predict 
MACE. In this study, MACE was composed of cardiac death, recurrent MI, and non-fatal 
ischaemic stroke. The secondary aims were to examine the relationship between the 
three markers, and to determine how a patient’s inflammatory status was classified 
with the three markers. We found that there was no significant difference in the 
proportion of patients with markers in the highest quartile among the cases (those who 
developed MACE within a year) compared with the controls (those who did not develop 
MACE). We also found no significant difference between the cases and the controls 
when the number of elevated markers (in Quartile Four) were added together. It was 
postulated that the variance in time of symptom onset (median of 4 days ± IQR 3-6 days) 
might have contributed to the negative findings. Only a moderate correlation was found 
between CRP and IL-6, which indicated that a patient’s inflammatory status (having 
excess or little inflammation) varied depending on the individual marker chosen for 
analysis. This signified that measuring only one biomarker would not accurately 
characterise a patient’s inflammatory state. 
The results of the previous two studies suggested that combining multiple 
biomarkers could be more powerful than a single biomarker approach. Since CRP was a 
relatively stable marker of acute inflammation and since it was not predictive of MACE, 
our attention turned to the value of cytokines as a better way to represent excess 
inflammation. Therefore, we conducted a systematic review in Chapter 4 that 
investigated whether a combined cytokine approach was superior to an individual one 
to predict MACE in ACS patients.186 Ten out of 907 papers from EMBASE, Medline and 
Cochrane databases met the eligibility criteria required to answer our question. These 
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10 studies had considerable heterogeneity in terms of methodology and study design, 
with acceptable or poor internal validity. Collectively, the studies had mixed findings on 
the relationships between individual cytokines and MACE, with some finding a 
significant association and others finding no association for the same cytokine. Four of 
the 10 studies did a combined marker analysis, with all showing a significant association 
with MACE. Therefore, a combined cytokine approach seemed superior to an individual 
approach, although this result required confirmation with further studies. However, 
these studies used simple methods of combining the cytokines that assumed the 
cytokines were independent of each other. Another method of combining markers into 
a prognostic score that accounts for collinearity required further investigation. 
Additionally, the studies could not answer which cytokines should be measured or when 
it was best to measure cytokines to capture pathological inflammation. 
In the second study, we believed that the time the blood samples were collected 
from symptom onset might have been a confounder that affected the findings. 
Therefore, we decided to investigate it in the fourth study. The aims were to explore 
the dynamic variation in cytokine concentrations over the acute and chronic phases 
following AMI, determine when peak cytokine levels occurred in the acute phase to 
capture pathological inflammation, and investigate potential drivers of variation in 
cytokine levels between patients to determine if they could influence the cytokine levels 
found at certain timepoints. There was considerable variation in cytokine 
concentrations (IL-1β, IL-6, IL-8, IL-10, MCP-1 and RANTES) both between patients and 
within patients over time. None of the cytokines showed clear trends over time, except 
for IL-6, which peaked on Day 1 for 52% of the patients. This study was unable to answer 
whether sampling time was an important factor to consider in AMI studies. Out of the 
clinical risk factors and surrogate markers of infarct size that were measured (LVEF and 
AUC TnT), only smoking status was associated with peak IL-6 levels. The majority of the 
variation in observed cytokine levels could not be explained by these common risk 
factors. Overall, the study results reflect the complexities of the inflammatory network 
that are not fully understood. Although the trends for cytokine levels over time and an 
optimal sampling timepoint could not be determined from this study, it appeared that 
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cytokine levels varied over time. We concluded that sampling time might be important 
to consider when designing future studies. 
From Chapter 4, we found that a combined cytokine approach might be superior 
to individual cytokines when predicting MACE, but alternative approaches that could 
combine non-independent cytokines were required and the optimal cytokine panel 
remained unknown. This led us to our final study, where we aimed to explore whether 
a more complex mathematical approach would be appropriate for creating a combined 
cytokine score. As PCA could account for collinearity between the cytokines and retain 
maximal variance, this was used to create a combined cytokine score in Chapter 6. A 
secondary aim was to determine what additional information these cytokines could 
provide regarding inflammation beyond common risk factors. Six cytokines collected 
two days following symptom onset were analysed from 320 patients and two significant 
PCA component scores were added to create the combined cytokine score. Weak 
correlations were found between six out of 15 pairs of cytokines. There was a significant 
variation in cytokine levels, which could not be fully explained by the weak correlations 
between several of the clinical risk factors (such as age, BMI, peak TnT, sex and diabetes) 
and some of the individual cytokines, component scores and the combined score. 
Overall, this study showed that PCA could be used as a method to create a combined 
cytokine score in the AMI context. However, it required further investigation whether 
the resulting PCA-derived score would be able to predict adverse outcome. 
The final study was a continuation of the study in Chapter 7, where we sought to 
investigate if a PCA-derived score could predict MACE and therefore be representative 
of pathological inflammation.187 Out of the individual cytokines, IL-6 and IL-8 were 
significantly associated with MACE on univariate analysis, so they were combined into 
an IL-6-IL-8 score by PCA. The first component score, combined cytokine score and the 
IL-6-IL-8 score were also significantly associated with MACE on univariate analysis. 
However, only IL-6 levels above 3.11pg/mL and IL-6-IL-8 scores above -0.141 were 
independently predictive of MACE. The IL-6-IL-8 score also had a greater OR than IL-6 
alone (2.77 versus 2.18), indicating that a combined cytokine approach might be 
stronger than a single cytokine approach. However, which cytokines to include in a 
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combined score remains unknown and validation of these findings in an independent 





Within each chapter, there have been limitations that were addressed in those 
respective chapters. However, there are also overarching limitations throughout this 
thesis that must be mentioned. For example, having limited resources (such as samples, 
time, and finances) made it difficult to re-run laboratory analyses of cytokines with 
levels outside of the detectable range. Doctoral theses are commonly constrained by 
time, so patient recruitment was designed to fit into the specific timeframe of this 
thesis. It would always be more desirable for more extensive patient recruitment, as 
smaller differences observed may have become statistically significant with larger 
cohorts.  
A certain limitation that requires further discussion is the use of MACE as an 
endpoint, which has been used throughout this thesis. Although MACE increases the 
power of a study by grouping several outcomes together, it does contain a few flaws. 
As stated in Chapter 1, there is no gold standard definition of MACE and it may 
encompass some or all adverse cardiovascular events. These individual adverse events 
that make up MACE are, to varying degrees, all driven by inflammatory processes that 
occur as a result of ACS. However, they are also driven by other factors, such as ACS 
management,292 underlying chronic inflammation from comorbidities,292 and non-
modifiable patient factors (for example, age, as seen in Chapters 2 and 7). In Chapters 
2, 3, and 7, we controlled these potential confounders via the study design (case-
control) or via multivariate analysis. However, we were unable to control all potential 
drivers of MACE and it is unknown if they influenced any of the study results in this 
thesis.  
This thesis chose to largely focus on elevated levels of inflammatory markers as 
“pathological” inflammation, which led to a few limitations. Hypothetically, 
“underactive” inflammation may also be pathological and may lead to other adverse 
outcomes, such as the reduced lymphocyte counts found in the MACE group in Chapter 
2. However, we did not explore in detail and no studies to date appear to have directly 
investigated this in the ACS context. A few immunosuppressive agents in MI patients 
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have been associated with increased risks of adverse outcomes, such as anakinra in the 
MRC-ILA Heart trial and colchicine in the Colchicine Cardiovascular Outcomes Trial 
(COLCOT).146,156 Although we controlled significant confounders of elevated 
inflammation such as cancer, we did not explore underlying chronic inflammation that 
is a characteristic of atherosclerotic disease and may be more prominent in some 
patients due to common comorbidities, such as diabetes.208 This could have influenced 
which patients were more likely to develop MACE. Additionally, we were unable to 
control all factors influencing the levels of inflammatory markers in our study design, 
such as aspects of routine clinical care that might modulate inflammatory levels (e.g. 
medications, time to reperfusion and PCI). 
In this thesis, inconsistencies in the association between the same cytokines and 
MACE were observed. For example, IL-6 was not associated with MACE in Chapter 3, 
but was found to be an independent predictor in Chapter 7. This is consistent with the 
findings in our systematic review (Chapter 4), where different associations with MACE 
and IL-6, IL-10 and IL-18 were found among the 10 studies included in the review. The 
reason for the differences were not explored in this thesis. Those inconsistencies make 
it difficult to confirm or exclude certain markers as significant contributors of excess 
inflammation and/or predictors of MACE. However, the inconsistencies supported our 
hypothesis that individual cytokines would be insufficient to represent pathological 
inflammation and predict MACE alone. 
This thesis did not aim to characterise all contributors of pathological inflammation 
in the ACS context. With the numerous cytokines and other inflammatory markers that 
have been discovered to date, and with the time constraints of completing this thesis, 
we were only able to measure a selected number of inflammatory markers. These 
markers were carefully chosen, based on their existing use in clinical practice or based 
on the literature. While we were unable to determine an optimal inflammatory marker 
panel for MACE prediction, it may be that expanding the number and/or type of 
inflammatory markers that are investigated may shed more light on which markers best 
represent pathological inflammation. However, the results of our studies are 
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informative for future investigators who may wish to explore aspects of pathological 
inflammation not covered within this thesis. 
A final limitation is that the exploration of multiple sophisticated methods to create 
a combined cytokine score was not covered within the scope of this thesis. We started 
with simple methods that had previously been used in the literature, such as ratios and 
simple addition scores. However, ratios do not allow for more than two inflammatory 
markers to be combined, and simple addition scores assume independence between 
the markers, which may not be true. In Chapters 6 and 7, PCA was successfully used to 
create a combined IL-6-IL-8 score that was predictive of MACE. The PCA-derived score 
is a proof-of-concept and requires validation in an independent cohort. PCA is a more 
sophisticated method that does not assume independence between markers and 
reduces concentrations of multiple markers into fewer scores. There are also other 
mathematical approaches which have not been explored in this thesis, such as EFA and 
SEM. These methods have been used to characterise biomarkers in the setting of other 
diseases, such as subdural haematoma and diabetes.293,294 Further investigation is 
required to compare which mathematical approach is best for characterising 




8.3 Future directions 
As discussed in the previous section and in the Discussion sections of Chapters 2 to 
7, this thesis contained unavoidable limitations. It is logical that the next study beyond 
this thesis aims to explore the major limitations or unanswered questions, which are: 
-    The imperfections of MACE as an endpoint, 
- The question of the importance of time in characterising pathological 
inflammation, as discussed in Chapter 5, 
-    Which cytokines should be included to create an optimal panel for characterising 
excess inflammation and predicting MACE, and 
-    How best to combine cytokines to create a predictive score. 





Figure 8.2  Summary of proposed study 
This figure is a schematic summary of the proposed study, outlining the population, 
sampling timepoints (blood samples and cMRI), laboratory analysis techniques, 
outcome and mathematical methods for characterising cytokine scores and their 
association with the outcome. This figure was created using Biorender.com, Toronto, 
Canada. PCA - principal component analysis; SEM - structural equation modelling.
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There are two possible options for deciding the study population. One is having a 
strict eligibility criterion that allows for a more homogeneous study population and 
reduces the risk of confounders affecting the outcome of interest. A disadvantage of 
this type of study population is that the results will be less generalisable to the whole 
population. The other option is to have a study population that is more reflective of the 
general population, with more variable patient characteristics. However, the increased 
variability in patient characteristics means that a larger study population is needed to 
manage the additional “noise” from this variability with statistical methods. We 
propose a study population of STEMI patients admitted to the hospital within six hours 
of symptom onset, which reflects the stricter approach. A more homogeneous 
population will enable us to better characterise pathological inflammation. In addition, 
we aim to record the dynamic changes in cytokine concentrations over time to capture 
pathological inflammation (peak cytokine levels). This prevents us from including 
NSTEMI and UA patients who are commonly admitted to the hospital beyond six hours 
following symptom onset. 
In Chapter 5, we were unable to determine an optimal timepoint that could capture 
peak cytokine levels for the majority of cytokines. Measuring peak levels is important 
to investigate pathological inflammation. Due to the clinical feasibility and patients’ 
willingness to have multiple venepunctures for a study, we chose to only collect blood 
samples every 24 hours until discharge, which usually occurred three to four days 
following admission. The eligibility criteria for the study in Chapter 5 included patients 
who had been admitted to the hospital within 24 hours, which prevented us from 
collecting multiple samples before 24 hours. Some cytokines are believed to peak 
before 24 hours, such as IL-1β, which has a half-life of four hours.295 In addition, invasive 
procedures such as PCI may increase the inflammatory levels in a patient.296 Therefore, 
to capture dynamic changes of cytokine levels more accurately, we propose: multiple 
sampling timepoints within the first 48 hours of admission (at admission and at six, 12, 
24, 36 and 48 hours following admission), daily measurements until seven days post-
admission, a timepoint at 10 days to capture subacute inflammatory levels, pre- and 
post-PCI sampling timepoints (if not already covered by another existing acute 
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timepoint) and chronic timepoints at six weeks and six months. This will allow 
pathological inflammation to be characterised. 
In Chapter 5, a cohort of 23 AMI patients allowed us to investigate the trends in 
cytokine concentrations across time, but the population size was insufficient to 
investigate potential drivers of cytokine variation, which was not the main aim of the 
study. Hence, the study in Chapter 5 could not answer what might have affected the 
observed variation. In this proposed study, a cohort of 100 patients, for example, would 
provide more power to investigate potential drivers of differences in cytokine 
concentrations between patients. 
As mentioned in the previous section, MACE is an imperfect endpoint, as acute 
inflammation due to ACS is not the only contributor. Thus, for this study we propose 
the use of myocardial salvage index as the endpoint. Myocardial salvage index measures 
the difference between the area at risk from perfusion deficits and final infarct size.297  
It is a surrogate marker for long-term adverse outcomes and can reduce follow-up time 
because it is measured relatively acutely following ACS.297 Using myocardial salvage 
index will remove the confounder of underlying chronic inflammation and may more 
directly link to acute inflammation. Myocardial salvage index has been associated with 
some acute inflammatory markers post-ACS in previous studies, such as WBC counts 
and GDF-15.298,299 Cardiac magnetic resonance imaging (cMRI) is the most common 
imaging modality used to measure myocardial salvage.297 However, other imaging 
modalities, such as technetium-Sestamibi single-photon emission computerised 
tomography (SPECT), may be used depending on various clinical and logistical 
indications.297  
It is unknown which inflammatory markers best characterise excess inflammation. 
In Chapter 2, NLR and LMR were only able to characterise pathological inflammation to 
a small degree. In Chapter 3, CRP was not found to be associated with MACE. Therefore, 
we chose to focus on cytokines, which are more direct markers of inflammation in ACS, 
and are present in peripheral blood. We propose to continue measuring only cytokines 
in this study as there are many cytokines that have yet to be investigated. It may be 
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possible that other types of inflammatory markers are required to fully characterise 
pathological inflammation or to create a stronger predictive score for adverse 
outcomes. It will be appropriate to investigate this following the proposed study. 
As mentioned earlier, based on our findings in this thesis and from reading the 
literature, there are no strong indications on which cytokines should be included or 
excluded in an AMI population. Therefore, it may be of benefit to firstly have a screening 
cytokine panel to guide which cytokines to investigate further. One way this can be done 
is by using a technique such as a membrane human cytokine antibody array. It is a semi-
quantitative method that combines the techniques of an ELISA and chemiluminescent 
Western blot.300 It is commercially sold as a multiplex array that can measure up to 274 
cytokines per array.300 A disadvantage is that it provides relative densities rather than 
concentrations of cytokines. However, it fulfils the purpose of being a starting point to 
narrow down the potential markers of interest for an optimal panel. Another 
disadvantage is that only up to eight samples can be measured per array. As seen in the 
studies of this thesis, there is a significant variation in cytokine levels among ACS 
patients, so a relatively larger study population is required to determine with certainty 
which markers are or are not of potential interest in the ACS context. However, using a 
membrane antibody array is still cost-effective.  
Once the list of cytokines has been narrowed down to the ones of interest, a highly 
sensitivity multiplex assay should be used to measure the cytokine concentrations. With 
increasing technological advances, there are a number of different assay techniques 
commercially available. These include CBA, Luminex assays, mass cytometry, proximity 
extension assays and single molecule arrays.278 Advantages of these multiplex assays 
are that they reduce the sample volume needed for analysis, reduce the time needed 
to measure multiple cytokines, and have high sensitivity and specificity.278 These 
benefits make multiplex assays an appealing technique to quantify multiple cytokines. 
Which assay to use will depend on factors such as the economic cost and the detectable 
range of the cytokine concentrations. 
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As mentioned in the previous section, there are other complex mathematical 
approaches that have yet to be trialled for creating cytokine scores in AMI patients. SEM 
is one mathematical approach that allows investigators to explore the direct and 
indirect relationships between many variables via multiple equations without assuming 
independence.301 The mathematical techniques within SEM can correct small 
population to variable ratios, such as a population size of 57 with 25 variables of 
interest.302 These reasons are attractive for SEM to be used in this proposed study, 
because inflammation contains a complex network of numerous collinear markers. The 
relationships between numerous markers, clinical risk factors and MACE can be fully 




Overall, the findings of this thesis suggested that a combined biomarker approach 
might be more strongly predictive of MACE and therefore more able to represent 
pathological inflammation. Simple methods for combining inflammatory markers, such 
as ratios and the addition of a few elevated markers, were insufficient for MACE 
prediction. The limitations of these simple methods meant they were less suitable to be 
used to create prognostic scores. As a proof-of-concept, PCA could be used to create a 
combined IL-6-IL-8 score that was predictive of MACE in our cohort. This proved that 
more complex mathematical techniques could be used to create prognostic 
inflammatory scores out of collinear biomarkers in the AMI context. We attempted to 
investigate the best sampling timepoint for measuring cytokine concentrations that was 
reflective of pathological inflammation. However, due to the large variations in cytokine 
concentrations over time, our study was unable to conclude an optimal sampling time. 
Nevertheless, the foundations laid by the findings of this thesis are important for future 
investigations into finding an optimal inflammatory panel, an optimal sampling 
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